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Cancer cachexia is a constellation of symptoms affecting many cancer patients as their disease progresses.
These include loss of muscle mass as well as function, and the utility of computed tomography (CT) in
defining this muscle loss has come to the fore in recent years. It is not clear, however, the degree to which
CT can be relied on when defining cachexia, interpreting Quality of Life (QoL) metrics, and how this relates
to biochemical and functional assessments of skeletal muscle clinically.
Accordingly, the aim of this work was to assess the relationship between CT body composition analysis
(CT-BCA) measurements, the consensus cancer cachexia definition, QoL metrics, biochemical, and functional
assessments of skeletal muscle.
The hypothesis was that there would be a relationship between CT-BCA measurements and muscular
assessment, and that this could be used to inform future research directions.
Patients for this study were recruited from a single tertiary referral centre and were identified through cancer
MDTs, and elective admissions. Blood was taken, and CT scans performed, as part of routine clinical work.
QoL metrics and functional assessments were performed pre-operatively. Additional blood samples, and Rectus
Abdominis muscle samples were obtained intra-operatively. Rectus samples were snap-frozen in optimal cutting
temperature compound (OCT) and stored at -80C before being sectioned and fibre diameters measured using an
automated process. Muscle protein content was measured using a standard bicinchoninic acid (BCA) method.
CT analysis was performed using validated semi-automated software. Statistical analysis was performed in R.
194 patients were recruited into 3 groups (n,M:F): Live donor nephrectomy (LDN) (53, 24:29) (healthy control),
Vascular (AAA) (52, 44:8) (non-cancer control), Upper GI cancer (UGIC) (89, 62:27).
Using published criteria utilising both CT-BCA and body mass index (BMI) cut-points, the prevalence of
sarcopenia was (n, %): LDN (21, 39.6), AAA (29, 55.8), UGIC (42, 47.2). Cachexia according to published
cancer cachexia consensus definition criteria was present in (n, %): AAA (11, 21.2), UGIC (53, 59.6). The
v
prevalence of patients meeting cancer cachexia definitions in the vascular cohort was unexpected, and may
represent a previously unrecognised component of this disease. Using the healthy control group (LDN) to define
population-specific cut-points in order to assess prevalence of sarcopenia produced values which excluded the
majority of patients.
Differences in QoL metrics were noted between patient groups, with better values noted in LDN patients
as could be expected (Mean Overall QoL (lower number indicates better QoL): LDN 6, AAA 30.1, UGIC
29.0). There were, however, few statistically and clinically significant differences in reported QoL metrics or
in objective functional measures when patient groups were segregated by CT measures. This may represent
the preservation of QoL in a pre-operative cohort; patients sufficiently fit for surgery are likely to have good
function and thus QoL, or it may represent a lack of sensitivity of QoL questionnaires to detect aspects or
areas of concern to pre-operative patients.
An initial analysis of protein content and CT variables suggested a relationship between skeletal muscle
radiodensity (SMD) and protein content. On inclusion of the entire cohort, however, there was no strong
demonstrable relationship between CT variables and muscle protein content. This continued to be the case
after segregation by CT and BMI cut-points. Attempting to define “normal” muscle protein content utilising the
healthy control group was negated by the wide range of measured values across all cohorts: (All,M,F microg/mg
wet weight) LDN (44.45-335.4, 59.59-303, 44.45-335.4), AAA (42.4-312.96, 42.4-300.33, 62.63-312.96), UGIC
(30.99-314.82, 30.99-314.82, 31.84-250.95).
Muscle fibre cross-sectional area (CSA) was investigated graphically initially. Using this technique, it was
possible to partially separate groups of muscle CSA using CT. When using more mathematical methods,
however, it was not clear that these separations were significant. Additionally, the derived weighted mean
value did not demonstrate a strong relationship with CT variables.
Using anastomotic leak following Ivor-Lewis Oesophagectomy as a surrogate for severe inflammation allowed
investigation of this mechanism of cachexia development. Comparison of pre-operative with post-operative scan
results produced changes in CT variables which may further confound interpretation (mean skeletal muscle area
(SMA) pre- vs post-operative: Male 154.4 vs 162.9, Female 85.4 vs 122.9, mean SMD pre- vs post-operative:
Male 32.1 vs 28.1, Female 36.6 vs 27.7). These suggest a possible underlying inflammatory reason for changes
seen late in cachexia, and a possible masking of early deterioration in muscle mass.
Currently-used CT cut-points for sarcopenia find higher than expected prevalence in healthy groups, and whilst
population-specific values should be derived, they may not always represent a true reflection of muscularity in
all groups. Pre-operative patients of all types have globally preserved function and QoL, and more sensitive
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metrics are required for this group of patients. CT changes may not reflect QoL reduction until the disease
is advanced. The relationship between CT muscle variables and individual components of biochemical muscle
composition is unclear and further consideration of alternate muscle constituents such as the nucleus and the
sarcoplasmic retuculum is warranted. Inflammation has a marked impact on CT variables, and interpretation
of CT variables should include an assessment of systemic inflammation. The current linear paradigm relating
muscle mass to function and hence to patient outcome may need to be reconsidered, and this will potentially
have an impact on informing the design of and recruitment to future cachexia intervention trials.
CT is a useful tool in the assessment of skeletal muscle and the variables provided can help to indicate prognosis.
CT does not, however, reliably inform about QoL; patient function; or muscle constituents; and should not be




Cancer is a common disease affecting many patients over the course of their lives. As the disease progresses,
there is often loss of muscle - this is termed muscle wasting - and as this progresses the patient may develop
a condition called “cachexia”. This condition was first recognised by the Ancient Greeks who understood that
it represented a state where the patient was likely to have a poor outcome and die relatively rapidly.
More modern definitions of cachexia use CT scanning to measure the amount of muscle present, and use
thresholds to say whether patients do or do not have cachexia. Another measurement obtained from CT scans
is the density of muscle (how much of the scan x-rays are absorbed by it) and this has also been shown to
relate to poor outcomes for patients with low density muscle.
We looked to find how the published thresholds (which were calculated from a North American study) related
to Scottish patients, and to see how many of these patients had low muscle mass (sarcopenia), or low muscle
mass with weight loss (cachexia). We were interested in whether these scan measures related to Quality of
Life measures, to actual physical function measures (such as how fast patients could walk), and to measures
of the component parts of muscle (such as protein, and the size of muscle fibres).
There were 194 patients recruited, in cancer, vascular, and healthy live kidney donor groups. We found cachexia
in vascular patients, which was unexpected, and we also found more sarcopenia in the healthy control group
than we expected.
Looking into Quality of Life, we found that healthy patients had better quality of life than patients with disease,
but that CT scan variables did not seem to relate particularly well to quality of life. We also found that our
patients had well-preserved physical function, which would be expected from their pre-operative status.
We then looked into the relationship between CT scan measurements and results of laboratory analysis of
protein and muscle fibre size. Although there were some interesting changes in muscle fibre area when we
looked at the graphs, these changes disappeared when we looked at them mathematically. When we looked
at the relationship between CT scan measurements and laboratory protein measures we found there was not a
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strong relationship to be found.
We used a group of patients who had undergone cancer operations and who had developed complications, and
used existing scans from these patients to investigate the effects of severe complications on CT measurements.
This analysis showed that there was a measurable effect of the complication, and that this effect may be
important to consider when analysing CT measurements of other patients.
It seems that CT cut-points from North American studies do not translate well to Scottish populations. It
also seems that CT measures are not able to predict Quality of Life scores in pre-operative patients, nor are
they able to predict walking speed in the same group. Further, the relationship between CT measurements
and laboratory test results is not clear. It may be that the relationship between CT measurements and muscle
function is not a straight line and instead follows a curve. This is likely to have an impact on future designs
of clinical cachexia trials and on which patients should be involved in these.
CT is useful in helping to predict cancer patient outcomes, but it can not be relied upon to predict patient
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The term “cachexia” originates from Ancient Greece, from the the words “kakos”, meaning bad, and “hexis”
meaning habit or state. Indeed, Hippocrates described this condition in the context of cardiac cachexia with
the description:
“The flesh is consumed and becomes water; this follows disease of the spleen, of the liver, and leucophlegmasia
and dysentery and severe diarrhoea. As a result of the impurities, the abdomen fills with water; the feet and
legs swell, the shoulders, clavicles, chest and thighs melt away. If you begin treatment at the beginning, before
the accumulation of water becomes excessive, you must administer purgatives which evacuate water or phlegm
… the regimen of food, drink, exercise and walking will be until the patient becomes thin and dry, but only
until the flesh becomes as strong as possible. This illness is fatal, above all through progression of ascites.
[Regardless of cause] the treatment is similar; but few survive”[1]
Importantly, the description of widespread oedema and ascites, together with the description that the flesh
will “melt away”, matches well with the experience in cancer clinical practice. Indeed, some 50-80% of cancer
patients develop cachexia at some point in their journey [2,3]. The importance of this is not an academic
finding. In fact, the development of cachexia can have significant consequences for the surgeon, the oncologist,
and others involved in patient care. Specifically, it is known that patients developing cachexia are less well able
to tolerate surgery and chemotherapy, and are more likely to develop complications from these procedures and
interventions, potentially precluding their further management [2–4].
1.1.1 Cachexia into the modern era
Moving on from ancient times, in the early 20th century Osler described cachexia in a number of conditions
including cancer, and noted that emaciation was part of cachexia though it did not define it alone [5]. A more
detailed description was provided by Taylor in 1915 [6], who arranged the causes of cachexia under 2 main
headings:
“1. Absorption of decomposition products, toxins, etc. from primary tumour and its metastasis, and 2.
interference with the functions of the various organs”
Taylor’s description of the effects of these disturbances, and particularly with regards to the loss of weight
related to this, was shown in a 1980 study by Dewys et al [2] who noted the effect of weight loss on patient
ability to tolerate chemotherapy.
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Following this, and as discussed below, there was interest in body composition analysis. This was initially
carried out utilising dual-energy x-ray absorptiometry, with a new concept of “Sarcopenia” being coined in the
1990s [7], meaning low muscle mass. The concept of measuring muscle mass and muscle loss allowed for more
precise definitions of what was meant by cachexia, sarcopenia, and the interplay between the terms.
As time progressed, multiple definitions of cachexia were proposed [8–10] , and the problems inherent in having
a lack of consensus as to the diagnosis and categorisation of cachexia became increasingly obvious, as described
by Fox et al [11]. It was against this background, that a group proposed an international consensus definition
of cancer cachexia.
1.1.2 International Consensus
In the 2011 consensus statement on cancer cachexia, the authors defined the condition as a “multifactorial
syndrome characterised by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that
cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment”
[12]. This condition affects up to 80% of cancer patients (depending on the type of cancer) [13]. The clinical
impact of this condition may result in patients being unable to undergo treatment for their disease (whether
surgery or chemotherapy), and in general results in worse outcomes. The diagnosis of cancer cachexia requires
the fulfilment of one of three criteria:
- Weight loss (WL) >5% over past 6 months (in absence of simple starvation)
- BMI (Body Mass Index) <20 and any degree of WL >2%
- Appendicular skeletal muscle index consistent with sarcopenia and any degree of WL >2%
The consensus definition acknowledged that at the time of publication there was “a paucity of reference values”
but suggested a “generally accepted rule [of] an absolute muscularity below the 5th percentile”.
These criteria were investigated and validated by Blum et al in 2014 [14]. The validation showed that patients
who fulfilled cachexia criteria had a shorter survival time than those who did not. Additionally, the validation
confirmed that those meeting cachexia criteria demonstrated increased symptomatology, and exhibited a lower
performance phenotype. More recently, however, a Belgian study [15] investigated the discriminatory abilities
of Fearon et al in comparison to an earlier cachexia definition by Evans et al [16], finding that the earlier
criteria showed greater discrimination with regards to overall survival when applied to the same population.
The Evans et al criteria, however, used DXA values to define “low of fat-free mass index” rather than computed
tomography (CT).
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Of note, the criteria used in Fearon et al were defined by converting DXA cut-points to CT using CT body
composition analysis (CT-BCA) work done by Mourtzakis et al [17]; however these have since been superseded
by BMI-stratified criteria developed by Martin et al [18], also based upon CT values.
Additional work subsequent to the international consensus definition attempted to further categorise patients
within the cachexia diagnosis by building on the foundation of WL and BMI expressed in the statement[19].
This study utilised outcome data from a series of 8160 cancer patients from Europe and North America, and
attempted to utilise clinical measures alone to sub-categorise these patients according to subsequent outcome.
The authors used a training set to define combinations of WL and BMI which would allow the assignment of
a BMI/WL score, and a validation set to confirm their hypothesis. Although able to define severity grades
from 0-4 which appeared to match with survival, the datasets used were retrospective, contained a mixture of
tumour types, and had a wide range of WL (including a number of patients who gained weight and were thus
excluded). The training and validation samples within this study also came predominantly from the palliative
and medical oncological settings, and as such may not reflect the experience of those patients undergoing
surgical treatment with a view to cure. The BMI/WL score was validated prospectively, and found to be useful
for predicting patient outcome [20], however again this validation cohort was composed of palliative cancer
patients and the applicability to a surgical cohort is uncertain.
1.1.3 Relationship between Consensus Definition and Other Nutritional Assessment
Tools
This consensus definition can be shown to interlink with other nutritional approaches to patient assessment.
For example the malnutrition universal screening tool (MUST), which is in routine clinical use [21], records
height, weight, and WL as part of the calculation used to assign risk group to the patient under study. These
measurements complement those outlined in the consensus definition. Additionally, the patient-generated
subjective global assessment [22] also uses degree of WL in calculating nutritional risk score. It includes a
self-reported measure of patient function, and as such interlinks with the consensus definition’s assertion that
cachexia leads to progressive functional impairment. These measures were developed prior to the publication
of the consensus definition, and it could be said that the definition is in part based on the principles underlying
these tools.
Work which has been undertaken subsequent to the publication of the consensus definition has included both
BMI and percentage WL as part of the classification system [19], as discussed above.
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1.1.4 Terminology
As noted above, there have been numerous attempts to define particular terms in relation to muscle loss in
the presence or absence of disease. This terminology was summarised by MacDonald [23], in which article the
need for clear terms of definition was argued. To this end, and for the avoidance of doubt and confusion, the
current report will use terms as defined here:
1. “Cachexia” will be defined in accordance with the International Consensus as laid out above.
2. “Sarcopenia” will be defined as having low skeletal muscle mass; that is, having a skeletal muscle index
below that of a validated cut-point. The term skeletal muscle index (SMI), and the cut-points to be applied
will be discussed below and in Chapter 3.
3. “Skeletal Muscle Area (SMA)” is the area of skeletal muscle in cm2 at the level of L3 measured across the
entire L3 CT scan slice.
4. “Skeletal Muscle Index (SMI)” is SMA indexed for height by dividing SMA by the square of the patient’s
height in metres.
5. “Skeletal Muscle Radiodensity (SMD)” is the mean Hounsfield Unit (HU) measurement of the radiodensity
of skeletal muscle at the level of L3 measured across the entire L3 CT scan slice
1.1.5 Phase of Cachexia
The cachexia syndrome, as described in the 2011 consensus statement, exists as a continuum extending from
no cachexia, through pre-cachexia, into cachexia, and ultimately, refractory cachexia and death [12]. In these
phases, the latter 3 were described as having clinical relevance. Pre-cachexia included those in whom early
changes in metabolism and clinical signs preceded involuntary WL. The cachectic phase is described above,
but excludes those who have entered the refractory phase. This refractory phase is described as cachexia
which is clinically refractory because of very advanced or rapidly progressing cancer which does not respond
to treatment. In cases with features consistent with the cachexia diagnosis, severity stratification as described
above can be useful for prognostication and in discussion with patients. However, use of the scale requires strict
vigilance from attending physicians. At the early end of the scale, the difference between “no cachexia” and
“pre-cachexia” is subtle and can be difficult to distinguish. Early intervention is advocated in the consensus
statement (except in refractory cachexia), and to this end, the future identification of early biomarkers is
important to aid clinicians in the diagnosis of “pre-cachexia”. At the severe end of the scale, the accurate
diagnosis of refractory cachexia is reliant on monitoring the patient’s overall clinical condition and the specific
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response of their tumour to treatment.
1.1.6 Staging and Severity Criteria of Cachexia
Although mentioned in the Fearon et al International Consensus definition of cachexia, the stage and severity of
cachexia were not strictly defined by any particular parameter. Accordingly, in order to better enable prognosis
in cachexia, it was necessary to more closely investigate this.
Using a large dataset (8,160 cancer patients), Martin et al were able to investigate and categorise WL and BMI
levels that most strongly correlated with reduced survival [19]. The authors found that duration of survival
reduced with increasing levels of WL, and that survival was also affected by starting BMI. Across all BMI
categories, increased WL led to reduced survival, but those with low starting BMI were less tolerant of WL
than those with higher BMI. Finding that degree of WL affects survival lends credence to the suggestion that
cachexia has degrees of severity, even within the distinct phases of the syndrome. In order to better quantify
the severity of cachexia, scoring systems or reproducible cut-off values below which survival time is impacted
upon are required. One technique to stage the severity of existing cachexia is the use of body composition
analysis to quantify skeletal muscle index.
1.1.7 Clinical Utility of Phase and Staging Criteria
Both the phase and the stage of cachexia can and should be used to identify and stratify patients for inclusion
in randomised controlled trials (RCTs). The clinical priority at this juncture will be to identify patients with
pre-cachexia in order to institute prophylactic interventions, thus avoiding the recruitment of patients with
refractory cachexia and a significantly reduced lifespan. Previous trials in cancer cachexia have been plagued
by patient attrition rates as high as 50% and in the future, to extract meaningful results, this situation must
be avoided [24].
1.1.8 Recent Intervention Trials in Cachexia
The last few years have seen the published results of five phase 3 randomised, double blind placebo-controlled
trials in patients with stage 3 or 4 non-small cell lung cancer (NSCLC). In the ROMANA 1 and 2 trials,
anamorelin, an oral ghrelin receptor agonist (Helsinn) was able to increase LBM over a 12-week treatment
period, but not the co-primary endpoint of handgrip strength (HGS) [25]. The results of the ROMANA
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3 extension study (a further 12 weeks of treatment for those patients with a preserved Eastern Co-operative
Oncology Group (ECOG) performance status (PS) 2 or less) confirmed drug safety/tolerability and maintenance
of weight/symptom improvement, but once again did not demonstrate an improvement in HGS compared with
placebo [26]. In comparison, in the POWER 1 and 2 studies, treatment with enobosarm, a non-steroidal
selective androgen receptor modulator (SARM) (GTx), was associated with an increase in LBM, but not the
functional co-primary endpoint of >10% improvement in stair climb power after 84 days [27]. These studies
support the hypothesis that both ghrelin analogues and SARMs may be beneficial for the amelioration of
cancer cachexia, but they also highlight the current difficulties in clinical trial design. Future trials must give
consideration to: inclusion criteria, by avoiding the recruitment of refractory patients but ensuring consistency in
the identification of patients early in the disease continuum (ROMANA 1/2 required patients to be weight-losing
or underweight, whereas POWER 1/2 did not); treatment protocols, including drug dosage and the adoption of
multimodal interventions (the MENAC trial incorporating exercise, nutrition and anti-inflammatory medication
is currently recruiting and aims to establish a standard of care for cachectic patients, ClinicalTrials.gov
Identifier NCT02330926); and outcome measures/biomarker of therapeutic response, particularly with regards
to functional improvement.
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1.2 Pathophysiology Underlying Cachexia
The ability of imaging to assess presence, phase, and stage of cachexia is useful. What is not assessed by
imaging, however, are the underlying processes which lead from a previously healthy patient to a cachectic
patient. There are multiple proposed mechanisms leading from health to cachexia, including alterations in
protein metabolism; alterations in adipose tissue metabolism; alterations in glucose metabolism; systemic
inflammation (SI); and neurochemical effects of biochemical mediators.
1.2.1 Systemic Inflammation
Previous studies have shown that SI is one of the chief drivers of skeletal muscle wasting in cancer cachexia
[28], and that SI can be used to predict outcomes in both operable [29] and non-operable [30] cancers. These
include colorectal [31,32] and soft-tissue [33] cancers, but similar effects were seen in a systematic review of
all cancer types [34]. SI and the hepatic acute phase protein response are major components of the early
metabolic response to surgery (‘the flow phase’) [35], a treatment that many cancer patients undergo. SI is
often evidenced by an elevated plasma C-reactive protein (CRP), and an elevated CRP together with a reduction
in plasma albumin levels can signify an expected poor prognosis. This relationship was found to be able to
predict outcome in a series of advanced lung cancer patients [36] and was termed the Glasgow Prognostic
Score (GPS). Subsequent work allowed expansion of this score to preoperative patients undergoing colorectal
resection [37,38], and further work has refined the score to its current form as the modified GPS. This ability
to predict outcome following tumour resection has been shown to hold true in differing global hemispheres, and
using different methods for measuring inflammation [39]. The repeated value of the prediction score underlines
the important nature of SI in cancer cachexia.
1.2.1.1 Effect of Systemic Inflammation on CT-BCA
In their study investigating the association between SI and CT-BCA variables, particularly SMI and SMD,
Dolan et al [40] used a cohort of 650 colorectal cancer patients undergoing resection to show this relationship.
Dolan et al used previously-published cut-points for both SMI [18] and for SMD [41] having assessed their
data and chosen the most suitable values. Dolan et al found that there was indeed a significant relationship
between CT-BCA and SI as measured by the modified Glasgow Prognostic Score (mGPS), in that those with
higher mGPS had lower SMI and SMD. It was not possible to investigate the magnitude of the relationship
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using this study design, but this aspect of CT-BCA and SI is one which should be analysed.
In order to ascertain the degree of influence of SI on CT-BCA variables, and with particular regard to the
muscle components of CT-BCA, it is important to construct a model with which to perform the investigation.
As mentioned above, the use of murine models in cachexia research is fraught with problems. These relate
to the relative volume of tumour burden when compared to animal size, to the rapidity of tumour growth,
and to tumour behaviour when induced. As such, it would be better to construct a human model of SI in
the presence of cancer and cancer cachexia where possible. Understandably, there are ethical concerns around
inducing severe SI in humans and particularly in humans with cancer and cancer cachexia.
On this background, using a human model requires that the condition under investigation be one which is known
to exhibit a degree of SI such as oesophageal cancer [42]. Additionally, to further add to the inflammatory
burden, including patients who had not only undergone operative resection but anastomotic leak would allow
assessment of changes in CT-BCA in the presence of severe and sudden SI over and above that induced by the
tumour. Anastomotic leak after Ivor-Lewis Oesophago-Gastrectomy (ILOG) has an incidence of around 11%
in some series [43]. Additionally, the nature of ILOG means that the surgical anastomosis is constructed within
the chest. As such, any inflammatory response arising from breakdown of this anastomosis and impacting
on CT-BCA is a reflection of SI rather than local inflammatory changes. Further, CT is often used in the
diagnosis and follow-up of such anastomotic leaks [44], meaning that there should be CT scans available from
multiple time-points, including at time of diagnosis of disease, at time of diagnosis of anastomotic leak, and
at time of follow-up. These factors make patients suffering anastomotic leak after ILOG an ideal population
in which to investigate the magnitude of effect of SI on CT-BCA; whether this effect would be visible over
a short time-frame; and whether any observed changes follow a pattern which could be explained by current
knowledge of SI.
1.2.2 Protein Metabolism
Previous studies on muscle protein synthesis and turnover have suggested that the presence of cancer
significantly reduces the rate of protein synthesis [45,46], resulting in low muscle mass. The effect of
feeding on rates of protein synthesis and breakdown were investigated using labelled amino-acids in a study
by van Dijk et al [47]. This study showed that in pancreatic cancer patients with cachexia, basal protein
turnover was elevated relative to healthy controls. Feeding appeared to improve the overall protein balance
in cachectic patients through the mechanism of reduced protein breakdown, whilst protein synthetic rate
9
remained unchanged. This contrasted with the healthy control group, in whom an equivalent relative increase
in post-prandial anabolism took place, but in whom both protein synthetic and breakdown rates were increased
in response to feeding. Thus, post-prandial anabolism was similar between cancer patients and controls
but differences in protein balance appeared to occur through different mechanisms: reduction in catabolism
in cancer patients, and an increase in both anabolism and catabolism in controls. Additionally, Deutz et
al [48] found that the amino-acid and protein content of food preparations administered and ingested was
important when considering muscle synthetic rates. Specifically formulated medical food with controlled
protein, leucine, carbohydrate, and fat content increased anabolic rates in cancer patients in contrast to
standard food preparations, suggesting a potential role for such supplements as part of a multi-modal cachexia
intervention. Measurement of protein synthetic rates in previous studies have potentially been subject to
confounding factors inherent in the isotope labelling process. For example, infusions of labelled amino-acids,
specifically leucine, may increase protein synthetic rates due to the sudden increase in the presence of these
amino-acids if using a flooding dose technique. This is less of a problem using primed constant infusion tracer
methods. However, in either technique, patients are frequently immobilised and fasted during the infusion and
measurement process. This does not represent normal functioning and thus may not reflect normal protein
metabolism. The main drawback to these measurements though is the short-term nature of the observation.
To counter this, MacDonald et al [49] designed a human protocol for a method of radio-isotope labelling with
heavy water to allow an analysis of protein synthetic rates over the course of 13 days, which more closely
reflects the natural conditions of muscle metabolism. Following this method, the same group investigated
the differences in myofibrillar protein synthesis rates between cancer patients and controls [50]. Perhaps
surprisingly, the study performed did not show the expected differences in synthetic rates between the cancer
and the control groups. Instead, they found a small but potentially important mismatch in protein synthetic
and breakdown rates in the cancer group. In comparison with controls, in whom the rates of synthesis
and breakdown were balanced, there was a 2.6% difference between synthesis and breakdown in the cancer
patients. This led the group to suggest that although the difference is small, it may be sufficient to account
for the previously noted reduction in muscle volume and protein content in pancreatic cancer patients. The
results of this study would suggest that the focus for therapeutic intervention in cancer cachexia should be on
the reduction of protein breakdown rather than the promotion of protein synthesis.
Another possible mechanism underlying muscle wasting relates to inter-organ nitrogen transfer. It has long
been known that catabolic states such as those found post-trauma can result in skeletal muscle protein
breakdown to aid transfer of nitrogen to the abdominal organs including the liver [51,52]. This increased
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nitrogen availability may in part be explained by an increase in liver protein synthetic rate [53], which includes
the production of cytokines and other pro-inflammatory mediators [54]. The alteration of skeletal muscle
protein turnover homeostasis, with a move towards reduced synthesis and maintained breakdown rates [55,56],
may result in a reduction in skeletal muscle mass which may in part be explained by these mechanisms coupled
with a noted increased inflammatory state seen in cancer patients [57,58]. Accordingly, investigations querying
the relationship between muscle protein content and SI may yield insights into clinically-relevant biochemical
findings.
1.2.2.1 The Assessment of Muscle Protein Content
An assumption underpinning CT-BCA in cachexia quantification is that there is a relationship between CT
variables and muscle constituents. There have been studies looking at the physiological basis behind SMD and
muscle fat content [59], and work has been done to ascertain the effect of contrast media on CT-BCA variables
[60,61], again underpinning the proposed relationship between CT-BCA and muscle components. Whilst there
are multiple component parts of skeletal muscle, one part which is possible to test for is that of protein.
The protein content of human muscle in ”reference man” was derived from experiments measuring total body
nitrogen [62]. These experiments were performed in the 1950s, and used 3 samples measuring 0.5-2.0g of
skeletal muscle from 4 males killed in ”street accidents“. These males were aged 21, 27, 40, and 43 years old,
but the authors do not describe any anthropometric data or underlying conditions associated with these victims,
and do not mention the presence or otherwise of malignancy or other wasting diseases. The conversion from
tissue nitrogen (in g/kg) to weight of protein was calculated using a multiplication factor of 6.25 as described
by Janney [63]. In the article quoted however, Janney describes how the factor of 6.25 is derived from an
assumption that 16% of muscle protein is nitrogen. Janney also describes an increased percentage of muscle
protein due to nitrogen in ”higher animals” of up to 16.7%. Nevertheless, this technique underpins the muscle
protein content quoted in “standard” reference tables [64].
Accordingly, the protein content of skeletal muscle in healthy, non-deceased individuals as assessed by modern
analytical techniques is unknown. Whilst clearly a whole-body nitrogen measurement may more accurately
delineate muscle protein content than a copper reduction technique, it is unlikely in the modern era to find
healthy, deceased subjects who have been adequately phenotyped (outwith a capital punishment regime) and
the ethics of utilising such samples in the numbers required to reduce the chance of error are questionable.
The assessment and classification of cachexia is important for patient prognostication and treatment guidance.
Modern cross-sectional imaging techniques, combined with software planimetry, have been proposed as one
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method for the assessment of skeletal muscle and fat volume in cachectic patients. In this technique, the
anatomical limits of different tissue areas are defined by radio-density. measured in HU. Lean mass (LM) and
total fat mass can then be predicted by calculating skeletal muscle and fat areas at the level of the third lumbar
vertebra (L3), and extrapolating these values to the whole body by using validated regression equations [17].
Increased fat infiltration of skeletal muscle (myosteatosis) results in lower SMD on CT [59]. Low SMI [18],
as assessed by CT, has been shown to be associated with poor prognosis in a wide range of solid epithelial
malignancies. Moreover, reduced SMD is also thought to be an independent predictor of adverse outcome
in respiratory and GI cancer patients [65]. However, it is not known whether reduced SMD may also reflect
variation in skeletal muscle protein content. The relationship between skeletal muscle protein content and
clinical phenotyping has been investigated by Johns et al [66]. In this study, the rectus abdominis muscle
biopsies of upper GI cancer patients were assessed for protein content against a number of clinical cachexia
phenotypes (I - WL >5%; II - WL >10%; III - Low muscularity on CT without WL; IV - Low muscularity AND
>2% WL). The investigators found a significant difference in muscle protein content in those in classes I and
IV of their cachexia definitions compared to those who were not. The assumed association between WL and
muscle protein content serves to underpin a relationship between biochemistry and clinical phenotyping.
1.2.2.2 Skeletal Muscle Fibre Cross-Sectional Area
Human muscle is composed of multiple fibres which can be classified according to their speed of contraction
- giving FTIIa (fast) and Non-FTIIa (slow) fibre types. The component parts of the fibres - in particular the
Myosin Heavy Chain (MyHC) - have been shown to be universally affected by cancer cachexia irrespective
of type of MyHC [67]. Additionally, it was noted in a paper by Johns et al [66] that differences in CSA of
muscle fibre types could be elicited in cancer patients depending on the clinical classification used to determine
“cachexia” or ”no cachexia”. The researchers found that a combination of WL and CT-BCA variables was
of most utility in defining the patient phenotype with greatest change in muscle fibre CSA. The importance
of this finding is that it illustrates the combined utility of both clinical and imaging-based measures to define
cachexia, and shows the need to combine these for a fuller understanding of the underlying changes seen in
human muscle.
In addition, changes in SMD have been shown to be of prognostic import in cancer and cancer cachexia [18,68].
There have been investigations into the components of skeletal muscle which contribute to radio-density [59].
This review notes reduction in muscle attenuation with advanced disease, with obesity, with age, and with
degenerative conditions. Although Stephens et al [69] showed an increase in intramyocellular lipid droplets in
12
cancer patients, there have been few other studies investigating individual muscle components.
What is also worth considering is the contribution of the cell wall to the radio-density of tissue. Although the
contents of individual cells contribute a greater volume per cell than the cell wall, it may be that an increased
number of smaller cells, as demonstrated by Johns et al, could serve to increase the tissue radio-density by
having a proportionally greater mass of cell wall.
Accordingly an investigation into muscle CSA, which will include a measure of cell wall, should help to answer
whether there is a strong relationship between SMD and this neglected component of skeletal muscle.
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1.2.3 Mediators of Cachexia
Moving on from underlying pathophysiological mechanisms leading to cachexia, it is worth considering
mediators leading to these processes. Multiple possible mediators of cachexia have been proposed, falling into
the general categories of:
• Neuro-endocrine stress response
• Tumour products
Investigation of mediators within these categories using animal models, however, is subject to problems. Each
animal model appears to have a different predominant mediator, meaning that generalisability is reduced.
Large-scale human studies are lacking, and with incomplete crossover from animal models to humans, this
is a hindrance to progress in the field. Additionally, (and as seen in studies of sepsis), the complexity and
redundancy of mediator cascades have precluded cause and effect intervention studies.
SI has been shown to be involved in the cachexia process [28], as discussed above. Indeed, there have
been multiple studies investigating the effect of elevated concentrations of acute phase response proteins on
cachexia and patient survival [70,71], each demonstrating a relationship between SI and worsening cachexia
with associated decrease in patient survival. Cytokines involved in SI have been found to be elevated in cachexia
[72], and these include interleukin (IL)-1, IL-2, IL-6 and IL-8, as well as tumour necrosis factor (TNF)-alpha and
interferon-gamma [72]. Additionally, the Ubiquitin/Proteasome pathway has been investigated as a mediator
of cachexia due to its effect on protein degradation within skeletal muscle [54]. These molecules have become
accepted as mediators of cachexia, and some newly-described potential mediators are discussed below.
1.2.3.1 Parathyroid-Hormone-related Protein (PTHrP)
The role of Parathyroid-Hormone (PTH) and Parathyroid-Hormone-related protein (PTHrP) in cachexia was
described by Kir et al [73] in 2014. In this paper, the team investigated the role of excessive thermogenesis
and the browning of adipose tissue in cancer cachexia in a Lewis Lung Cancer (LLC) murine model. Using
a combination of cell culture and knockout methods, the group could show that inhibition of PTHrP in
tumour-bearing mice markedly reduced the degree of muscle atrophy and fat browning in these mice compared
to controls. Interestingly, whilst the injection of PTHrP into previously naïve tumour-bearing mice resulted
in significant muscle atrophy, the injection of the protein into healthy mice did not. This led the team to
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conclude that whilst PTHrP has a role to play in the excessive thermogenesis and muscle atrophy of cancer
cachexia in the LLC model, it must act with a co-factor as yet undetermined. The study also found a reduction
in LM in human cancer patients with increased PTHrP. This observation was unrelated to caloric intake or
to SI as measured by serum CRP concentrations. These results agree with previous work on human cancer
patients [74], and the possibility of a co-factor requirement for cachexia development may explain why patients
with primary hyperparathyroidism do not develop muscle wasting. Following on from this initial study, the
group then investigated the effect of Parathyroid-Hormone Receptor (PTHR) presence or absence in knockout
mice undergoing 5/6 nephrectomy to simulate renal failure-associated cachexia [75]. They demonstrated that
removal of PTHR from the adipose cells greatly reduced not only browning of the fat, but also the rate of
muscle loss in these mice, despite being unable to fully deplete the receptor from the skeletal muscle. In
further studies using the LLC model, the group similarly could demonstrate an apparent protection from the
development of cachexia in mice whose adipose tissue was depleted of PTHR. It remains to be seen the degree
to which fat-muscle crosstalk affects the phenomenon demonstrated by PTH but with the encouraging murine
experience with anti-PTH antibodies [73] this may yet represent a possible therapeutic avenue to be explored.
1.2.3.2 TNF-related Weak Inducer of Apoptosis (TWEAK)
The discovery of TNF-related weak inducer of apoptosis (TWEAK) by Chicheportiche et al [76], and subsequent
work by Dogra et al in 2007 of the effects of TWEAK on skeletal muscle [77], has prompted ongoing
investigation into the precise role of TWEAK on muscle wasting. Discovery of a TWEAK receptor [78]
and up-regulation of TWEAK in both murine and human hepatocellular carcinoma [79] has led to increasing
interest in the role of the TWEAK-Fibroblast growth factor-inducible 14 (Fn14) axis in human cancer and
cachexia [80]. Studying healthy individuals, Raue et al [81] investigated the induction of both TWEAK and
Fn14 in human skeletal muscle following either resistance or running exercise. Taking serial muscle biopsies,
the team measured TWEAK protein and mRNA levels and found them to be elevated in the recovery period
following exercise. Interestingly, there was a rise in Fn14 mRNA and protein induction suggesting that, whilst
the presence of TWEAK within skeletal muscle is involved in metabolism and turnover, the induction of its
receptor Fn14 has more of an effect on skeletal muscle metabolism and turnover in the post-exercise period.
Using cultured myotubes, Bhatnagar et al [82] investigated the effect of TWEAK on cell atrophy. They found
that the addition of TWEAK to the cell cultures resulted in increased expression of factors previously found to
be involved in muscle wasting, such as MuRF1, and Beclin 1. To confirm the action of TWEAK, the team used
an autophagy inhibitor prior to TWEAK incubation and found reduced levels of autophagy. The group found
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activation of both caspases and NF-KB in response to TWEAK incubation, which led to their speculation that
TWEAK induces autophagy through a number of possible pathways. An interesting discovery of the effect of
anti-Fn14 antibodies on tumour-bearing mice has additionally made the field slightly more complicated [83].
Using murine models to test the effects of anti-Fn14 antibodies on Fn14-bearing tumours, Johnston et al
noticed a reduction in the rate and severity of cachexia exhibited by these mice. Using knockout mice for
both TWEAK and Fn14, the investigators found that administration of anti-TWEAK antibodies did not have
the same reduction in the rate and severity of cachexia development, leading them to conclude that it is the
expression of Fn14, rather than the secretion of TWEAK, which is more important in cachexia. These findings
in both healthy humans and murine cancer models suggests that there is a close relationship between TWEAK
and Fn14, and that Fn14 may be of increased relevance in skeletal muscle metabolism.
1.2.3.3 Angiotensin II (Ang-II)
In their investigation of the effects of Angiotensin II (Ang-II) on insulin-like growth factor, Brinks et al noted
a marked loss of weight in rats infused with Ang-II and that this effect was reduced in rats given losartan
[84]. In humans, reduced WL in cardiac cachexia was also noted in a heart failure group given enalapril
[85]. Following this, the research group including Tisdale et al undertook multiple studies of the effects of
angiotensin-converting-enzyme inhibitors (ACE-i), showing both reduced protein synthesis [86] and increased
protein catabolism [87] in murine myotubes. In their review of the effects of Ang-II, Yoshida et al [88] discussed
the effects of the hormone initially in the context of cachexia associated with congestive heart failure (CHF) and
chronic kidney disease (CKD). It was noted within these populations that there were high levels of circulating
Ang-II, and that those patients taking angiotensin-converting-enzyme inhibitors (ACE-i) did not lose as much
weight as others in the group. Extrapolation from this non-cancer group encouraged investigation in a mouse
model, again suggesting that Ang-II has a role in the propagation of SI and the promotion of the cachectic
state. Following on from this, work recently done by Penafuerte et al [89] has used an innovative casual
network analysis technique (CAN) to identify molecules likely to be acting as mediators or regulators of the
cachectic process. This involves the assessment of multiple cytokines in plasma, as well as their upstream
regulators, and the mRNA segments related to these. The CAN techniques allow a modelling of complex,
multi-faceted systems of interacting mediators to be reduced to more readily understandable schematics based
on probabilities of association. This analysis gave Ang-II as a master upstream regulator of cachexia, and
specifically pre-cachexia (where patients have not yet deteriorated sufficiently to meet previously-published
cut-offs associated with worsened survival [18]). This prediction was validated in the patient cohort by showing
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a negative correlation between Ang-II levels and survival. At the genetic level, Johns et al [90] investigated
a cohort of cancer patients, looking at single nucleotide polymorphisms (SNPs). Comparing patients with
>2% WL and low SMI with weight-stable patients, there were significant correlations between SNPs coding
for angiotensin converting enzyme (ACE) and cachexia. Penafuerte et al [89] hypothesised that Ang-II is
among the major molecular mechanisms driving cancer cachexia, and it is to be hoped that this may provide
another possible therapeutic avenue for a commonly used medication in the form of the ACE-inhibitor. Whilst
not specifically a study of cancer cachexia, a retrospective observational study observed that patients taking
enalapril for heart failure were at lower risk of WL and demonstrated associated improved survival [91]. These
results would seem to support related hypotheses regarding the potential clinical benefit of ACE-i. Although
incompletely understood, the role of ACE and Ang-II in the molecular mechanism of cancer cachexia remains
relevant and an exciting possible target for intervention.
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1.3 Imaging in Body Composition Analysis
Within both the international consensus definition of cachexia [12] and the European Working Group on
Sarcopenia in Older People (EWGSOP) statement on age-related sarcopenia [92] are defined cut-offs below
which the patient is considered to have low muscularity. These cut-off values were determined by population
studies using two standard deviations below the mean of young healthy males and females to define those with
sarcopenia [7]. These cut-offs are expressed in terms familiar to the users of DEXA. In choosing cross-sectional
techniques to use for body composition analysis it is important to recognise not only the clinical advantages
inherent in each modality, but also the limitations posed by differing techniques [93], as well as the background
behind the use of the most common modality: CT.
1.3.1 History of CT in Body Composition Analysis
The original definition of Sarcopenia was made by Baumgartner et al [7] who defined this condition as having
a skeletal muscle appendicular mass lower than 2 standard deviations from the mean of a healthy volunteer
cohort. This definition was based on the DEXA findings of some 132 Caucasian males and females with mean
ages 46 and 41.5 respectively as described by Gallagher et al [94]. It is interesting to note that the populations
described in each of these studies vary in number, and the method of reporting age in the paper by Gallagher
et al is of mean and standard deviation rather than mean and range. Accordingly, although Baumgartner et
al report the age and ethnicity of their participants to be between 18 and 40 years and non-Hispanic white,
the article detailing the cohort (Gallagher et al) details a wider age range in fewer subjects. This disparity is
perhaps slightly concerning but may be the result of ongoing recruitment and sample selection. In any case,
the analysis by Baumgartner et al provided the foundation for research into muscle wasting using radiological
techniques.
As the importance of SMI became increasingly relevant to the field of cancer cachexia, and with the increasing
clinical use of CT in diagnostic and prognostic assessment of cancer patients, Mourtzakis et al used 31 lung
and colorectal cancer patients who had undergone both DEXA and CT to develop an equation whereby CT
muscle area (SMA) values and indices (SMI) and DEXA appendicular muscle mass values could be compared
[17]. This allowed routinely-performed clinical CT scans to be re-analysed for prognostication and opened the
field to those who did not have access to DEXA as part of standard clinical practice. The equation, and the
cut-points it produced, were then validated in a larger cohort of cancer patients [17]. The cut-point derived
was one below which the patients appeared to have a shorter life expectancy, and seemed to show there was
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an important physiological link between SMI and survival.
As briefly touched on above, the values obtained from CT scan interpretation were those of SMA. These values
were derived from a single CT slice at the L3 level and are measured in cm2. As seen in routine clinical practice,
patients exhibit differing body habitus phenotypes, and thus there is a need to define a characteristic against
which to normalise this SMA measure. In a similar fashion to that used to calculate BMI, the patient’s height
is measured in metres and then squared. SMA is then divided by the resulting figure to give a measurement
in cm2/m2 - the SMI. This figure can then be used to generate inter-individual analyses, having removed a
source of confounding.
Following on from the work by Mourtzakis et al, Martin et al recognised the importance of obesity in the
assessment of SMI [18]. Specifically, in order to carry an increased body mass, there must be an increased
muscle mass compared to a non-obese individual of similar height. This is analogous to weight-lifters (obese,
carrying more weight) having greater muscle mass than non-weight-lifters (non-obese, carrying less weight).
Nevertheless, this increased muscle mass does not necessarily represent a trend towards “normality”, rather the
obese individual may still have a relative paucity of skeletal muscle and still be “sarcopenic” despite having a
muscle mass greater than the cut-points previously described. Accordingly, and using a cohort of 1,732 lung
and colorectal cancer patients, Martin et al produced cut-points which were both sex-specific and BMI specific
[18]. In addition, the authors used the other information available through CT body composition analysis to
produce further physiologically reasonable cut-points. Specifically, Martin et al investigated SMD as imaged
by CT.
The radio-opacity or radio-density of items when scanned by CT is calculated according to a specific formula
devised by Dr Hounsfield [95], and these values have as their reference points both air and water. When
scanning human subjects, particular body tissues will produce distinct values measured in Hounsfield Units
(HU). On this scale, the radiodensity of water is zero HU, whilst the radiodensity of air is -1000 HU. In theory,
an increase in muscle protein should thus result in a measurable and strong correlation with changes in muscle
radio-density (SMD). This theory is investigated and in greater depth in Chapter 7.
Unrelated to muscle cell protein content directly, the findings of Martin et al relating low SMD to poor
outcome in the lung and colorectal cancer cohort discussed above sparked wider interest. Having noted this
effect of SMD on outcome, Rollins et al [68] investigated this further in a cohort of palliative pancreatic
cancer patients, finding that low SMD was significantly associated with worsened outcome in this group. In
order to ensure these results were not confounded by alterations in CT scan contrast phase, the Rollins et al
also investigated whether there was a significant difference in muscle radio-density depending on scan phase.
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Utilising routine clinical investigations, they were able to compare multiple CT scan phases and found that
although statistically significant differences between the phases under investigation existed, it was possible to
use specific mathematical equations to convert radiodensity from one phase to another [60]. This work was
highly useful in demonstrating the comparability of multiple CT scan phases, allowing diverse patient groups
to be investigated and stratified equally.
1.3.1.1 Importance of BMI Characteristics in CT Body Composition Analysis (CT-BCA)
Within the UK, and across the world, the national and international trend is one of an increasing prevalence
of obesity [96]. Given this demographic, which has changed even in the short time since Baumgartner et al
produced their original findings, it is reasonable to split populations not only by sex, but also to include a
measure of whether these individuals are overweight. The paper by Martin et al [18] investigated this trend,
and produced sex- and BMI-specific cut-points for prognostication in their cohort. They found that in males,
there was a difference between low BMI (<25) and high BMI males in terms of their SMI cut-points; but not
in females, for whom a single cut-point alone gave prognostic value. These cut-points reflected the observed
higher SMI in males, and also the observed higher SMI in obese males. It is currently unclear why females
should not display the same weight-related differences.
1.3.1.2 Importance of SMI in CT-CBA
As mentioned above the original BCA variable was appendicular muscle mass, which was indexed to height, and
was also measured using CT to give CT-BCA. There have been multiple studies investigating the relationship
of SMI to outcome in cancers of all types. Carrara et al [97] recently found low SMI relating to tumour stage
in pancreatic cancer, while Villasenor et al [98] encountered a similar finding in breast cancer. This study used
a longitudinal analysis over 10 years and concluded that those who demonstrated sarcopenia on preoperative
DEXA retained a poorer prognosis even to the end of the follow-up period. Although utilising a less validated
technique (psoas area) at a less validated level (L4 vs L3), nevertheless a relationship between low muscle mass
and operative complication rate was found. Also using psoas area, Sabel et al [99] found a similar relationship
in Stage III melanoma patients, with SMI being an independent predictor of worse survival. Indeed, this impact
of low SMI has been seen in older patients with cancer [100]; in hepatocellular cancer [101]; in metastatic
colorectal cancer [102]; and in B-cell lymphoma [103]. Low SMI has also been implicated in increased operative
complication rates in squamous oesophageal cancer [104], and in an increased cardiovascular risk profile in
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Korean male surviving cancer patients [105]. These studies, although utilising a variety of methods to assess
muscularity, do all point to a significant impact of muscularity on survival.
1.3.1.3 Importance of SMD and Contrast Phase in CT-BCA
An alternative way to assess muscle nutritional response to pharmacological intervention using CT would be to
assess muscle “quality” rather than “quantity”, by measuring the radio-density of skeletal muscle in Hounsfield
Units. The effect of low SMD on outcome has been noted in several diseases. In pancreatitis, Grinsven et
al found a decrease in muscle radio-density during the course of the disease resulted in poorer survival [106].
Similar findings were noted in pancreatic cancer by van Dijk et al [107] where in a prospective study involving
199 patients with head of pancreas cancer, medium or low muscle radio-density was associated with worsened
survival. Poorer survival was also noted in patients with endometrial cancer studied by Paula et al [108], and
in palliative pancreatic cancer studied by Rollins et al [68]. In these cohorts, the combination of low muscle
index with low SMD appeared to worsen outcome. In the latter study, previously published muscle index and
density cut-points [18] were used to stratify patients into sarcopenic/normal and myosteatotic/normal. Both
sarcopenia and myosteatosis carried poorer prognosis, but in combination these factors were synergistic in their
survival reduction. However, there is some preliminary evidence that SMD may correlate more closely with
physical function (PF) in elderly cancer patients compared with SMI [109]. The inference, in line with the
observations of Martin et al [18], is that low SMD is the result of altered muscle composition at a cellular level,
and that protein is replaced by intramuscular fat. However, once again, this assumption may not represent the
entire picture. This is discussed in greater depth in Chapter 7.
Similar to SMI, it seems that radio-density cut-points also require specific development for each population
under study. Studies performed by differing centres have found differing radio-density cut-points apply to
their cohorts [107,110], and a recent review noted similar findings [111] throughout the literature. Increasing
interest in muscle radio-density has led to concerns regarding the effect of intravenous CT contrast media on
body composition variables derived from scans performed in different phases. Earlier authors did not disclose
which CT scan phases were used in their manuscripts [17,18]. However, work carried by van Vuht et al [61]
investigated 50 liver transplant patients undergoing triple-phase CT scans and found statistically and clinically
significant differences in SMD between non-contrast and contrast-enhanced scan phases, but not in muscle area.
Applying the Martin et al [18] criteria to these values, resulted in 80% having low SMD in unenhanced scan
phases whilst 50% and 38% had low SMD in arterial and portal venous phases respectively. The findings from
Rollins et al [60] in a population of pancreatic cancer patients was that there was a statistically significant
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difference between contrast phases on CT, however there was a linear relationship between these phases
which could be translated via simple equations to provide comparable values. In more closely defining the
relationship between contrast phase, these authors have moved the literature forward to allow abdominal
CT scans performed for any clinical indication to be compared. However, such phase-dependent values will
obviously impact on any statistical relationship with PF outcome measures. This problem can be compounded
further by other CT technique-dependent variables such as tube potential [112]. Authors are now turning to
complex non-linear trimodal regression analysis techniques of entire radiodensitometric muscle distributions to
compare with standard CT metrics and lower limb muscle function [113].
1.3.1.4 Controversies in CT-derived Sarcopenia
Concern has been raised, however, in the use of CT scanning for this purpose with specific regard to the
EWGSOP definition of sarcopenia. This definition includes a requirement for the quantification of muscle
function as well as volume. Safer and Safer have repeatedly questioned the use of CT planimetry alone to assess
sarcopenia, stating the requirement in the EWGSOP statement to include muscle function assessment[114].
Other issues raised by Safer and Safer, and Cintosun et al, include the specific lumbar levels used for analysis,
comparison with other imaging modalities, and differences between scanners as possible confounders [115,116].
In response to these questions, the authors of the articles criticised acknowledge the absence of muscle function
assessment but draw attention to pragmatic reasons for this: the pathophysiological differences between
sarcopenia and cachexia; the large studies validating CT as an imaging modality; and the standardisation
of modern CT scanners [117–120]. In addition, the specific impact of low muscle volume on prognosis
and morbidity [18], as well as the recent review confirming this phenomenon across the reported literature
[111], support the use of CT-derived cut-offs as markers for increased morbidity and mortality in cancer
patients. However, equally, it should be remembered that low muscle volume is a binary measure that does
not acknowledge the dynamic process of skeletal muscle wasting. Furthermore, CT-derived sarcopenia may not
equate with muscle protein content (as discussed in Chapter 7), therefore raising questions as to its utility as an
outcome measure in interventional trials. In a recent editorial and linked paper, Baracos [121] and Rutten et al
[122] argue that a recent trend for utilising psoas major alone for assessment of skeletal muscle in the context of
sarcopenia has significant limitations. Specifically, the relationship of psoas area to whole body muscle volume
was unclear, as was the relationship of psoas area to overall survival. Additionally, the cut-points derived by
Martin et al [18] were from a Canadian cohort which from the Alberta census consists of a 70% European
origin population [123]. It is known that for DEXA scanning, cut-points for defining sarcopenia are different
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in European populations and Asian populations. Specifically, the EWGSOP [124] defines low muscle index in
European females below 5.5 kg/m2, whereas in a Korean population Kwon et al [125] found the cut-point to
be 4.4 kg/m2. Similarly for CT derived variables, Fujiwara et al [126] found different cut-points in a Japanese
cohort to those developed in the Canadian group. It therefore seems that population-specific cut-points for
SMI need to be derived in any trial population before assessing muscle function. Some studies have shown that
it is sarcopenic obesity that carries the worst clinical risk [127], whereas more recently, the negative prognostic
impact of subcutaneous fat [128,129] has been demonstrated.
1.3.1.5 Adipose Tissue in CT Imaging
Other variables obtained from CT analysis include the area and radio-density of visceral and subcutaneous
adipose tissue (VAT and SAT). These have garnered attention as potential predictors of survival in cancer
patients [128]. In their study, Ebadi et al investigated the relationship between visceral and subcutaneous
adiposity and the effect of these on survival in sarcopenic and non-sarcopenic cancer patients; reporting a
significant relationship between low subcutaneous adiposity and worse survival after adjustment for known
survival predictors. Although interesting, the majority of these patients had stage IV disease, and the utility of
VAT and SAT values and cut-points for clinical decision-making requires further study.
1.3.2 Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) is an increasingly attractive form of cross-sectional imaging, and is now
considered equivalent to CT as the gold standard imaging methodology for skeletal muscle volume analysis
[12,92,130]. MRI scanning has been used in sports medicine [131] and in muscular dystrophy [132] to monitor
the effect of injury or disease progression on the volume of scanned muscle. Recent advances in automation have
shown this technique to be feasible in a whole-body context, allowing the definition and direct measurement
of total skeletal muscle volume within a patient [133]. In contrast to CT scanning, which uses a single slice
and algorithmic conversion to a height-based index [18], direct measurement using MRI has clear advantages.
Firstly, the entire volume of scanned muscle is measured directly rather than inferred or calculated. Secondly,
there is no need for ionising radiation. Thirdly, it should be possible to use MRI to determine water and fat levels
within a particular muscle, as myosteatosis has been shown to have an adverse prognostic effect on patients
with pancreatic, gastric, and lung cancer, as well as non-cancer inflammatory conditions [68,69,134–136].
Disadvantages to MRI scanning do exist, however, and include the labour-intensive nature of interpreting each
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scan; the cost in terms of the scanner and the staff required to run the scans; and the demand on patients – each
scan takes 20-60 mins in a claustrophobic scanner environment with strict requirement for exact repositioning
for reproducibility. Additionally, CT scanning is routinely used in clinical cancer practice in contrast to MRI,
and so additional scaning is not required for CT-BCA analysis unlike MRI.
Overall, the field of contemporary body composition analysis is highlighting the the importance of low SMI
as an independent adverse risk factor in cancer patient survival. As sarcopenia definitions continue to require
measures of muscle function, it may be time to separate the syndrome of sarcopenia from isolated low muscle
volume, and rename the latter condition myopenia [137].
1.3.3 Assessment of Physical Function (PF) Outcome Measures
The identity of the best PF outcome measure to relate nutritional outcome measures, including CT, is unknown.
There is a lack of PF tests that specifically analyse upper abdominal/L3 muscle activity. Equally, it is an
unproven assumption that L3-CT should, in some way, correlate with either targeted assessments of isolated
limb strength and power, or complex whole-body assessments of PF (e.g. Timed-Up and Go-Test (TUG)) [138].
This is further investigated in Chapter 6. Some have previously advocated physical activity meters as devices
to measure global patient function in the free-living environment [139,140]. The advantage of such devices is
that they offer multiple outcome measures from a single application. However, once again, for the purposes of
clinical trial design, a single outcome measure is required to be pre-chosen as co-primary endpoint. HGS has
been used widely in nutritional studies in this role, and has been validated in various populations [141,142].
However, as described previously, it was unsuccessful in the ROMANA studies. From a clinical perspective,
it might seem that measures of upper limb PF might be less meaningful or less affected by pharmacological
intervention when compared with measures of lower limb PF, which in turn might dictate activities of daily
living and overall exercise limitation. However, stair climb power was unchanged in the POWER studies.
Despite these negative findings, and with no clear relationship between SMI or SMD and PF, studies continue
to report CT-BCA findings relating to poor patient outcome, as mentioned above. Thus, there is a need
to understand which PF test relates best to CT-BCA; which PF test relates best to outcome; and whether
CT-BCA with or without PF testing can be shown to relate to muscle biochemistry as a means of explaining
the outcomes observed.
Another aspect of PF measures, and as mentioned above in relation to CT-BCA, is the normalisation of such
measures. As described above, CT-BCA SMI is calculated by taking the skeletal muscle area of the L3 CT
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slice and indexing it for height by dividing the area measured by patient height in metres, squared. When
considering PF, however, the measures reported above are commonly presented either as raw values (in the
case of the timed up-and-go (TUG) test) or having been assessed alongside other measures and combined into
a single score which is sub-divided to give a series of categories (such as the Edmonton Frail Scale - dividing
patients into Not Frail, Pre-Frail, and Frail)[143].
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1.4 CT and Patient Status
As described above, cachexia has been defined by international consensus as “a multifactorial syndrome
characterised by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot
be fully reversed by conventional nutritional support and leads to progressive functional impairment” [12]. The
clinical importance of the latter part of the definition is in the stress on ”progressive functional impairment”.
This can be measured objectively, by techniques such as those proposed by Cruz-Jentoft et al [92] in their
EWGSOP definition paper recommending HGS and gait speed analysis as measures of muscle function.
Additionally, patient assessment can include measures of QoL including patient-reported outcome measure
(PROM) tools to quantify aspects of health which may be affected by disease. These can include measures of
symptomatology, and of patient-reported functioning distinct from objective measurements.
1.4.1 What Is Function And Why Is It Important?
Patient PF can be described in terms of specific muscle function, such as that assessed by HGS or gait speed,
or in terms of a more global function, such as that assessed by Eastern Clinical Oncology Group (ECOG) score
[2]. Specific muscle function tests like HGS have the advantage of objectivity in their assessment, allowing
for cut-points to be produced and definitions to be written [92]. How well these tests translate into real-world
settings is unclear, however. Other tests investigating particular muscle groups, though more globally, include
the timed up-and go (TUG) test. This involves the patient rising from a seated position, walking 3m, turning,
and returning to their original seated position. It has shown good inter- and intra-observer reliability [144]. This
type of test is more pragmatic and easier to perform in a clinic setting with minimal equipment than a HGS test.
Additionally, if measured separately, the walking components can be used to measure gait speed [145] which is
one of the suggested definitions of sarcopenia in the EWGSOP statement. When investigating the function of
patients in a more global fashion, the ECOG score mentioned above allows the clinician to subset their patients
into groups depending on function as a whole, rather than as a measurement of a specific muscle set [4]. In this
paper, Oken et al suggest a scale of ability from 0 (fully active, able to carry out pre-disease activity without
restriction) to 5 (dead) allowing not only a comparison of patients between study centres, but also allowing
the clinician to monitor patient progress throughout their disease course (see Table 1.1). More recent work by
Blagden et al has suggested that ECOG scores assessed by patients agree with those assessed by oncologists in
the majority of cases [146], suggesting that both doctor-reported and patient-reported functional assessments
may have validity. In their study, Blagden et al also showed that in line with other previous studies, ECOG
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score did correlate with survival in a lung cancer population, whether patient-scored or oncologist-scored. This
being the case, the inclusion of patient-reported functional assessment in current and future studies has merit.
Additionally, work by Laird et al [147] has shown concordance between ECOG score and patient-reported
measures of PF as quantified in patient-reported questionnaires. These are discussed below. The inclusion of
both patient-reported function and patient-reported symptomatology should provide an increased ability for
the researcher to understand and interpret patient PF.
With the increasing age of the population, a concept coming increasingly to the fore is that of frailty [148].
In this position paper, Bergman et al discuss the concept of frailty as a specific syndrome and draw from
existing literature possible defining features of what could make a patient frail. They note that it is likely to
be impossible to clearly separate frailty from ageing, and also note that one component of frailty is that of
progressive muscle weakness. This is not dissimilar to concepts encountered in considering the effect of age on
sarcopenia, and it is reasonable to suggest that these factors interplay to cumulatively affect individual patients.
In their paper discussing the assessment of frailty in acute care, Hilmer et al [149] note that controversy exists
regarding the definitions of frailty. They argue that despite this, it is important to find some common features
which can be elicited by either clinicians or non-clinicians and which can be used to guide interventions and
produce a prognosis in the frail. To this end, the group investigated the Edmonton Frail Scale (EFS), which had
previously been developed and validated against a specialist assessment of frailty [143]. Hilmer et al produced
a reported scale (REFS) based on the EFS, though not requiring a TUG to be performed. This was validated
against a specialist assessment of frailty in a similar fashion to the validation of the EFS, and allows patients
to be classified into Not Frail, Apparently Vulnerable, Mild Frailty, Moderate Frailty, and Severe Frailty.
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Table 1.1: ECOG Score and Definitions
ECOG Score Definition
0 Fully active, able to carry on all pre-disease performance without
restriction
1 Restricted in physically strenuous activity but ambulatory and able to
carry out work of a light or sedentary nature, e.g., light house work,
office work
2 Ambulatory and capable of all selfcare but unable to carry out any work
activities; up and about more than 50% of waking hours
3 Capable of only limited selfcare; confined to bed or chair more than
50% of waking hours
4 Completely disabled; cannot carry on any selfcare; totally confined to
bed or chair
5 Dead
1.5 What Is Quality of Life (QoL) And How Is It Measured?
In his narrative review of QoL [150], Post explores the origins of the concept of ”Quality of Life” and how the
concept has become more central to healthcare since 1948. In it, Post quotes an editorial by Elkinton [151]
from which the following is taken:
”What every physician wants for every one of his patients old or young, is not just the absence of death but
life with a vibrant quality that we associate with a vigorous youth. This is nothing less than a humanistic
biology that is concerned, not with material mechanisms alone, but with the wholeness of human life, with the
spiritual quality of life that is unique to man. Just what constitutes this quality of life for a particular patient
and the therapeutic pathway to it often is extremely difficult to judge and must lie with the consciousness
of the physician.”
This early idea of the meaning of ”Quality of life” includes the suggestion that it is unique and individual to
each patient, and thus will have to be investigated and quantified on an individual basis to have true meaning.
This is clearly very different to such performance metrics as the ECOG score mentioned above, and will require
a different technique to elicit.
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1.5.1 Patient-Reported Outcome Measures
The technique used in evaluating QoL in patients is that of PROMs. As a method of driving clinical trials, this
has gained traction recently, and has resulted in the production of an addendum to the original CONSORT
statement [152] which includes guidelines on the inclusion of PROMs in trial design and reporting [153]. In it,
the authors recognise the increasing use of PROMs to “inform patient-centred care” and detail the points at
which the PROMs chosen should be justified and reported. The idea of using PROMs to inform patient-centred
care and of involving patients in the trials carried out to investigate their diseases signals a move away from
paternalistic approaches towards increased patient autonomy.
1.5.2 The Relationship Between QoL and CT
The relationship between between CT body composition variables and QoL has been investigated by Bye et al
[154] in a lung cancer population. They found non-linear relationships between some aspects of the QLQ-C30
and SMI, and that the SMI had to drop below specific “break-points” before a visible relationship was observed.
This suggests that there is not a true linear relationship between muscle index and PROM PF, or between
muscle SMD and PROM PF, in patients with advanced lung cancer. It is not clear from that particular
study, however, what the relationship between CT variables and QoL may be in a preoperative surgical upper
gastrointestinal cancer population, or in other populations.
To this end, the current study included the use of validated QoL questionnaires. The EORTC QLQ-C30 with
add-on module OG25 questionnaire [155] was chosen due to the main instigative focus of the current study being
on patients with upper GI cancer. The base QLQ-C30 contains questions regarding QoL which are applicable
to all populations under study, and to demonstrate differences between populations all were asked to complete
the OG25 module in addition. The second questionnaire used was the EuorQoL EQ5D-3L questionnaire [156]
which was chosen as a general and global QoL assessment tool. Both of these questionnaires have been
validated in European populations, and provide insight into global QoL as well as into specific symptomatic





The overall aim of this study was to assess CT-BCA in order to ascertain whether CT-BCA is accurate
in assessing a number of assumptions, and its potential validity for future use as an outcome measure in
interventional trials.
The study aimed to assess this in a staged fashion:
1. Assessing CT-BCA cut-points
• Applying published cut-points to recruited patients
• Deriving a new cut-point from recruited patients
• Comparing new and published cut-points
2. Assessing patient quality of life
• Comparing quality of life between patient groups
• Assessing the utility of CT-BCA cut-points to show differences in quality of life within patient groups
3. Assessing objective patient function
• Measuring patient function
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• Using linear regression to demonstrate a relationship between CT-BCA and function
• Assessing utility of CT-BCA in showing differences in function by CT-BCA cut-point
4. Assessing muscle protein content
• Comparing skeletal muscle protein content between patient groups using modern techniques
• Defining a relationship between CT-BCA and muscle protein content
• Utilising CT-BCA cut-points to show differences in protein content between groups
5. Assessing skeletal muscle fibre cross-sectional area
• Assessing the difference in cross-sectional area between patient groups
• Assessing the difference in cross-sectional area between CT-BCA cut-point groups
• Assessing the relationship between CT-BCA and cross-sectional area
6. Assessing the relationship between systemic inflammation and CT-BCA
• Defining a human model of severe systemic inflammation
• Assessing differences in CT-BCA before and after onset of severe inflammation





3.1 Recruitment of Patients
Patients were recruited to the study from 3 groups:
- An upper GI cancer (UGIC) group included patients with oesophageal, gastric, and pancreatic cancer.
These patients were chosen due to their high incidence of cachexia, and because their preoperative staging
investigations included abdominal CT scans. Resectional surgery included Ivor-Lewis Oesophago-Gastrectomy
(ILOG), thoraco-abdominal oesophago-gastrectomy, thoracoscopic oesophago-gastrectomy, laparoscopic-assisted
oesophago-gastrectomy, gastrectomy, and pancreatico-duodenectomy.
- A vascular aortic (AAA) group included patients who were undergoing aortic surgery for aneurysmal disease,
including both abdominal and thoracic. These patients were chosen for their expected age and co-morbidity
match with the UGIC group, and because their operative planning investigations included abdominal CT
scans. Operative surgery included tube, bifurcated, and multi-limb synthetic graft repair. Both thoracic and
abdominal aneurysm repair required exposure and incision of the rectus abdominis muscle.
- A healthy live donor nephrectomy (LDN) group who had completed the living donor workup and were
donating one of their kidneys. These patients were chosen as a selected healthy group with minimal disease,
and because their workup included abdominal CT scans. Nephrectomy was carried out either through a
single-incision laparoscopic surgical port or utilising a hand-assisted laparoscopic technique.
Patients in each group were identified independently by the clinical team overseeing their care.
Those in the UGIC group were identified at a weekly multidisciplinary team meeting (MDT) which reviewed
all patients referred with upper GI cancer and stratified them into those for resectional surgery and those not.
Once identified by the MDT, these patients were approached in clinic and recruited into the study in line with
the study protocol as approved by the local research ethics committee (REC).
Those in the AAA group were identified by the vascular team at the time of their admission the day before
their aortic surgery, and were approached and recruited as above.
Patients in the LDN group were identified by the transplant surgical team in advance of attendance at their
preoperative clinic, and approached at this clinic.
In line with guidance from the REC, all patients were provided with written information, and were allowed to
decline recruitment, or to withdraw from the study at any time.
To assess the effects of inflammation on CT-BCA, a database of patients undergoing ILOG between 2012 and
2016 was queried to find those who had suffered anastomotic breakdown. These patients had their CT scans
analysed as described below, and phenotyping data was garnered from their medical records.
34
3.2 Sample Size Calculation
This was an exploratory study investigating new relationships between CT-BCA and patient phenotype, and
thus a power calculation is difficult to perform a priori. In order to generate a potential sample size for ethics
validation the outcome of a previous study investigating dystrophin glycoprotein complex dysfunction [157] were
used. This study had shown statistically differences in dystrophin glycoprotein complex dysfunction between
cancer patients and healthy controls using a sample size of 27 and 14 respectively.
It was felt that aiming for an increase in sample size from 27 to 40 in each group would allow valid comparisons
to be made between each group, and accordingly a total sample size of 120 patients was set as a target in
agreement with the regional ethics committee.
3.3 Patient Phenotyping
Physical parameters including height, weight, and weight loss amount and duration were collected to allow
calculation of body mass index (BMI) and percent weight loss from normal. Patients were asked to complete
timed-up-and-go test [144], which was timed in segments to allow gait speed calculation [145]. In this test,
patients were asked to stand, walk to the end of a pre-measured 3m distance, turn, return to their seat and
sit down. Both walking laps were measured, and the gait speed calculated from these.
Patient past medical history was collected, as were lists of medications. From this, the Charlson Co-morbidity
Index (CCI) [158] and the Scottish Co-morbidity Scoring System (SCSS) [159]. Although in more common
use, CCI gives more weight to conditions now considered controllable (such as the human immunodeficiency
virus and the acquired imunne deficiency syndrome), whilst SCSS has been validated in a Scottish population
[160] and uses international criteria (such as the New York Heart Association Heart Failure Classification) to
stratify co-morbidities. Patients also completed the patient component of the patient-generated subjective
global assessment (PG-SGA) [22], and quality of life questionnaires. From the PG-SGA, a patient-reported
ECOG score was derived. Patients also completed the Edmonton Frail Scale (EFS) [143], and the reported
EFS (rEFS) [149]. At the time of surgery, American Society of Anaesthetists (ASA) score [161] was collected.
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3.4 Quality of Life (QoL) analysis
During their clinic visit, patients completed the EORTC-QLQ-C30+OG25 questionnaire [155] and the EQ5D-3L
questionnaire [156].
3.4.1 QLQ-C30
The QLQ-C30 from the EORTC group is a well-recognised, validated questionnaire covering QoL aspects
related to cancer patients. The base questionnaire is designed to be generic and captures many domains
common to all cancer patients. Additionally, the generic QoL aspects were felt to be useful for comparison
with the AAA and LDN groups to demonstrate expected differences according to disease state. The QLQ-C30
also has a modular component which allows tailoring to particular tumour types. Both the At the time of study
design the EORTC cachexia add-on for the QLQ-C30 was unavailable, and at present (2019) the questionnaire
is still undergoing validation. Accordingly, the OG25 additional component was chosen to cover both the
expected oesophageal and the gastric cancer patients. The inclusion of a specific vascular patient-reported
outcome measure (PROM) was not performed, as at the time of study design there was only one PROM of
that sort available [162] (the SF36 noted in Duncan et al [162] is a generic QoL tool) and the further addition
of questionnaires was felt to be a burden on the patients recruited.
The QLQ-C30+OG25 was analysed in keeping with the instructions [155], and scores were converted to
percentages according to weighting also in keeping with the reporting manual. This conversion was performed
using QoLR [163], a quality of life package for R statistical software. A difference in reported QoL of >10
points was felt to be clinically significant, as suggested by the QLQ-C30+OG25 instruction manual [155].
3.4.2 EQ5D-3L
The EQ5D-3L from the Euroqol group was also administered to patients in clinic prior to surgery. This is a
generic QoL PROM and allows patients to score 5 domains in 3 levels from best to worst. The final page
includes a 100-point scale for indicating overall QoL at time of administration. Analysis was conducted between
the overall QoL scales in each questionnaire as a continuous scale.
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3.4.3 Timing of Questionnaire Administration
With the data available, it was not possible to accurately ascertain what proportion of patients recruited
undertook a QoL assessment before, and what proportion after, any chemotherapeutic regime was undertaken.
Upon investigating further, however, it was possile to see a separation of dates between recruitment and
operation at around the 50 days mark. Taking this as a possible threshold, differences in symptomatology were
investigated to ascertain differences between scores over/under 50-days.
3.5 CT Body Composition Analysis (CT-BCA)
Preoperative staging CT scans were analysed at L3 level using semi-automated Slice-O-Matic software v4.2
(Tomovision Montreal-Canada), which defines whole-slice area and radio-density measurements of skeletal
muscle, subcutaneous fat, and visceral fat. This technique requires the investigator to select the L3 CT scan
slice. Following this, the software utilises HU values to tag areas of the scan image as muscle or other tissues.
The total area of the tagges muscle is the SMA (in cm2). This value is the divided by the square of the
patient’s height in metres to give SMI. Mean HU measurement is taken across the whole area tagged as
skeletal muscle across the entirety of the chosen slice. In practice, and as described by Heymsfield et al [164],
tissues between -29 and 150 HU were tagged as skeletal muscle by the software. Following this a manual
review of each slice was undertaken to ensure that extraneous tissue was not erroneously tagged (this review
gives the “semi-automated” nature of the analysis). It was then this area of tagged tissue which was used for
the measurements detailed above.
At the outset of the research project, training was undertaken in use of the software to ensure appropriate CT
scan slice level was chosen for analysis, that the software was being utilised correctly, and that measurements
obtained from the software were appropriate. This was performed over 20 CT scans, which were selected by
the trainer and then analysed by the trainee.
Skeletal muscle are measurement was indexed for height by dividing skeletal muscle area by the square of the
patient height in metres, producing Skeletal Muscle Index (SMI, cm2m2) [17] and then stratified into “Normal”
and “Low” according to published cut-points [18] as seen in Table 3.1.
It was recognised that multiple software packages are available for CT-BCA, including Slice-O-Matic, ImageJ,
and OsiriX. Both Slice-O-Matic and ImageJ have previously been investigated to ascertain whether there is
agreement between packages in terms of values obtained from CT-BCA, and have been found independently
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Table 3.1: Martin et al Cut-Points
Patient Type SMI Cut-Point (cm2/m2) SMD Cut-Point (HU)
Low BMI Male <43 <41
High BMI Male <53 <33
Low BMI Female <41 <41
High BMI Female <41 <33
Table 3.2: CT Phase Conversion Equations
Phase Conversion Equation
Non-contrast to Arterial SMDa = 0.973 x SMDnc + 3.747
Non-contrast to Portal Venous SMDpv = 0.957 x SMDnc + 6.723
Arterial to Portal Venous SMDpv = 0.979 x SMDa + 3.213
to agree[165,166]. Slice-O-Matic has also been compared to OsiriX, and whilst the values obtained from these
packages were statistically significantly different, the authors felt that these differences were unlikely to have
clinical relevance [167]. The authors of this study did, however, recommend that a single software package was
used for CT-BCA analysis, to prevent confusion. Accordingly, as Slice-O-Matic and ImageJ have previously
repeatedly and independently been shown to concur in CT-BCA measurements a repeat comparison was not
performed, and the Slice-O-Matic software package was chosen for use due to availability, software ergonomics,
and user experience.
Muscle radio-density was acknowledged to be an important factor in CT-BCA [68], and CT scan phase was
also noted to be of relevance [61]. Accordingly, published equations were used to convert values obtained from
arterial and non-contrast phase scans to portal venous phase equivalents [60] as shown in Table 3.2:
3.6 Cachexia Definition
As discussed in Chapter 1, the International Consensus definition of cachexia includes 3 criteria for diagnosis
[12]. As also mentioned in Chapter 1, and in the Consensus definition, muscularity criteria should be sex-specific
and should take in to account the presence of overweight or obesity. The criteria by which patients can be
diagnosed with cachexia are presented in Table 3.3, and the CT-BCA cut-points in use in this study are
presented in Table 3.1.
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Table 3.3: International Cachexia Consensus Definition
Criteria Definition
1 Weight loss >5% over past 6 months (in absence of simple starvation)
2 BMI <20 and any degree of weight loss >2%
3 Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss >2%
3.7 Weight loss and BMI
As discussed in Chapter 1, the analysis by Martin et al [19] relating BMI and weight loss percentage to
outcome in a series of cancer patients gives a BMI/weight-loss score which can be calculated for each patient
according to where they lie on the chart seen in Figure 3.1. This score was utilised to subdivide patients by
BMI/weight-loss category for further analysis.





0 0 1 1 3
1 2 2 2 3
2 3 3 3 4
3 3 3 4 4
3 4 4 4 4









Figure 3.1: BMI/weight-loss Score Matrix
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3.8 Sample collection
Under general anaesthesia, at the time of planned surgery, tissue samples of approximately 1cm x 1cm x
1cm size were taken by the operating surgeon. This was from the rectus abdominis muscle at the time of
laparotomy for the UGIC and AAA patients. The muscle samples from the LDN group were collected at the
time of laparoscopic port insertion (either single-incision laparoscopic surgical port or hand-assistance port),
also from the rectus abdominis muscle.
Skeletal muscle tissue samples were cleaned of obvious adipose and connective tissue and then divided into
aliquots: 4 were paced into cryovials and then snap-frozen in liquid nitrogen. 2 further aliquots were aligned
in the line of their fibres in Optimum Cutting Temperature (OCT) compound before being snap-frozen in
isopentane which had been cooled in liquid nitrogen. All of these muscle samples were then stored at -80
degrees C until analysis.
Blood was taken in 2 x serum gel tubes and 1 x ethylene dia-amine tetra-acetic acid (EDTA) tube during
anaesthetic induction or via an in-dwelling arterial catheter intra-operatively. The samples were centrifuged at
1500G for 10 mins then the serum was divided into 2ml aliquots and snap-frozen before being stored at -80C.
The EDTA cell pellet was snap-frozen and stored at -80C however the serum gel cell pellet was discarded due
to gel beads mixing through the cells.
3.9 Biochemical analysis
3.9.1 Skeletal Muscle Protein Content
The skeletal muscle biopsies were pulverized and weighed using an analytical balance (Mettler Toledo), then
lysed with Phosphosafe Extraction Reagent (Merck Millipore, Billerica, Mass., USA) before being homogenized
and centrifuged. The supernatant was analysed for total soluble protein (including myofibrillar and cystosolic)
content using commercially available BCA protein assay kits (Pierce Biotechnology, Thermo Fisher Scientific,
Rockford, IL).
This work was carried out by Dr Carsten Jacobi in Basel, who describes the process in depth as below:
“Patient samples were first powdered (covaris protocol) then powder was weight out on a precision scale and
lysed in phosphosafe buffer using precellys protocol and centrifuged. Lysate Supernatant was subjected to
protein concentration measurement with BCA and 10µg of total protein was loaded per PolyAcrylamide Gel
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Electrophoresis (PAGE) slot for Western Blot and another PAGE gel for coomassie staining of each sample
in order to normalize the Western Blot signal on the proteome (imaging of the coomassie stained PAGE and
Western Blot and evaluation using Fiji).” 1. The protein determination by the BCA method, here technical
replicates (n=3) were used
2. In addition as an orthogonal verification, samples were separated by PAGE and all proteins visualized by
coomassie staining. The “whole protein stain” was scanned and quantified using Fiji and determine the optical
density of the complete stain.
3.9.2 Skeletal Muscle Fibre Cross-Sectional Area
Muscle fibre cross-sectional area was ascertained as follows: Initially, a microtome was used to thinly slice the
OCT-embedded samples. The frozen muscle sections were co-stained for laminin (L9393, Sigma-Aldrich, Buchs,
Switzerland) and myosin heavy chain type I or IIa to distinguish each fibre type (BA-D5 for type I, SC-71 for
type IIa). The paraffin sections were stained for phospho-STAT3 (D3A7, Cell Signaling Technologies, Danvers,
MA, USA) with a Ventana discovery XT (Roche group, Tucson, USA) to identify cells by presence of nuclei.
Images of the entire tissue section were acquired using a VS120 slide scanner (Olympus Corporation, Tokyo,
Japan). The distribution of myosin heavy chain fibre types, the cross section area of the individual fibres in the
section, and the phospho-STAT3 positive nuclei and staining density were analysed using the proprietary image
analysis platform ASTORIA (Automated Stored Image Analysis) developed by Novartis/Preclinical Safety.
This work was carried out by Dr Carsten Jacobi in Basel.
3.10 Statistical analysis
Statistical analysis was performed in R [168]. Quality of life data was analysed with QoLR [163]. Tables
were constructed using FinalFit [169]. After graphical analysis for normality, parametric and non-parametric
statistical tests, including two-tailed t-tests were conducted where appropriate, as were Chi-Squared tests, and
linear regression. A p value of <0.05 was taken to indicate statistical significance, and differences in means
were assessed individually to ascertain clinical significance. As this was an exploratory analysis, corrections for
multiple testing were not applied. For the QLQ-C30+OG25 scores, a difference of >10 points was taken to
indicate clinically relevant differences in symptomatic and functional domain scores. Multivariable analysis was
performed utilising the olsrr package [170] in R. The data were tested for normality, and a series of candidate
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variables were chosen based on their univariate relationship with the variable under test. Stepwise regression
was then undertaken, with p < 0.1 used as the threshold for inclusion in the model, and p > 0.3 used as the
threshold for exclusion from the model. Following model production residual diagnostics were performed to
ensure the model was robust, including qq-plotting, Shapiro-Wilk test, Kolmogorov-Smirnov test, Cramer-von
Mises test, and Anderson-Darling test. The Breusch Pagan test was used to assess for heteroskedasticity.
Models passing these tests were reported using FinalFit [169], and those failing were discarded.
3.11 Missing data
An initial missing data anlaysis was conducted using the multiple options available in the FinalFit package
[169], as described in the relevant technical manual. The outcomes from this did reveal missing data, and the
patterns of this.
During the initial phase of the study, permissions for use of various questionnaires were awaited prior to use.
Accordingly, there are a number of cases in which the participants did not complete various questionnaires.
Whilst this may not be strictly a “missing completely at random” case, there is no obvious or explicable
relationship between the missing data and other observed data. It could also be argued that the failure to
offer questionnaires to initially recruited patients could reflect a degree of sampling bias. Additionally, and
when considering the types of answers generated by the questionnaires when applied to participants completing
them, it was felt that imputation may not be appropriate and accordingly analysis was conducted using list-wise
deletion. This reduces the number of cases to analyse, but does not introduce other potential sources of error.
Similarly, for objective physical measurements such as gait speed, when not measured in the clinical environment
it was felt more suitable to analyse complete cases rather than impute for missing data.
With regards to the biochemical data, due to constraints from the external laboratory analysing the physical
samples, not all patients had all of their samples analysed. This is particularly notable for the muscle fibre size
cross-sectional area. Again, and as this is a relatively new field, it was not felt that attempting to impute data
would be appropriate and so complete case analyses were performed.
Overall, the missingness of any particular data points was not felt to be in any way related to any observed
data values. Accordingly the missing data were treated as missing completely at random. As this was an
observational study looking to ascertain the presence or absence of a relationship between patient phenotype
and any of the outcomes as discussed in each individual chapter, it follows that each variable has potential
as an explanatory variable, and so imputation should not be used. As mentioned above tests were conducted
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Demographics of Recruited Patients
Between December 2015 and August 2017 194 patients were recruited, of 3 broad types (n, Male(%)): Live
donor nephrectomy (LDN) (53, 24(45.3%)); Vascular aortic (AAA) (52, 44(84.6%)); and Upper GI Cancer
(UGIC) (89, 62(69.7%)) patients. Mean age overall was 63 years (range 25-90).
As discussed in the Methods chapter, data were plotted to assess normality, and parametric and non-parametric
statistical tests were then applied accordingly.
4.1 LDN Patients
Within this patient group, mean age was 51.7 years (25-77). A further breakdown of other collected phenotypic
data by sex is presented in Table 4.1. Males were taller (176.9 v 162.4cm, p < 0.001), heavier (79.9 v 67.6Kg,
p < 0.001), and had greater SMI (51.5 v 42cm2/m2, p < 0.001) than females. There was no statistically
significant difference in weight loss, gait speed, or rates of sarcopenia between the sexes.
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Table 4.1: LDN Patient Demographics
Sex N (total) N (missing) All Female Male p
Age 53 0 Mean (SD) 51.7 (12.2) 50.8 (15.0) 52.4 (9.5) 0.627
Height (cm) 53 0 Mean (SD) 168.9 (10.0) 176.9 (6.7) 162.4 (7.2) <0.001
Weight 53 0 Mean (SD) 73.2 (13.0) 79.9 (12.2) 67.6 (10.9) <0.001
Weight Loss (%) 53 0 Mean (SD) 3.7 (10.7) 1.6 (3.8) 5.4 (13.9) 0.196
BMI 53 0 Mean (SD) 25.6 (3.1) 25.6 (3.2) 25.6 (3.1) 0.971
SMI 53 0 Mean (SD) 46.3 (6.7) 51.5 (5.5) 42.0 (3.9) <0.001
Sarcopenia 53 0 No 32 (60.4) 15 (62.5) 17 (58.6) 0.996
Yes 21 (39.6) 9 (37.5) 12 (41.4)
SMD 53 0 Mean (SD) 42.1 (7.2) 43.0 (7.6) 41.3 (6.9) 0.414
Gait Speed (m/s) 41 12 Mean (SD) 1.6 (0.3) 1.6 (0.4) 1.7 (0.3) 0.334
Cachexia 53 0 No Cachexia 40 (75.5) 18 (75.0) 22 (75.9) 1.000
Cachexia 13 (24.5) 6 (25.0) 7 (24.1)
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include
Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square test for categorical variables, and the
likelihood ratio chi-square test from the proportional odds model for ordinal variables.
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Table 4.2: AAA Patient Demographics
Sex N (total) N (missing) All Female Male p
Age 52 0 Mean (SD) 66.5 (10.4) 65.1 (10.1) 74.2 (8.8) 0.021
Height (cm) 52 0 Mean (SD) 173.9 (9.8) 176.4 (8.1) 160.1 (6.2) <0.001
Weight 52 0 Mean (SD) 83.6 (21.7) 88.0 (20.0) 58.9 (12.9) <0.001
Weight Loss (%) 52 0 Mean (SD) 1.4 (6.1) 1.3 (6.3) 2.0 (4.7) 0.751
BMI 52 0 Mean (SD) 27.2 (5.1) 28.0 (5.0) 22.9 (4.1) 0.008
SMI 52 0 Mean (SD) 47.7 (8.7) 49.0 (8.3) 40.4 (7.8) 0.009
Sarcopenia 52 0 No 23 (44.2) 19 (43.2) 4 (50.0) 1.000
Yes 29 (55.8) 25 (56.8) 4 (50.0)
SMD 52 0 Mean (SD) 33.3 (9.8) 33.2 (10.5) 33.8 (4.5) 0.859
Gait Speed (m/s) 38 14 Mean (SD) 1.3 (0.4) 1.3 (0.3) 1.6 (0.8) 0.158
Frailty Category 35 17 No Frailty 30 (57.7) 29 (65.9) 1 (12.5) 0.208
Pre-frail 4 (7.7) 3 (6.8) 1 (12.5)
Frail 1 (1.9) 1 (2.3)
(Missing) 17 (32.7) 11 (25.0) 6 (75.0)
Cachexia 52 0 No Cachexia 41 (78.8) 35 (79.5) 6 (75.0) 1.000
Cachexia 11 (21.2) 9 (20.5) 2 (25.0)
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include
Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square test for categorical variables, and the
likelihood ratio chi-square test from the proportional odds model for ordinal variables.
4.2 AAA Patients
Within this patient type, mean age was 66.5 years (29-90). Again, more detailed phenotypic data is presented
although it should be noted that the number of females in this patient type is low. The data are presented in
Table 4.2.
In the AAA patient type, males were younger (65.1 v 74.2 years, p = 0.03), taller (176.4 v 160.1cm, p <
0.001), heavier (88 v 58.9Kg, p < 0.001), and had higher SMI (49.0 v 40.4cm2/m2) than females. The other
statistically significant difference noted is calculated from weight and height.
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4.3 UGIC Patients
In the UGIC patient type, mean age was 67.6 (47-87). These patients consisted of gastric (n=18); oesophageal
adenocarcinoma (n=45), oesophageal squamous carcinoma (n=10), and pancreatic (n=12) cancer patients. 1
patient had a sarcomatoid oesophageal cancer, and 3 patients did not have their tumour type recorded This
was due to their cases being investigated in other health boards and no record of pathological investigation
available in the study centre. Clinical staging information is shown in Table 4.3; and pathological staging is
shown in Table 4.4 where available. It is to be noted that some patients were diagnosed with their tumours
at their local institutions and these reports frequently do not code sufficient information to allow a clinical
tumour, nodal, and metastatic staging (cTNM). Additionally, where palliative operations were performed, the
tumours were not resected and thus pathological staging (pTNM) is not available. These cases are marked
“Unstaged”.
Demographic data are shown in Table 4.5. This reveals that male UGIC patients were taller (176.6 v 159.5cm,
p < 0.001), heavier (83.8 v 68.5Kg, p < 0.001), had higher SMI (48.7 v 42.9cm2/m2, p = 0.002), and had
a higher gait speed (1.5 v 1.3m/s, p = 0.011). There were no statistically significant differences in rates of
sarcopenia or cachexia between sexes.
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Table 4.3: Clinical Stage by Cancer Type and by Sex
































Table 4.3: Clinical Stage by Cancer Type and by Sex (continued)











Table 4.4: Pathological Stage by Cancer Type and by Sex




























Table 4.4: Pathological Stage by Cancer Type and by Sex (continued)

























Table 4.5: UGIC Patient Demographics
Sex N (total) N (missing) All Female Male p
Age 89 0 Mean (SD) 67.7 (9.3) 67.3 (8.7) 68.6 (10.7) 0.536
Height (cm) 89 0 Mean (SD) 171.4 (9.9) 176.6 (6.2) 159.5 (5.5) <0.001
Weight 89 0 Mean (SD) 79.1 (18.5) 83.8 (16.7) 68.5 (18.2) <0.001
Weight Loss (%) 89 0 Mean (SD) 6.6 (7.6) 7.0 (7.2) 5.6 (8.5) 0.449
BMI 89 0 Mean (SD) 26.9 (5.8) 26.9 (5.5) 26.9 (6.3) 0.986
SMI 89 0 Mean (SD) 47.0 (8.5) 48.7 (8.7) 42.9 (6.6) 0.003
Sarcopenia 89 0 No 47 (52.8) 30 (48.4) 17 (63.0) 0.301
Yes 42 (47.2) 32 (51.6) 10 (37.0)
SMD 89 0 Mean (SD) 34.9 (7.9) 34.7 (8.1) 35.3 (7.4) 0.746
Gait Speed (m/s) 58 31 Mean (SD) 1.4 (0.3) 1.5 (0.3) 1.3 (0.3) 0.014
Frailty Category 53 36 No Frailty 46 (51.7) 31 (50.0) 15 (55.6) 0.916
Pre-frail 7 (7.9) 4 (6.5) 3 (11.1)
(Missing) 36 (40.4) 27 (43.5) 9 (33.3)
Cachexia 89 0 No Cachexia 36 (40.4) 23 (37.1) 13 (48.1) 0.458
Cachexia 53 (59.6) 39 (62.9) 14 (51.9)
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include
Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square test for categorical variables, and the
likelihood ratio chi-square test from the proportional odds model for ordinal variables.
4.4 Demographic Comparisons Between Patient Types
Demographic assessments were carried out comparing each group with the others in a stepped fashion, to
ensure no comparisons were left undone. These are shown in Table 4.6 for LDN vs AAA patients, in Table 4.7
for AAA vs UGIC patients, and in Table 4.8 for LDN vs UGIC patients.
A subsequent “whole-cohort” comparison is included to allow easier comparison between all groups.
4.4.1 Demographic Comparison Between LDN and AAA Patients
This comparison was performed to assess the similarity or otherwise of the non-cancer patient types. This
reveals that the LDN patients were less predominantly male (35.3 v 64.7%, p < 0.001); younger (51.7 v 66.5
years, p < 0.001); shorter of stature (168.9 v 173.9cm, p = 0.016); lighter (73.2 v 83.6Kg, p = 0.012); had a
higher SMD (42.1 v 33.1, p < 0.001); had a higher gait speed (1.6 v 1.4m/s, p < 0.001); and had a greater
proportion of patients in the “No Frailty” category (56.5 v 43.5%, p = 0.05). There were no significant
differences in BMI; SMI; weight loss; or cachexia prevalence. This is to be expected when comparing a
selected healthy patient type with a type known to have long-standing disease.
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Table 4.6: LDN vs AAA Patient Demographics
Sex N (total) N (missing) All Female Male p
Sex 105 0 Male 68 (64.8) 24 (45.3) 44 (84.6) <0.001
Female 37 (35.2) 29 (54.7) 8 (15.4)
Age 105 0 Mean (SD) 59.0 (13.5) 51.7 (12.2) 66.5 (10.4) <0.001
Height (cm) 105 0 Mean (SD) 171.4 (10.2) 168.9 (10.0) 173.9 (9.8) 0.012
Weight 105 0 Mean (SD) 78.3 (18.5) 73.2 (13.0) 83.6 (21.7) 0.004
Weight Loss (%) 105 0 Mean (SD) 2.5 (8.7) 3.7 (10.7) 1.4 (6.1) 0.182
BMI 105 0 Mean (SD) 26.4 (4.3) 25.6 (3.1) 27.2 (5.1) 0.044
SMI 105 0 Mean (SD) 47.0 (7.7) 46.3 (6.7) 47.7 (8.7) 0.367
Sarcopenia 105 0 No 55 (52.4) 32 (60.4) 23 (44.2) 0.144
Yes 50 (47.6) 21 (39.6) 29 (55.8)
SMD 105 0 Mean (SD) 37.7 (9.6) 42.1 (7.2) 33.3 (9.8) <0.001
Gait Speed (m/s) 79 26 Mean (SD) 1.5 (0.4) 1.6 (0.3) 1.3 (0.4) <0.001
Frailty Category 74 31 No Frailty 69 (65.7) 39 (73.6) 30 (57.7) 0.050
(Missing) 31 (29.5) 14 (26.4) 17 (32.7)
Pre-frail 4 (3.8) 4 (7.7)
Frail 1 (1.0) 1 (1.9)
Cachexia 105 0 No Cachexia 81 (77.1) 40 (75.5) 41 (78.8) 0.858
Cachexia 24 (22.9) 13 (24.5) 11 (21.2)
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include
Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square test for categorical variables, and the
likelihood ratio chi-square test from the proportional odds model for ordinal variables.
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Table 4.7: UGIC vs AAA Patient Demographics
Sex N (total) N (missing) All Female Male p
Sex 141 0 Male 106 (75.2) 44 (84.6) 62 (69.7) 0.075
Female 35 (24.8) 8 (15.4) 27 (30.3)
Age 141 0 Mean (SD) 67.2 (9.7) 66.5 (10.4) 67.7 (9.3) 0.508
Height (cm) 141 0 Mean (SD) 172.3 (9.9) 173.9 (9.8) 171.4 (9.9) 0.151
Weight 141 0 Mean (SD) 80.8 (19.8) 83.6 (21.7) 79.1 (18.5) 0.202
Weight Loss (%) 141 0 Mean (SD) 4.6 (7.5) 1.4 (6.1) 6.6 (7.6) <0.001
BMI 141 0 Mean (SD) 27.0 (5.5) 27.2 (5.1) 26.9 (5.8) 0.726
SMI 141 0 Mean (SD) 47.2 (8.6) 47.7 (8.7) 47.0 (8.5) 0.639
Sarcopenia 141 0 No 70 (49.6) 23 (44.2) 47 (52.8) 0.419
Yes 71 (50.4) 29 (55.8) 42 (47.2)
SMD 141 0 Mean (SD) 34.3 (8.6) 33.3 (9.8) 34.9 (7.9) 0.278
Gait Speed (m/s) 96 45 Mean (SD) 1.4 (0.3) 1.3 (0.4) 1.4 (0.3) 0.076
Frailty Category 88 53 No Frailty 76 (53.9) 30 (57.7) 46 (51.7) 0.456
Pre-frail 11 (7.8) 4 (7.7) 7 (7.9)
Frail 1 (0.7) 1 (1.9)
(Missing) 53 (37.6) 17 (32.7) 36 (40.4)
Cachexia 141 0 No Cachexia 77 (54.6) 41 (78.8) 36 (40.4) <0.001
Cachexia 64 (45.4) 11 (21.2) 53 (59.6)
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include
Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square test for categorical variables, and the
likelihood ratio chi-square test from the proportional odds model for ordinal variables.
4.4.2 Demographic Comparison Between UGIC and AAA Patients
The AAA and UGIC patients were compared to ascertain how closely the patients of each type matched. The
data reveal that the patients of each type are more closely matched than the AAA with the LDN patients.
Comparing UGIC to AAA patients, the data show that the UGIC patients had more weight loss (6.6 v 1.4%,
p < 0.001); had a faster gait speed (1.4 v 1.4m/s, p = 0.045), and had fewer patients in the “No cachexia”
category (46.8 v 53.2%, p < 0.001). Other demographic differences did not reach significance, including
age; height; weight; SMI; and SMD. This could partly be expected as both the AAA and UGIC patients are
older and may thus have similar co-morbidities, but the lack of difference in SMI and SMD is slightly surprising.
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Table 4.8: UGIC vs LDN Patient Demographics
Sex N (total) N (missing) All Female Male p
Sex 142 0 Male 86 (60.6) 24 (45.3) 62 (69.7) 0.007
Female 56 (39.4) 29 (54.7) 27 (30.3)
Age 142 0 Mean (SD) 61.7 (13.0) 51.7 (12.2) 67.7 (9.3) <0.001
Height (cm) 142 0 Mean (SD) 170.5 (10.0) 168.9 (10.0) 171.4 (9.9) 0.156
Weight 142 0 Mean (SD) 76.9 (16.8) 73.2 (13.0) 79.1 (18.5) 0.041
Weight Loss (%) 142 0 Mean (SD) 5.5 (8.9) 3.7 (10.7) 6.6 (7.6) 0.062
BMI 142 0 Mean (SD) 26.4 (5.0) 25.6 (3.1) 26.9 (5.8) 0.119
SMI 142 0 Mean (SD) 46.7 (7.9) 46.3 (6.7) 47.0 (8.5) 0.627
Sarcopenia 142 0 No 79 (55.6) 32 (60.4) 47 (52.8) 0.482
Yes 63 (44.4) 21 (39.6) 42 (47.2)
SMD 142 0 Mean (SD) 37.6 (8.4) 42.1 (7.2) 34.9 (7.9) <0.001
Gait Speed (m/s) 99 43 Mean (SD) 1.5 (0.3) 1.6 (0.3) 1.4 (0.3) 0.001
Frailty Category 92 50 No Frailty 85 (59.9) 39 (73.6) 46 (51.7) 0.050
(Missing) 50 (35.2) 14 (26.4) 36 (40.4)
Pre-frail 7 (4.9) 7 (7.9)
Cachexia 142 0 No Cachexia 76 (53.5) 40 (75.5) 36 (40.4) <0.001
Cachexia 66 (46.5) 13 (24.5) 53 (59.6)
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include
Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square test for categorical variables, and the
likelihood ratio chi-square test from the proportional odds model for ordinal variables.
4.4.3 Demographic Differences Between UGIC and LDN Patient Types
A comparison between UGIC and LDN patients could be expected to reveal the greatest differences, and some
of these do appear in Table 4.8. The comparison reveals that the UGIC patient type was more predominantly
male (n= 62 v 24, p = 0.004); older (67.7 v 51.7 years, p < 0.001); had greater weight loss (6.6 v 3.7Kg, p
< 0.001); lower SMD (34.9 v 42.1 HU, p < 0.001); lower gait speed (1.4 v 1.6m/s, p = 0.005); and were
more likely to be cachectic (n=53 v 13, p < 0.001). This is not overly surprising. What is slightly surprising,
however, is the absence of significant difference in SMI. Although both patient types do not have statistically
significant differences in height or weight, the greater weight loss in UGIC patients could be expected to be
reflected in a reduced SMI. This is not the case, and it is difficult to reconcile this absence of difference with
the international consensus definition which includes the phrase “ongoing loss of skeletal muscle mass”. That
the weight loss is not reflected in reduced SMI could point to a higher starting SMI, loss of non-muscular
tissue, or a need for an alternative definition of cachexia.
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4.4.4 Combined demographics
Having examined all combinations of groups to ensure no important comparisons were missed, ANOVA
analysis was undertaken to compare all groups together, and to ensure values obtained for each group were
easily compared to those obtained from the entire cohort overall. This allowed an examination of how far
above or below the whole cohort mean each group was for each variable, and also allowed easy assessment of
categorical variables between groups. This analysis is shown in Table 4.9.
As can be seen, the differences between patient groups noted in the comparisons tabulated above are
demonstrated. Of particular note are the differences in age, (LDN 51.7 v AAA 66.5 v UGIC 67.7 p<0.001),
weight loss percent (LDN 3.7 v AAA 1.4 v UGIC 6.6 p=0.001), SMD (LDN 42.1 v AAA 33.3 v UGIC 34.9
p<0.001), and gait speed (LDN 1.6 v AAA 1.3 v UGIC 1.4 p<0.001). American Society of Anaesthetists
(ASA) grade also revealed a difference between groups in this analysis, with only LDN patients falling into
ASA 1 and having no ASA 3 or ASA 4 patients in this group. Neither the AAA or UGIC groups had any ASA
1 patients, which might be expected given they have either vascular disease or cancer, and interestingly the
AAA group had a higher percentage of ASA 3 patients than the UGIC group. Indeed, the AAA group was the
only one to have patients scored as ASA 4.
It was particularly interesting to note that there was no statistically significant difference between the groups
in BMI measurements, SMI measurements or in sarcopenia prevalence. This may be because the sarcopenia
cut-points depend on SMI values and BMI categories to divide patients into subsets, however it remained
clear that there was no difference in sarcopenia prevalence between groups. It is to be remembered that
these patients are pre-operative candidates and so could be expected to have relatively maintained skeletal
musculature compared to those at a later stage in their disease process.
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Table 4.9: Whole-cohort Demographics
Category N (total) N (missing) Live donor Vascular Cancer All p
Sex 194 0 Male 24 (45.3) 44 (84.6) 62 (69.7) 130 (67.0) <0.001
Female 29 (54.7) 8 (15.4) 27 (30.3) 64 (33.0)
Age 194 0 Mean (SD) 51.7 (12.2) 66.5 (10.4) 67.7 (9.3) 63.0 (12.5) <0.001
Height (cm) 194 0 Mean (SD) 168.9 (10.0) 173.9 (9.8) 171.4 (9.9) 171.4 (10.0) 0.040
Weight 194 0 Mean (SD) 73.2 (13.0) 83.6 (21.7) 79.1 (18.5) 78.7 (18.4) 0.015
Weight Loss (%) 194 0 Mean (SD) 3.7 (10.7) 1.4 (6.1) 6.6 (7.6) 4.4 (8.5) 0.001
BMI 194 0 Mean (SD) 25.6 (3.1) 27.2 (5.1) 26.9 (5.8) 26.6 (5.0) 0.178
SMI 194 0 Mean (SD) 46.3 (6.7) 47.7 (8.7) 47.0 (8.5) 47.0 (8.1) 0.688
SMD 194 0 Mean (SD) 42.1 (7.2) 33.3 (9.8) 34.9 (7.9) 36.4 (9.0) <0.001
Gait Speed (m/s) 137 57 Mean (SD) 1.6 (0.3) 1.3 (0.4) 1.4 (0.3) 1.5 (0.4) <0.001
ASA 187 7 1 42 (79.2) 42 (21.6) <0.001
2 11 (20.8) 3 (5.8) 50 (56.2) 64 (33.0)
3 44 (84.6) 35 (39.3) 79 (40.7)
4 2 (3.8) 2 (1.0)
(Missing) 3 (5.8) 4 (4.5) 7 (3.6)
Frailty Category 127 67 No Frailty 39 (73.6) 30 (57.7) 46 (51.7) 115 (59.3) 0.087
(Missing) 14 (26.4) 17 (32.7) 36 (40.4) 67 (34.5)
Pre-frail 4 (7.7) 7 (7.9) 11 (5.7)
Frail 1 (1.9) 1 (0.5)
Sarcopenia 194 0 No 32 (60.4) 23 (44.2) 47 (52.8) 102 (52.6) 0.253
Yes 21 (39.6) 29 (55.8) 42 (47.2) 92 (47.4)
Cachexia 194 0 No Cachexia 40 (75.5) 41 (78.8) 36 (40.4) 117 (60.3) <0.001
Cachexia 13 (24.5) 11 (21.2) 53 (59.6) 77 (39.7)
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include Wilcoxon-Kruskal-Wallis test for
continuous variables, Pearson chi-square test for categorical variables, ANOVA for 3-way comparisons, and the likelihood ratio
chi-square test from the proportional odds model for ordinal variables.
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4.4.5 Missing data
It can be seen from the tables above, and in particular Table 4.9 that some measured variables have numbers
of missing data. In particular, the variables relating to gait speed and to frailty have high numbers of missing
data. This relates to delays in the provision of permissions to use certain questionnaires, and does potentially
pose a problem for analysis. The treatment of missing data is discussed in the Methods chapter, but briefly a




CT Use In Defining Sarcopenia And
Cachexia
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As described in the Introduction chapter, the clinical relevance of CT-BCA has previously been investigated.
Applying previously-described criteria to the current study population will allow assessment of their relevance
to a preoperative surgical cancer cohort, and an assessment of how applicable these cancer-derived cut-points
are in assessing selected “healthy” patients.
5.1 Hypothesis and research questions
5.1.1 Hypotheses
Published CT-BCA and cancer cachexia definitions apply well to recruited patients.
Cut-points derived from recruited patients match published values.
SMI values will be higher in healthy patients.
Cachexia will be seen in cancer patients only.
5.1.2 Research questions
• What are the means and differences in means of skeletal muscle CT-BCA variables in each group?
• What is the distribution of patients into normal and low CT-BCA categories if published criteria are
applied to the current cohort?
• How well do cut-points derived from the literature apply to the current cohort?
• How well do cut-points derived from the current cohort relate to the published literature?
• How can cancer cachexia definitions be applied to non-cancer groups?
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5.2 Methods for Assessing CT Use In Defining Sarcopenia And
Cachexia
Between December 2015 and August 2017, 197 surgical patients were recruited to an observational study
investigating the relationship between body composition, clinical phenotyping, and biochemistry. Patients
were from one of 3 distinct groups: Upper GI cancer (UGIC), vascular aortic patients (AAA), and live kidney
donors (LDN). Each patient was known to have had a pre-operative CT scan which was analysed at L3 level as
described in Chapter 3, defining area measurements of skeletal muscle. These area measurements were indexed
for patient height and BMI in a standard fashion [18]. CT phase corrections were carried out using equations
published by Rollins et al [60]. Previously-published CT-BCA cut-points were applied [18]: normal BMI male
SMI <43cm2m2, high BMI male <53cm2m2, normal BMI female <41cm2m2, high BMI female <41cm2m2;
normal BMI male SMD <41 HU, high BMI male <33 HU, normal BMI female <41 HU, high BMI female
<33 HU. Statistical analysis and data plotting were carried out using R [168]. New cohort-derived CT-BCA
cut-points, in the absence of outcome data, were calculated by sex as described by Baumgartner et al [7]
and by BMI as described by Martin et al [18]: specifically 2 standard deviations below the mean of a healthy
population, in this case the LDN patients.
5.3 Results of the Assessment of CT Use In Defining Sarcopenia And
Cachexia
5.3.1 Demographics for CT use in Sarcopenia and Cachexia
Basic demographics for the study cohort split by Normal CT Muscularity and Low CT Muscularity are presented
in Table 5.1, and split by Normal and Low SMD are presented in Table 5.2.
These show that there was no significant difference across patient types, or in each sex by muscularity. They
do, however, reveal that patients with low SMI were statistically significantly older than those with normal SMI
(60 vs 66.3 years, p < 0.001). Patients with low SMI also had statistically significantly lower SMD (38.5 vs
34.1 HU, p < 0.001). When considering the SMD split, patients with low SMD were older (59 vs 69.6 years, p
< 0.001) and had lower SMI (48.0 vs 45.3 cm2/m2). There were statistically significantly more UGIC patients
in the normal SMD than the low SMD group (66 v 55, p < 0.001).
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Table 5.1: Demographic Distribution by CT Muscularity
Dependent: CT Muscularity Normal Low muscularity p
Group Live donor 32 (31.4) 21 (22.8) 0.253
Vascular 23 (22.5) 29 (31.5)
Cancer 47 (46.1) 42 (45.7)
Sex Male 64 (62.7) 66 (71.7) 0.239
Female 38 (37.3) 26 (28.3)
Age Mean (SD) 60.0 (11.9) 66.3 (12.4) <0.001
BMI Mean (SD) 27.1 (5.3) 26.1 (4.6) 0.141
Height (cm) Mean (SD) 169.7 (9.9) 173.3 (9.9) 0.013
Weight (Kg) Mean (SD) 78.5 (18.3) 78.9 (18.7) 0.884
SMI Mean (SD) 51.3 (7.5) 42.2 (5.7) <0.001
SMD Mean (SD) 38.5 (8.0) 34.1 (9.5) 0.001
Note:
Tests used include Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson
chi-square test for categorical variables, and the likelihood ratio chi-square test from
the proportional odds model for ordinal variables.
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Table 5.2: Demographic Distribution by CT Radio-density
Dependent: Muscle Radio-density Normal Low Radio-density p
Group Live donor 45 (32.8) 8 (9.0) <0.001
Vascular 26 (19.0) 26 (29.2)
Cancer 66 (48.2) 55 (61.8)
Age (Years) Mean (SD) 59.0 (12.4) 69.5 (8.6) <0.001
Sex Male 93 (67.9) 63 (70.8) 0.754
Female 44 (32.1) 26 (29.2)
BMI Mean (SD) 26.6 (4.8) 27.1 (5.6) 0.458
Height (cm) Mean (SD) 170.7 (9.0) 172.8 (10.5) 0.109
Weight (Kg) Mean (SD) 77.8 (16.4) 81.9 (21.6) 0.105
SMI Mean (SD) 48.0 (8.1) 45.3 (8.2) 0.014
Protein Content Mean (SD) 123.6 (68.7) 129.2 (78.9) 0.653
Note:
Tests used include Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square
test for categorical variables, and the likelihood ratio chi-square test from the proportional odds
model for ordinal variables.
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Table 5.3: SMD comparison between groups
Comparison Sex Difference 1st Mean 2nd Mean Lower CI Upper CI p value
UGIC vs LDN
Male 8.27 42.99 34.72 4.51 12.03 0.00006
Female 6.03 41.34 35.32 2.16 9.89 0.00287
UGIC vs AAA
Male -1.57 33.16 34.72 -5.33 2.20 0.40950
Female -1.48 33.84 35.32 -5.93 2.96 0.49392
LDN vs AAA
Male 9.84 42.99 33.16 5.40 14.27 0.00004
Female 7.51 41.34 33.84 3.23 11.79 0.00172
5.3.2 Distribution of SMI and SMD
The histograms of SMI and SMD were assessed as a whole cohort, by sex, and by patient type within each sex.
These are shown in Figure 5.1 and Figure 5.2 for SMI, and in Figure 5.3 and Figure 5.4 for SMD. Whilst there
do appear to be differences between patient types, statistical testing did not reveal any significant differences
in SMI in either male or female patients between types.
Statistical testing did, however, reveal significant differences in SMD between patient types, particularly
between “healthy” and “not healthy” (LDN vs either UGIC or AAA) patients in both males and females.
Interestingly, the difference in mean SMD was greater between LDN and AAA (M = 9.84, F = 7.51) than
between LDN and UGIC (M = 8.27, F = 6.03). Also of interest is the finding that SMD does not statistically
significantly differ between UGIC and AAA patients. This similarity between cancer and vascular patient
CT-BCA has not been previously reported. These findings are shown in Table 5.3.
As previously discussed in Chapter 4, there are differences between these groups other than SMD. These
possible confounding factors between groups were assessed to ascertain their relationship with SMD. Of these,
only weight consistently showed a relationship with SMD across all patient groups. The relationship was seen
in all patient groups, however, and appeared consistent on testing. Additionally, the differences in weight
between groups was less than the standard deviation of weights in each group and accordingly it was not felt
that these differences would account for the differences in SMD.
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Patient Type Live donor Vascular Cancer
Skeletal Muscle Index Histogram by Patient Type
Figure 5.1: Patient Type SMI Density Curve
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Patient Type Live donor Vascular Cancer
Skeletal Muscle Index Histogram by Patient Type
Figure 5.2: Patient SMI Density Curve Split by Type
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Live donor Vascular Cancer
Skeletal Muscle Radio−density Histogram by Patient Type
Figure 5.3: Patient Type SMD Density Curve
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Live donor Vascular Cancer
Skeletal Muscle Radio−density Histogram by Patient Type
Figure 5.4: Patient SMD Density Curve Split by Type
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Table 5.4: Number and Percentage of Patients of each Type by CT Muscularity
Patient Type Sex/BMI Muscularity by SMI n(%) per Type Total per Type
Live donor
Female Normal 17 (32.1%) 53
Female Low 12 (22.6%) 53
Low BMI Male Normal 6 (11.3%) 53
Low BMI Male Low 3 (5.7%) 53
High BMI Male Normal 9 (17%) 53
High BMI Male Low 6 (11.3%) 53
Vascular
Female Normal 4 (7.7%) 52
Female Low 4 (7.7%) 52
Low BMI Male Normal 6 (11.5%) 52
Low BMI Male Low 6 (11.5%) 52
High BMI Male Normal 13 (25%) 52
High BMI Male Low 19 (36.5%) 52
Cancer
Female Normal 17 (19.1%) 89
Female Low 10 (11.2%) 89
Low BMI Male Normal 15 (16.9%) 89
Low BMI Male Low 6 (6.7%) 89
High BMI Male Normal 15 (16.9%) 89
High BMI Male Low 26 (29.2%) 89
The distribution of SMI and SMD by sex, BMI where appropriate, and patient type are shown in Figure 5.5,
and Figure 5.6 respectively. The distributions shown are detailed in Table 5.4 for SMI and in Table 5.5 for
SMD. This reveals a startling prevalence of sarcopenia amongst healthy (LDN) patients, with 21 of 53 (39.6%)
of selected healthy kidney donors exhibiting CT-BCA sarcopenia. Patients of AAA type also exhibited CT-BCA
signs of sarcopenia, with 29 of 52 (55.8%) exhibiting CT-BCA sarcopenia. Interestingly 42 of 89 (47.2%) UGIC
patients exhibited CT-BCA sarcopenia, revealing that AAA patients had greater prevalence of sarcopenia than
UGIC patients.
Testing did not reveal a relationship between SMI and more advanced disease stage in the UGIC group.
The relationship between SMI, SMD, and BMI/weight-loss stage was considered as described in Chapter 3. In
this case, the BMI/weight-loss stage as described by Martin et al [19] was applied across the entire cohort, to
each group, and by sub-groups to investigate SMI and SMD. It was initially possible to demonstrate differences
in SMI and SMD across the whole cohort between patients in different BMI/weight-loss classes. Weight,
weight-loss percent, and BMI also showed significant differences between classes however as these parameters
formed part of the class calculation they were disregarded. Upon looking more closely into patient groups,
however, the differences in SMI and SMD disappeared.
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Table 5.5: Number and Percentage of Patients of each Type by CT Radio-Density
Patient Type Sex/BMI Radio-Density by SMD n(%) per Type Total per Type
Live donor
Low BMI Male Normal 7 (13.2%) 53
Low BMI Male Low Radio-Density 2 (3.8%) 53
High BMI Male Normal 12 (22.6%) 53
High BMI Male Low Radio-Density 3 (5.7%) 53
Low BMI Female Normal 8 (15.1%) 53
Low BMI Female Low Radio-Density 2 (3.8%) 53
High BMI Female Normal 16 (30.2%) 53
High BMI Female Low Radio-Density 3 (5.7%) 53
Vascular
Low BMI Male Normal 8 (15.4%) 52
Low BMI Male Low Radio-Density 4 (7.7%) 52
High BMI Male Normal 11 (21.2%) 52
High BMI Male Low Radio-Density 21 (40.4%) 52
Low BMI Female Low Radio-Density 4 (7.7%) 52
High BMI Female Normal 3 (5.8%) 52
High BMI Female Low Radio-Density 1 (1.9%) 52
Cancer
Low BMI Male Normal 9 (10.1%) 89
Low BMI Male Low Radio-Density 12 (13.5%) 89
High BMI Male Normal 21 (23.6%) 89
High BMI Male Low Radio-Density 20 (22.5%) 89
Low BMI Female Normal 3 (3.4%) 89
Low BMI Female Low Radio-Density 8 (9%) 89
High BMI Female Normal 9 (10.1%) 89
High BMI Female Low Radio-Density 7 (7.9%) 89
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CT Muscularity Normal Low
CT Muscularity by Sex and BMI
Figure 5.5: Patient SMI and Sarcopenia by Group, Sex, and BMI
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CT Radio−density Normal Low
CT Radio−density by Sex and BMI
Figure 5.6: Patient SMD by Group, Sex, and BMI
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5.3.3 Applying cancer cachexia criteria to non-cancer patients
The international consensus definition of cachexia includes both CT and weight-loss criteria [12], as discussed
in greater depth in Chapter 1 with this classification being applied as discussed in Chapter 3. Whilst accepting
that the definition applies to cancer patients, it seemed reasonable as a point of interest to ascertain how many
of the other non-cancer patients may fall under the diagnostic criteria.
In performing the analysis, the LDN group were excluded, as although many of these patients reported weight
loss, this was intentional and designed to either allow them entry to the LDN programme, or to speed their
recovery after surgery.
The AAA cohort did not report intentional weight loss, but many did report that their weight had decreased
and given that a visible proportion of these patients had low SMI by published criteria they were included in











Percentage of Patients Meeting Cachexia Criteria
Figure 5.7: Percentage of Patients Meeting Cachexia Criteria
76
5.3.4 Multivariable Analysis of CT-BCA
As described in Chapter 3, a multivariable analysis was conducted to ascertain any significant relationships
between CT-BCA and patient phenotype. Stepwise model construction to predict SMI identified group, BMI,
sex, SMD, Eastern Clinical Oncology Group (ECOG) score, weight, weight loss (WL) category, weight loss
percentage, and Edmonton frail scale (EFS) category as being of potential interest in relation to SMI. This
model is shown in Table 5.6.
When considering the effect of each of these predictors for SMI, it is important to note that within the WL
category predictor, the 2% WL + low muscularity (LM) category includes SMI as part of the definition, and
so whilst there is a significance relating to this it should be considered in this context. Additionally, when
considering BMI it has to be remembered that SMI is indexed for height in a similar fashion to BMI and so this
should be noted when interpreting the model. This leaves sex and ECOG score 2 as the remaining predictors
of SMI. As noted above, there is a difference in SMI by sex, with females having lower SMI. ECOG score 2
relates to reduced physical activity, which is an understandable potential predictor of SMI. Additionally, the
Akaike information criterion suggests that this is not a well-fitting model.
Similarly, stepwise model construction was carried out to predict SMD. This identified age, sex, weight, SMI,
and ECOG score as being of potential interest, and the model is shown in Table 5.7.
When considering the significance of each of the SMD potential predictors, these do appear slightly easier to
explain. Age, female sex, weight, and SMI all appear to be statistically significant components of a multivariable
SMD prediciton model. The Akaike information criterion assessing fitting of the model, however, reveals a
poorly fitting model.
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Table 5.6: Multivariable Analysis Predicting SMI
Dependent: SMI unit value Coefficient (univariable) Coefficient (multivariable)
Group Live donor Mean (sd) 46.3 (6.7) - -
Vascular Mean (sd) 47.7 (8.7) 1.37 (-1.80 to 4.54, p=0.394) -2.50 (-5.82 to 0.82, p=0.139)
Cancer Mean (sd) 46.9 (8.6) 0.61 (-2.06 to 3.28, p=0.653) 0.93 (-2.00 to 3.85, p=0.532)
BMI [15.0,48.0] Mean (sd) 46.9 (8.2) 0.81 (0.63 to 0.99, p<0.001) 1.34 (0.84 to 1.84, p<0.001)
Sex Male Mean (sd) 49.2 (8.2) - -
Female Mean (sd) 42.0 (5.6) -7.14 (-9.28 to -5.01, p<0.001) -9.77 (-13.06 to -6.49, p<0.001)
SMD [11.3,59.5] Mean (sd) 46.9 (8.2) 0.04 (-0.08 to 0.16, p=0.473) 0.22 (0.08 to 0.37, p=0.003)
ECOG SCore 0 Mean (sd) 46.8 (6.9) - -
1 Mean (sd) 48.1 (9.7) 1.30 (-1.17 to 3.77, p=0.299) 0.33 (-2.08 to 2.74, p=0.786)
2 Mean (sd) 36.2 (5.5) -10.61 (-18.60 to -2.63, p=0.009) -9.83 (-16.79 to -2.86, p=0.006)
3 Mean (sd) 44.9 (11.0) -1.95 (-9.13 to 5.22, p=0.592) -3.00 (-9.60 to 3.61, p=0.370)
Weight [38.0,137.6] Mean (sd) 46.9 (8.2) 0.22 (0.17 to 0.27, p<0.001) -0.14 (-0.31 to 0.03, p=0.101)
WL Category Weight Stable Mean (sd) 47.9 (8.6) - -
2% WL + LM Mean (sd) 40.8 (6.1) -7.10 (-10.98 to -3.23, p<0.001) -7.57 (-11.16 to -3.97, p<0.001)
5% WL Mean (sd) 46.8 (7.2) -1.12 (-3.40 to 1.17, p=0.335) -4.20 (-7.56 to -0.83, p=0.015)
Percentage Weight Loss [-18.1,51.2] Mean (sd) 46.9 (8.2) -0.03 (-0.16 to 0.10, p=0.603) 0.14 (-0.02 to 0.29, p=0.079)
EFS Category No Frailty Mean (sd) 46.8 (7.5) - -
Pre-frail Mean (sd) 49.8 (13.9) 3.01 (-2.08 to 8.11, p=0.244) 2.47 (-1.34 to 6.28, p=0.202)
NA NA NA NA 14.55 (-1.67 to 30.78, p=0.078) 18.68 (5.21 to 32.16, p=0.007)
Number in dataframe = 226, Number in model = 127, Missing = 99, Log-likelihood = -386.96, AIC = 805.9, R-squared = 0.61, Adjusted R-squared = 0.57
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Table 5.7: Multivariable Analysis Predicting SMD
Dependent: SMD unit value Coefficient (univariable) Coefficient (multivariable)
Age [25.0,90.0] Mean (sd) 37.8 (9.0) -0.36 (-0.44 to -0.27, p<0.001) -0.33 (-0.40 to -0.25, p<0.001)
Sex Male Mean (sd) 37.4 (9.5) - -
Female Mean (sd) 38.8 (7.7) 1.42 (-1.13 to 3.98, p=0.273) -2.28 (-4.42 to -0.14, p=0.037)
Weight [38.0,137.6] Mean (sd) 37.8 (9.0) -0.21 (-0.26 to -0.15, p<0.001) -0.31 (-0.37 to -0.26, p<0.001)
SMI [30.1,83.7] Mean (sd) 37.8 (9.0) 0.05 (-0.09 to 0.20, p=0.473) 0.23 (0.11 to 0.36, p<0.001)
ECOG SCore 0 Mean (sd) 39.5 (8.6) - -
1 Mean (sd) 34.3 (8.9) -5.25 (-7.94 to -2.57, p<0.001) -2.81 (-4.73 to -0.89, p=0.004)
2 Mean (sd) 27.9 (1.2) -11.59 (-20.27 to -2.91, p=0.009) -4.49 (-10.75 to 1.77, p=0.159)
3 Mean (sd) 32.5 (9.9) -7.00 (-14.79 to 0.79, p=0.078) -7.12 (-12.56 to -1.68, p=0.011)
Number in dataframe = 226, Number in model = 194, Missing = 32, Log-likelihood = -619.9, AIC = 1257.8, R-squared = 0.57, Adjusted R-squared = 0.56
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Table 5.8: Calculations Used to Derive New SMI Cut-Point
Sex BMI Min SMI Mean SMI Max SMI SD Mean - (2SD)
Male
Normal 40.4 47.3 52.9 4.7 37.9
High 44.2 54.0 61.3 4.4 45.2
Female
Normal 34.9 40.4 46.5 3.7 33.1
High 35.5 42.8 51.7 3.9 35.0
5.3.5 Deriving CT-BCA cut-points from current cohort
Having considered the application of previously published cut-points to the current cohort, attention was turned
to applying cut-points derived from the healthy controls recruited to the present study. It is known that the
number of patients used to define normality in laboratory tests are orders of magnitude greater than the
numbers present in this study. Indeed, when considering for example blood tests the reference range may be
derived from many tens of thousands of patient tests. Whilst clearly there are far fewer patients in the present
study, nevertheless some inferences can be made. The original work defining sarcopenia [7] used patients from
a previous study [94] which included 68 females and 64 males. This work defined sarcopenia in terms of DEXA
scanning results, and the translation to CT, performed by Mourtzakis et al[17] used 31 patients with concurrent
CT and DEXA to provide CT-BCA cut-points (Male <55.4cm2/m2, Female <38.9cm2/m2). The inclusion of
BMI as part of CT-BCA sarcopenia assessment was performed by Martin et al[18] using 1473 patients and
analysing patient outcome to stratify into those with good or poor outcome (High BMI male <53cm2/m2,
Normal BMI Male <43cm2/m2, High BMI Female <41cm2/m2, Normal BMI Female <41cm2/m2). Both the
Mourtzakis et al and the Martin et al studies used cancer patients to define their equations and cut-points.
As such, there has not been a series of healthy patients with CT-BCA performed to define cut-points using
the methods described by Baumgartner et al[7] until now. The de-novo cut-points were derived as described
in Chapter 3, subtracting two standard deviations (SD) from the mean, revealing calculations as detailed in
Table 5.8. It is to be noted that for some patient subgroups - specifically females - the “Mean - (2SD)” value
is actually below the minimum range of the data.
The results of this reveal the cut-points below, and as shown in Table 5.9 which includes previous cut-points
for comparison.
• 37.9 cm2/m2 for normal BMI males,
• 45.2 cm2/m2 for high BMI males,
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Table 5.9: Previously Published and Newly Calculated SMI Cut-Point Definitions
Cut-Point Source Year Male High BMI Male Female High BMI Female
Mourtzakis 2008 55.4 38.9
Consensus Definition 2011 55 39
Martin 2013 43 53 41 41
New 2019 37.9 45.2 34.14 35.0
• 33.1 cm2/m2 for normal BMI females, and
• 35.0 cm2/m2 for high BMI females
The breakdown of patients into each group is shown in Table 5.10 in numerical form, and in Figure 5.8 in a
graphical form.
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Table 5.10: Patient Distribution by New Cut-Point
Patient Type Sex New Cut-point SMI n Total (Percentage) Per Sex Total Patients Per Type
Live donor
Male Normal 23 24 (95.8%) 53
Male Low 1 24 (4.2%) 53
Female Normal 29 29 (100%) 53
Vascular
Male Normal 34 44 (77.3%) 52
Male Low 10 44 (22.7%) 52
Female Normal 5 8 (62.5%) 52
Female Low 3 8 (37.5%) 52
Cancer
Male Normal 49 62 (79%) 89
Male Low 13 62 (21%) 89
Female Normal 24 27 (88.9%) 89
Female Low 3 27 (11.1%) 89
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Dotted lines indicate calculated cut−points
Black = New Cut−Point, Red = Martin et al Cut−Point
Segregation by New Calculation of SMI Cut−Points
Figure 5.8: Distribution of Patients by Type and SMI by New Cut-point
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5.4 Discussion of CT use in Defining Cachexia and Sarcopenia
The figures presented in Table 5.1 show some differences between CT muscularity groups which are to be
expected, and some which are less obvious. A statistically significant increase in age in the low muscularity
group is in keeping with the development of sarcopenia as age increases [7]. The histogram in Figure 5.1
clearly shows that within each sex, there are marked and obvious differences in SMI distribution, even though
these do not reach statistical significance. If the LDN population were to be considered as “normal”, then it
can clearly be seen that male UGIC patients have a lower SMI distribution by comparison. Similarly, male AAA
patients have a lower mean SMI than LDN patients, but also a lower mean SMI than the UGIC group. This
would suggest that the presence of either upper GI cancer, or aortic vascular disease, has a notable reduction
effect on the indexed muscularity of males. Whilst the mechanism of this reduction in both groups is not fully
understood, it could be inferred that there is a common pathway resulting in loss of muscle mass independent
of a particular disease process. This is clearly important when considering the ongoing efforts to find both a
mechanism for the development of cachexia, and following on from this a target for intervention. It may be
that by comparing underlying biochemistry between both cancer and non-cancer patients, a potentially unifying
pathway may be derived.
When considering the female patients, the differences are less clear. The LDN group do appear to have a
greater density of patients with similar SMI, whilst the UGIC and to a lesser degree AAA patients have an
increased variability of muscularity. Whilst this may be a reflection of the relative numbers of female patients
within each group, nevertheless it could be expected that although histographic plot density peaks may be
smaller they should occur at around the same point in the absence of a differentiating factor - in this case
aortic vascular disease. Again, the clustering of LDN SMI could be considered to be “normal”, meaning that
the widening spread of SMI in the cancer and non-cancer disease cohorts may be an effect of the underlying
disease process. Interesting differences appear when patient SMD is segregated not only by sex but also by
patient type. As can be seen in Figure 5.3, both Male and Female patients show a marked decrease in SMD
when moving from “healthy” through ”non-cancer, vascular” to “cancer” patients (despite this not being a
continuum). There is a clear reduction in CT SMD between the LDN and the AAA group, and more markedly
between the LDN and the UGIC group. This is echoed in both males and females and suggests that for SMD
there is an effect of disease on SMD. Noting the distribution of the density curves, it can be seen that both
disease states studied confer a reduction in SMD. This is confirmed by the statistically significant differences
in SMD between groups as shown above.
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In considering the proposal that cachexia is an inexorable disease-related process resulting in muscle loss [12],
and with non-cancer research groups maintaining similar proposals [92], it could be expected that both the
LDN and AAA groups in this cohort would naturally have a higher SMI, and fewer sarcopenic patients, than
the cancer group. As can be seen in Figure 5.5, and in Table 5.1, this is not the case.
Of note, cachexia as a result of aortic vascular disease has not been described previously.
In trying to ascertain the reasons for these demonstrated differences in CT-BCA, both methodological and
population-specific factors must be taken into account.
In terms of methodology, the production of cut-points to predict prognosis from SMI make an assumption
that low SMI is a driving factor for the deterioration of patients with cancer. The assumption reasons that
low SMI means more advanced or aggressive disease and that is is the disease driving the low SMI and thus
the poor prognosis. If this were to be considered in the reverse, however, it may be that the findings of the
current study may make more sense. If as seen in the various histogram plots noted above there is a relatively
normal distribution of SMI in patients irrespective of disease state, then perhaps the SMI merely represents the
wide variety of the human condition. If so, it may then follow that in the preoperative phase of disease such a
distribution would not be unexpected, as these patients have yet to progress towards relentless skeletal muscle
loss. Were this to be the case, the observed similarities between the cancer and non-cancer groups would
not be unexpected. Accordingly, any cut-points derived from pre-operative cancer populations would need
to account for the preservation of functional state in these specific groups. Additionally, it may be that the
patients in whom prognosis was poor represented those who were already on a deteriorating pathway and had
already lost significant muscle mass and volume prior to analysis. If so, the tumour biology in these patients
may be somewhat more aggressive resulting in faster muscle loss and death, meaning that the low SMI seen
to give poor prognosis is in fact a reflection of the underlying disease rather than a contributor to it.
Although some conclusions may be drawn from the present study, it is important to recognise that the data
colected represent a “snapshot” of the patient’s journey. Thus it is impossible to ascertain with precision prior
muscularity, function m and symptomatology. Equally importantly, if not more so, is the weakness inherent in
the absence of longitudinal measures of patient function, weight loss or gain, symptomatology over time, and
survival. Accordingly, whilst there are worthwhile observations to be made, it should be remembered that, in
the words of Aristotle [171]:
“one swallow does not make a summer, nor does one day; and so too one day, or a short time, does not make
a man blessed and happy”
In terms of population-specific factors, it is known that worldwide different populations have differing
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musculature and that the application of a cut-point defined in one population to another may be inappropriate.
With this in mind, it may be that rather than a single unifying cut-point for wide populations (e.g. Caucasian,
African, Asian etc..) being applicable, a more local solution is required for each country or even county.
With regards to the Martin et al cut-points, these were derived from a Canadian registry as described by
Prado et al [65]. This dataset describes patients attending a particular hospital in northern Alberta, in which
the Caucasian population is around 70% [123]. It could be expected that in this context the muscularity
differences related to race or ethnic origin between the published cut-points and the current cohort would be
limited, however in addition the increasingly sedentary lifestyle and exercise choices of the Scottish population
need to be taken into account. Clearly a more active population will in general retain their musculature in
the absence of disease more than a sedentary population and this may be a contributing factor to the high
levels of sarcopenia seen in “healthy” kidney donors. Nevertheless, the difference in cut-points generated in
the current healthy control cohort and those derived from cancer patients is marked.
When considering SMD, the problem is rather more subtle. Knowing what a normal SMD is, and what it
represents is not certain especially in the field of cancer cachexia and sarcopenia. Interpreting deviations from
a perceived normal, therefore, is fraught with confounders. Firstly, it is unclear from where the normal came,
and in what population, and of what age. Although apparently specified, the demographics - upon which so
much will change and depend - are open to interpretation and depend upon the reader dissecting the Canadian
census to ascertain how many of the patients studied could potentially belong to a specific demographic,
geographic, and racial group. Further, and as discussed elsewhere, the impact of systemic inflammation (SI)
on the amount of tissue oedema present is unquantified in general, and is remarked in Martin et al specifically
[18]. An increase in tissue oedema will increase tissue water, and result in decreased radio-attenuation. This
remains to be addressed in the cachexia and sarcopenia literature, and is discussed in this thesis in Chapter 9.
Additionally, the relationship between SMD and muscle protein content is far from clear or linear, as discussed in
a following chapter, and thus other components of skeletal muscle and its surroundings within the tomographic
field must be considered. As suggested by Rollins et al [68], the replacement of muscle with fat may be a
significant contributing factor in cachexia, and will undoubtedly have an effect on muscle radio-density. As yet,




Relationship Between CT Variables,
Functional Status, and Quality Of Life
87
As described in the earlier introduction, there is an increasing interest in patient-reported outcome measures
(PROMs). PROMs evince patient quality of life (QoL) and as such can reflect the benefit or otherwise of
disease-related interventions in a patient-centred way unrelated to objective disease control measures such
as tumour clearance. Additionally, it is possible not only to quantify the QoL of patient groups but also to
ascertain the sensitivity of the questionnaires used in detecting QoL changes in a population whose health is
sufficiently preserved to undergo surgical intervention.
6.1 Hypothesis and Research Questions
6.1.1 Hypothesis
CT-BCA variables relate well to patient-reported QoL and objective functional measures and can
differentiate between groups
6.1.2 Research Questions
• How well-preserved or otherwise is QoL in a preoperative patient group?
• Can CT-BCA cut-points divide QoL into patient groups with higher or lower QoL scores?
• Can CT-BCA cut-points divide objective functional measurements into patient groups meeting or failing
to meet published function targets?
6.2 Methods of Assessing QoL and CT variables
Between December 2015 and August 2017, 197 surgical patients were recruited to an observational study
investigating the relationship between body composition, and QoL. Patients were from one of 3 distinct
groups: Upper GI cancer (UGIC) including those with oesophageal, gastric, and pancreatic cancer; vascular
aortic patients (AAA); and live kidney donors (LDN). Each patient was known to have had a pre-operative
CT scan which was analysed at L3 level using semi-automated Slice-O-Matic software v4.2 (Tomovision
Montreal-Canada), defining area measurements of skeletal muscle, subcutaneous fat, and visceral fat. These
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area measurements were indexed for patient height as described in Chapter 3, analysed and plotted using R
[168]. As CT scan phase is known to have an impact upon the radio-density of skeletal muscle as found by
van Vugt et al [61], the equations developed by Rollins et al [60] from a cohort of pancreatic cancer patients
undergoing triple-phase CT scans were applied. Specifically, the equation to convert arterial phase SMD to
portal venous phase SMD was applied where appropriate:
SMHUpv=(0.979*SMHUa)+3.213
Quality of life metrics were assessed using the ”EORTC QLQ-C30+OG25” and “EQ5D-3L” questionnaires.
With regards to the QLQ-C30+OG25 scoring, in line with the instruction manual the scores are divided into
symptomatic and functional domains. When scoring symptomatic domains, a lower score indicates fewer
symptoms or a better score within that symptomatic domain. When scoring functional domains, a higher
score indicates fewer functional impairments or a better score within that functional domain. Accordingly, a
patient with preserved quality of life would be expected to exhibit a low symptomatic domain score and a high
functional domain score. To increase ease of interpretation graphically, scales were assigned such that points
nearer the circumference indicated better performance, and QoL reduced towards the centre point of each
chart. Patient functioning was assessed using the Edmonton Frail Scale (EFS), the reported EFS (REFS), the
patient-generated subjective global assessment (PG-SGA), and the timed up-and-go test (TUG).
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6.3 Results of CT and QoL Analysis
Functional assessment data are presented in Table 6.1, and QoL data in Table 6.2 for symptomatic domains
and in Table 6.3 for functional domains.
Table 6.1: Demographic distribution of functional assessment
Dependent: Patient Group Live donor Vascular Cancer p
Sex Male 24 (45.3) 44 (84.6) 62 (69.7) <0.001
Female 29 (54.7) 8 (15.4) 27 (30.3)
Age (Years Mean (SD) 51.7 (12.2) 66.5 (10.4) 67.7 (9.3) <0.001
BMI Mean (SD) 25.6 (3.1) 27.2 (5.1) 26.9 (5.8) 0.178
Height (cm) Mean (SD) 168.9 (10.0) 173.9 (9.8) 171.4 (9.9) 0.040
Weight (Kg) Mean (SD) 73.2 (13.0) 83.6 (21.7) 79.1 (18.5) 0.015
Percentage Weight Loss Mean (SD) 3.7 (10.7) 1.4 (6.1) 6.6 (7.6) 0.001
Gait Speed (m/s) Mean (SD) 1.6 (0.3) 1.3 (0.4) 1.4 (0.3) <0.001
Timed Up-And-Go (s) Mean (SD) 7.9 (1.2) 10.3 (3.4) 9.0 (2.3) <0.001
SMI Mean (SD) 46.3 (6.7) 47.7 (8.7) 47.0 (8.5) 0.688
SMD (HU) Mean (SD) 42.1 (7.2) 33.3 (9.8) 34.9 (7.9) <0.001
ASA 1 42 (79.2) <0.001
2 11 (20.8) 3 (6.1) 50 (58.8)
3 44 (89.8) 35 (41.2)
4 2 (4.1)
ECOG 0 52 (98.1) 23 (44.2) 50 (56.2) <0.001
1 1 (1.9) 23 (44.2) 36 (40.4)
2 2 (3.8) 2 (2.2)
3 4 (7.7) 1 (1.1)
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include
Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square test for categorical
variables, and the likelihood ratio chi-square test from the proportional odds model for ordinal
variables.
90
Table 6.2: Demographic Distribution of All Quality of Life
Symptomatology Data
Dependent: cancercontrol Live donor Vascular Cancer p
Quality of life overall Mean (SD) 6.0 (10.7) 30.1 (22.2) 29.0 (22.8) <0.001
Fatigue Mean (SD) 3.2 (6.9) 25.5 (28.8) 20.9 (22.2) <0.001
Nausea and Vomiting Mean (SD) 0.0 (0.0) 4.5 (15.5) 11.9 (19.6) <0.001
Pain Mean (SD) 3.0 (9.9) 24.0 (33.1) 12.8 (21.0) <0.001
Dyspnoea Mean (SD) 1.3 (6.6) 17.0 (29.3) 8.2 (17.9) 0.001
Insomnia Mean (SD) 11.3 (19.8) 30.1 (35.7) 25.9 (30.7) 0.004
Appetite Loss Mean (SD) 0.0 (0.0) 13.1 (25.9) 24.3 (34.6) <0.001
Constipation Mean (SD) 1.3 (6.6) 7.1 (15.2) 14.0 (23.5) 0.001
Diarrhoea Mean (SD) 2.0 (8.0) 3.2 (9.9) 11.9 (21.9) 0.001
Financial Difficulties Mean (SD) 0.0 (0.0) 16.3 (32.9) 8.6 (23.4) 0.003
Dysphagia Mean (SD) 0.0 (0.0) 2.5 (8.9) 20.0 (27.9) <0.001
Eating Mean (SD) 0.0 (0.0) 10.6 (23.0) 28.2 (27.6) <0.001
Reflux Mean (SD) 2.3 (5.8) 8.7 (14.9) 14.2 (22.2) 0.001
Odynophagia Mean (SD) 0.0 (0.0) 4.2 (13.6) 18.8 (28.6) <0.001
Pain and discomfort Mean (SD) 2.0 (7.3) 14.1 (25.4) 18.3 (25.8) <0.001
Anxiety Mean (SD) 4.0 (9.9) 43.3 (28.8) 55.4 (27.1) <0.001
Eating with others Mean (SD) 0.0 (0.0) 1.9 (13.9) 13.3 (30.3) 0.001
Dry Mouth Mean (SD) 2.0 (8.0) 16.0 (26.8) 26.7 (32.0) <0.001
Trouble with taste Mean (SD) 0.0 (0.0) 5.2 (18.1) 15.8 (26.5) <0.001
Trouble swallowing saliva Mean (SD) 1.3 (6.6) 0.7 (4.7) 11.5 (27.0) 0.001
Choked when Swallowing Mean (SD) 0.0 (0.0) 3.2 (15.1) 8.2 (20.8) 0.014
Trouble with coughing Mean (SD) 7.3 (13.9) 19.9 (21.1) 28.7 (27.4) <0.001
Trouble Talking Mean (SD) 0.0 (0.0) 1.3 (6.5) 4.2 (12.3) 0.025
Weight Loss Mean (SD) 0.0 (0.0) 4.5 (17.5) 21.0 (32.3) <0.001
Hair Loss Mean (SD) 0.0 (0.0) 0.0 (0.0) 7.5 (14.2) 0.005
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Table 6.2: Demographic Distribution of All Quality of Life
Symptomatology Data (continued)
Dependent: cancercontrol Live donor Vascular Cancer p
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include
Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square test for categorical
variables, and the likelihood ratio chi-square test from the proportional odds model for ordinal
variables.
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Table 6.3: Demographic Distribution of All Quality of Life Functional
Data
Dependent: Patient Group Live donor Vascular Cancer p
Physical Functioning Mean (SD) 98.5 (4.7) 81.5 (20.9) 92.5 (11.3) <0.001
Role Functioning Mean (SD) 100.0 (0.0) 71.8 (35.8) 88.1 (22.4) <0.001
Emotional Functioning Mean (SD) 93.0 (10.0) 81.3 (23.8) 78.9 (22.8) 0.001
Cognitive Functioning Mean (SD) 97.7 (5.8) 86.2 (25.7) 87.2 (18.7) 0.003
Social Functioning Mean (SD) 100.0 (0.0) 78.8 (27.6) 84.0 (25.7) <0.001
Body Image Mean (SD) 100.0 (0.0) 96.2 (15.7) 86.7 (26.8) <0.001
Note:
NaN indicates missing values, NA indicates the test was unable to be run. Tests used include
Wilcoxon-Kruskal-Wallis test for continuous variables, Pearson chi-square test for categorical

































































Group Live donor Vascular Cancer
Symptomatic domains in study patients
(worsening symptomatology towards centre)
Figure 6.1: Quality of life Symptom Domains by Patient Type
6.3.1 Timing of Questionnaire Administration
As discussed in Chapter 3, it was not possible to be certain exactly which patients had completed QoL
questionnaires before, and which after chemotherapeutic interventions in the UGIC group. To further
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investigate this as a possible confounding factor, the time between consent and operation was examined.
This showed a split in the UGIC group at around 50-days, suggesting that those with >50-days to operation
underwent chemotherapy. An analysis of these subgroups revealed that symptomatic domains reached
significance between over/under 50-days in “hair loss” only. Differences in functional domains reached
significance in “role functioning” only. Time from consent to operation was mean 35.85 days, median 24 days,
range 0-143 days. From this, it seems reasonable to extrapolate that those with earlier operations do not have
substantially better or worse QoL than those with later operations - other than as noted above, and which
could be in keeping with chemotherapeutic side effects. Of note, no other domains were affected.
6.3.2 Symptomatic QoL Domains
These data can also be demonstrated in plot form, as shown in Figure 6.1 and reveal that the majority of
patients have preserved symptomatic domain scores. Initial interrogation of the patient groups revealed overall
differences in symptomatic domain scores, as shown in Table 6.4. A subsequent comparison between patient
groups, shown in Tables 6.5, 6.6, and 6.7 reveals that there were statistically significant differences between
all 3 patient groups for certain domains. These differences also reached clinical significance for some of the
symptomatic domains (defined by a difference in scores of >10 points) as discussed in Chapter 3.
As could be expected, the LDN group have the most preserved symptomatic domain responses compared to
both the UGIC and the AAA groups. In fact, and as seen in Figure 6.1, the responses returned by the LDN
group indicated an overall paucity of symptoms. This fits with the group being a selected healthy population,
and provides a useful baseline against which to measure a more unwell group.
When looking at the comparison between symptoms reported by the UGIC and the AAA groups (in Table 6.7)
it can be seen that in all domains reaching dual significance criteria apart from pain, the UGIC patients scored
greater symptomatology. Amongst the explanations for this could be that due to the operability of the cancer
group, their disease is at a relatively early stage and has not yet spread to adjacent structures or bone and
thus was not causing significant pain.
When comparing symptomatic domains within groups split by whether the patients are above or below the
Martin et al criteria for SMI and for SMD, the number of domains reaching both significance levels dropped
considerably. In the UGIC group, Financial Difficulties alone were highlighted, and were experienced more in
the normal SMI group than in the low SMI group. The pathophysiology behind this is unclear, and whilst
it is possible to speculate that those with normal or preserved SMI may be working in manual jobs (perhaps
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self-employed) and that this underlies the result, the data gathered do not allow hypotheses such as these to
be tested. In the AAA group, Appetite Loss alone was experienced more in those with low SMD than normal
SMD. Again, the pathophysiology behind this is unclear and hypothetical explanations for this difference were
not readily available. No other domains in any group reached both significance levels for either SMI or SMD.
Table 6.4: ANOVA Comparison of Symptomatology Scores Across All
Patient Groups
Dependent: Patient Group Live donor Vascular Cancer p
Quality of Life Overall Mean (SD) 6.0 (10.7) 30.1 (22.2) 29.0 (22.8) <0.001
Fatigue Mean (SD) 3.2 (6.9) 25.5 (28.8) 20.9 (22.2) <0.001
Nausea and Vomiting Mean (SD) 0.0 (0.0) 4.5 (15.5) 11.9 (19.6) <0.001
Pain Mean (SD) 3.0 (9.9) 24.0 (33.1) 12.8 (21.0) <0.001
Dyspnoea Mean (SD) 1.3 (6.6) 17.0 (29.3) 8.2 (17.9) 0.001
Insomnia Mean (SD) 11.3 (19.8) 30.1 (35.7) 25.9 (30.7) 0.004
Appetite Loss Mean (SD) 0.0 (0.0) 13.1 (25.9) 24.3 (34.6) <0.001
Consipation Mean (SD) 1.3 (6.6) 7.1 (15.2) 14.0 (23.5) 0.001
Diarrhoea Mean (SD) 2.0 (8.0) 3.2 (9.9) 11.9 (21.9) 0.001
Financial Difficulties Mean (SD) 0.0 (0.0) 16.3 (32.9) 8.6 (23.4) 0.003
Dysphagia Mean (SD) 0.0 (0.0) 2.5 (8.9) 20.0 (27.9) <0.001
Eating Mean (SD) 0.0 (0.0) 10.6 (23.0) 28.2 (27.6) <0.001
Reflux Mean (SD) 2.3 (5.8) 8.7 (14.9) 14.2 (22.2) 0.001
Odynophagia Mean (SD) 0.0 (0.0) 4.2 (13.6) 18.8 (28.6) <0.001
Pain and discomfort Mean (SD) 2.0 (7.3) 14.1 (25.4) 18.3 (25.8) <0.001
Anxiety Mean (SD) 4.0 (9.9) 43.3 (28.8) 55.4 (27.1) <0.001
Eating with others Mean (SD) 0.0 (0.0) 1.9 (13.9) 13.3 (30.3) 0.001
Dry Mouth Mean (SD) 2.0 (8.0) 16.0 (26.8) 26.7 (32.0) <0.001
Traouble with taste Mean (SD) 0.0 (0.0) 5.2 (18.1) 15.8 (26.5) <0.001
Trouble swallowing saliva Mean (SD) 1.3 (6.6) 0.7 (4.7) 11.5 (27.0) 0.001
Choked when Swallowing Mean (SD) 0.0 (0.0) 3.2 (15.1) 8.2 (20.8) 0.014
Trouble with coughing Mean (SD) 7.3 (13.9) 19.9 (21.1) 28.7 (27.4) <0.001
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Table 6.4: ANOVA Comparison of Symptomatology Scores Across All
Patient Groups (continued)
Dependent: Patient Group Live donor Vascular Cancer p
Trouble Talking Mean (SD) 0.0 (0.0) 1.3 (6.5) 4.2 (12.3) 0.025
Weight Loss Mean (SD) 0.0 (0.0) 4.5 (17.5) 21.0 (32.3) <0.001
Hair Loss Mean (SD) 0.0 (0.0) 0.0 (0.0) 7.5 (14.2) 0.005
Table 6.5: Welch 2-sided t-test of Mean Quality of Life Symptomatology
Results Between Cancer and Live Donor Patients Reaching both Clinical
and Statistical Significance
Domain Difference Cancer Live donor Low CI High CI p-value
Quality of life overall -23.012 6.000 29.012 -28.845 -17.180 <0.001
Fatigue -17.628 3.222 20.850 -22.888 -12.369 <0.001
Nausea and Vomiting -11.934 0.000 11.934 -16.265 -7.604 <0.001
Insomnia -14.593 11.333 25.926 -23.323 -5.862 0.001
Appetite Loss -24.280 0.000 24.280 -31.923 -16.637 <0.001
Constipation -12.658 1.333 13.992 -18.158 -7.159 <0.001
Dysphagia -20.000 0.000 20.000 -26.201 -13.799 <0.001
Eating -28.194 0.000 28.194 -34.332 -22.057 <0.001
Reflux -11.833 2.333 14.167 -17.027 -6.640 <0.001
Odynophagia -18.750 0.000 18.750 -25.116 -12.384 <0.001
Pain and discomfort -16.333 2.000 18.333 -22.407 -10.259 <0.001
Anxiety -51.417 4.000 55.417 -58.036 -44.798 <0.001
Eating with others -13.333 0.000 13.333 -20.072 -6.594 <0.001
Dry Mouth -24.667 2.000 26.667 -32.116 -17.217 <0.001
Trouble with taste -15.833 0.000 15.833 -21.732 -9.935 <0.001
Trouble swallowing saliva -10.189 1.333 11.523 -16.418 -3.961 0.002
Trouble with coughing -21.417 7.333 28.750 -28.634 -14.200 <0.001
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Table 6.5: Welch 2-sided t-test of Mean Quality of Life Symptomatology
Results Between Cancer and Live Donor Patients Reaching both Clinical
and Statistical Significance (continued)
Domain Difference Cancer Live donor Low CI High CI p-value
Weight Loss -20.988 0.000 20.988 -28.119 -13.856 <0.001
Table 6.6: Welch 2-sided t-test of Mean Quality of Life Symptomatology
Results Between Vascular and Live Donor Patients Reaching both
Clinical and Statistical Significance
Domain Difference Vascular Live donor Low CI High CI p-value
Quality of life overall 24.128 30.128 6.000 17.296 30.960 <0.001
Fatigue 22.312 25.534 3.222 14.066 30.557 <0.001
Pain 21.038 24.038 3.000 11.446 30.631 <0.001
Dyspnoea 15.660 16.993 1.333 7.217 24.104 <0.001
Insomnia 18.795 30.128 11.333 7.480 30.109 0.001
Appetite Loss 13.072 13.072 0.000 5.791 20.353 0.001
Financial Difficulties 16.340 16.340 0.000 7.083 25.597 0.001
Eating 10.577 10.577 0.000 4.176 16.978 0.002
Pain and discomfort 12.103 14.103 2.000 4.754 19.451 0.002
Anxiety 39.269 43.269 4.000 30.811 47.727 <0.001
Dry Mouth 14.026 16.026 2.000 6.254 21.797 0.001
Trouble with coughing 12.538 19.872 7.333 5.516 19.560 0.001
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Table 6.7: Welch 2-sided t-test of Mean Quality of Life Symptomatology
Results Between Vascular and Cancer Patients Reaching both Clinical
and Statistical Significance
Domain Difference Cancer Vascular Low CI High CI p-value
Pain 11.281 24.038 12.757 1.039 21.523 0.031
Appetite Loss -11.208 13.072 24.280 -21.659 -0.757 0.036
Dysphagia -17.543 2.457 20.000 -24.189 -10.897 <0.001
Eating -17.618 10.577 28.194 -26.398 -8.837 <0.001
Odynophagia -14.583 4.167 18.750 -21.929 -7.238 <0.001
Anxiety -12.147 43.269 55.417 -22.099 -2.196 0.017
Eating with others -11.410 1.923 13.333 -19.120 -3.700 0.004
Dry Mouth -10.641 16.026 26.667 -20.854 -0.428 0.041
Trouble with taste -10.605 5.229 15.833 -18.320 -2.889 0.007
Trouble swallowing saliva -10.869 0.654 11.523 -16.962 -4.776 0.001
Weight Loss -16.500 4.487 20.988 -25.064 -7.937 <0.001
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6.3.3 Patient-reported Functional Domains
Functional domain data collected are presented in Figure 6.2. This reveals, as expected, that the majority
of patients have generally preserved function. The LDN group have the most preserved function, with few
reductions. Perhaps slightly surprisingly, the AAA patients scored lower in the functional domains than the
UGIC patients. This could represent the relatively preserved character of the UGIC patients reaching resection
as compared to the more advanced stage of the AAA patients who have reached criteria for repair.
Comparisons between patient types are presented in Table 6.10, Table 6.11, and Table 6.12. These reveal
that, as expected, there are clinically and statistically significant differences between the LDN patients and
both other patient types across all domains other than ”Physical Functioning” between the LDN and the UGIC
group, and ”Body Image” between the LDN and the AAA group. In neither of these domains did the difference
reach clinical significance. In the comparison between UGIC and AAA patients, ”Physical Functioning” and
”Role Functioning” were better preserved in the UGIC group than the AAA group. This may again represent
the stage of disease at time of presentation for each group.
Testing within each group did not reveal any functional domain which reached both clinical and statistical
significance across any CT-BCA muscle variable. For completion, examples from the UGIC are shown in Table
6.8 for SMI cut-points, and in Table 6.9 for SMD cut-points.
As described in Chapter 3, the cut-points used were those defined by Martin et al for SMI (High BMI
Male <53cm2/m2, Normal BMI Male <43cm2/m2, High BMI Female <41cm2/m2, Normal BMI Female
<41cm2/m2), and for SMD (High BMI Male <33HU, Normal BMI Male <41HU, High BMI Female <43HU,
Normal BMI Female <41HU)[18].
Table 6.8: Welch 2-sided t-test of Mean Quality of Life Functionality
Results Within UGIC Patients by Martin et al SMI Cut-Points
Domain Difference Normal SMI Low SMI Low CI High CI p-value
Physical Functioning -3.460 90.909 94.369 -8.283 1.362 0.157
Role Functioning -2.818 86.822 89.640 -12.712 7.076 0.572
Emotional Functioning -8.483 75.000 83.483 -18.220 1.253 0.087
Cognitive Functioning -2.754 85.985 88.739 -11.060 5.553 0.511
Social Functioning 2.795 85.227 82.432 -8.488 14.078 0.623
Body Image -6.369 83.721 90.090 -17.872 5.133 0.273
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Table 6.9: Welch 2-sided t-test of Mean Quality of Life Functionality
Results within UGIC Patients According to Martin et al SMD Cut-Points
Domain Difference Normal SMD Low SMD Low CI High CI p-value
Physical Functioning 0.267 92.632 92.364 -4.764 5.299 0.916
Role Functioning -3.048 86.486 89.535 -13.154 7.058 0.55
Emotional Functioning 1.513 79.678 78.165 -8.890 11.916 0.772
Cognitive Functioning 0.898 87.719 86.822 -7.460 9.256 0.831
Social Functioning -0.337 83.772 84.109 -11.708 11.035 0.953

































Group Live donor Vascular Cancer
Functional Domains in Recruited Patients
(higher score shows improved functioning)
Figure 6.2: Quality of life Functional Domains by Patient Type
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Table 6.10: Welch 2-sided t-test of Mean Quality of Life Functionality
Results Between Live Donor and Cancer Patients Reaching both Clinical
and Statistical Significance
Domain Difference Live donor Cancer Low CI High CI p-value
Role Functioning 11.875 100.000 88.125 6.896 16.854 <0.001
Emotional Functioning 14.125 93.000 78.875 8.378 19.872 <0.001
Cognitive Functioning 10.424 97.667 87.243 5.993 14.855 <0.001
Social Functioning 16.049 100.000 83.951 10.357 21.742 <0.001
Body Image 13.333 100.000 86.667 7.362 19.305 <0.001
Table 6.11: Welch 2-sided t-test of Mean Quality of Life Functionality
Results Between Live Donor and Vascular Patients Reaching both
Clinical and Statistical Significance
Domain Difference Live donor Vascular Low CI High CI p-value
Physical Functioning 16.995 98.533 81.538 11.049 22.941 <0.001
Role Functioning 28.205 100.000 71.795 18.243 38.167 <0.001
Emotional Functioning 11.750 93.000 81.250 4.587 18.913 0.002
Cognitive Functioning 11.449 97.667 86.218 4.116 18.781 0.003
Social Functioning 21.154 100.000 78.846 13.460 28.848 <0.001
Table 6.12: Welch 2-sided t-test of Mean Quality of Life Functionality
Results Between Cancer and Vascular Patients Reaching both Clinical
and Statistical Significance
Domain Difference Cancer Vascular Low CI High CI p-value
Physical Functioning -10.951 81.538 92.490 -17.241 -4.661 0.001
Role Functioning -16.330 71.795 88.125 -27.396 -5.265 0.004
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6.3.4 Objective functioning
As an objective measure of physical functioning, gait speed measured in metres per second (ms-1) was felt to
be useful in line with the EWGSOP consensus [124]. This defines “0.8ms-1” as a cut-point below which patient
function can be said to have objectively deteriorated. The current cohort gait speed is presented in Figure
6.3 with colours and shapes representing CT-BCA, and in Table 6.13. As shown, there were 3 UGIC and 2
AAA patients in the whole cohort with gait speed under this 0.8ms-1 cut-point. Additionally, the distribution
of patients above and below the CT-BCA cut-points does not appear to allow categorisation of patients.
Attempts to use linear regression to explore relationships between CT_BCA muscle variables and gait speed
failed. There were no statistically significant relationships found between gait speed and either SMI or SMD.
Narrowing the focus of the analysis to look at UGIC, AAA, and LDN groups did find a statistically significant
relationship between gait speed and SMI in the LDN group (p = 0.0482), however the relationship was very
weak (R2 = 0.073). Subdividing the patient groups by sex revealed a weak relationship in the female UGIC
group (R2 = 0.270, p = 0.011).
Investigating SMD and gait speed revealed a weak relationship across the whole cohort (R2 = 0.057, p =
0.003). However this disappeared when looking at individual patient groups; patient groups by sex; and a
relationship was only seen in high BMI AAA males: though this was again weak (R2 = 0.13, p = 0.04).
6.3.5 EQ5D-3L Questionnaire
Across all patient types, there were so few patients reporting anything other than “normal” responses to the
EQ5D questionnaire that it rendered attempts at analysis futile.
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Table 6.13: Gait Speed by Patient Type and Sex/BMI Subgroup
Patient Type Sex/BMI Subgroup Min Gait Speed Mean Gait Speed Max Gait Speed
Live donor
Female 1.190 1.683 2.198
Low BMI Male 1.230 1.650 2.490
High BMI Male 1.105 1.535 1.935
Vascular
Female 0.974 1.583 2.459
Low BMI Male 0.948 1.206 1.835
High BMI Male 0.389 1.293 1.729
Cancer
Female 0.792 1.280 1.881
Low BMI Male 0.796 1.514 1.967
High BMI Male 0.619 1.493 2.055
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Gait Speed in each patient group by BMI and sex subgroups
according to CT−BCA criteria




As noted in Chapter 1, there is agreement between patient-reported performance status and physician-assigned
performance status [146]. What has not been reported is whether this performance status translates to
mirror patient-reported QoL measures. To this end, both the symptomatology and functional domains were
interrogated to ascertain how well performance status related to PROM responses. This was initially performed
across the entire cohort, as seen in Table 6.14 for symptomatic and Table 6.15 for functional domains. As
can be seen, there is statistical significance in the differences in score by ECOG status across the majority of
domains. This is in keeping with higher performance status patients having lower symptomatology and better
functionality, and supports the concordance between physician-assigned and patient-reported performance
status.
When attempting to ascertin whether these differences held true in each patient group, it became clear that
the distribution of patients across performance status was not equal. In each group there were reasonable
numbers of ECOG 0 (LDN 49; AAA 23; UGIC 44) patients. Numbers of ECOG 1 patients were maintained
in AAA (23) and UGIC (35) groups but not in the LDN (1) group. There were few ECOG 2 (LDN 0; AAA
2; UGIC 1) and ECOG 3 (LDN 0; AAA 4; UGIC 1) patients, and no ECOG 4 or higher patients. Given the
paucity of lower performance status patients in each patient group, the per-group analysis was not performed.
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Table 6.14: Patient-reported Symptomatic Domains by Performance
Status
Dependent: ECOG Score 0 1 2 3 p
Quality of life overall Mean (SD) 13.9 (16.3) 36.3 (21.6) 55.6 (9.6) 60.0 (32.5) <0.001
Fatigue Mean (SD) 8.1 (11.9) 29.2 (26.7) 63.0 (33.9) 64.4 (28.8) <0.001
Nausea and Vomiting Mean (SD) 3.4 (9.5) 10.7 (20.7) 0.0 (0.0) 33.3 (40.8) <0.001
Pain Mean (SD) 5.7 (12.6) 21.5 (29.2) 50.0 (50.0) 70.0 (29.8) <0.001
Dyspnoea Mean (SD) 4.9 (13.4) 14.7 (26.5) 22.2 (38.5) 20.0 (44.7) 0.008
Insomnia Mean (SD) 15.8 (23.5) 31.6 (35.8) 66.7 (33.3) 66.7 (33.3) <0.001
Appetite Loss Mean (SD) 7.5 (19.3) 22.0 (34.8) 55.6 (38.5) 60.0 (43.5) <0.001
Constipation Mean (SD) 7.2 (16.9) 10.2 (20.8) 33.3 (33.3) 6.7 (14.9) 0.092
Diarrhoea Mean (SD) 3.7 (12.3) 13.6 (22.4) 0.0 (0.0) 0.0 (0.0) 0.002
Financial Difficulties Mean (SD) 2.9 (13.6) 13.2 (29.2) 44.4 (50.9) 60.0 (43.5) <0.001
Dysphagia Mean (SD) 4.9 (13.2) 15.8 (28.7) 27.8 (20.0) 28.9 (36.5) 0.001
Eating Mean (SD) 9.6 (17.3) 21.9 (29.4) 44.4 (37.6) 55.0 (48.4) <0.001
Reflux Mean (SD) 4.8 (10.3) 16.1 (23.6) 5.6 (9.6) 36.7 (27.4) <0.001
Odynophagia Mean (SD) 6.4 (15.5) 12.1 (27.1) 16.7 (28.9) 43.3 (43.5) 0.001
Pain and discomfort Mean (SD) 9.4 (19.4) 14.7 (22.1) 50.0 (44.1) 40.0 (54.8) <0.001
Anxiety Mean (SD) 28.0 (31.4) 54.2 (25.6) 77.8 (19.2) 46.7 (36.1) <0.001
Eating with others Mean (SD) 2.6 (14.1) 11.3 (28.1) 33.3 (57.7) 20.0 (44.7) 0.005
Dry Mouth Mean (SD) 10.7 (19.0) 26.0 (35.6) 0.0 (0.0) 60.0 (36.5) <0.001
Trouble with taste Mean (SD) 4.1 (13.4) 14.4 (27.3) 33.3 (33.3) 26.7 (43.5) <0.001
Trouble swallowing saliva Mean (SD) 1.7 (7.4) 13.8 (30.6) 0.0 (0.0) 6.7 (14.9) 0.001
Choked when Swallowing Mean (SD) 3.2 (13.2) 7.9 (21.7) 0.0 (0.0) 0.0 (0.0) 0.266
Trouble with coughing Mean (SD) 18.8 (21.2) 24.3 (29.6) 22.2 (19.2) 6.7 (14.9) 0.305
Trouble Talking Mean (SD) 0.3 (3.1) 5.6 (14.1) 0.0 (0.0) 6.7 (14.9) 0.001
Weight Loss Mean (SD) 6.3 (18.6) 16.9 (31.8) 0.0 (0.0) 40.0 (43.5) 0.002
Hair Loss Mean (SD) 0.7 (5.0) 7.2 (14.1) 0.0 (NA) 11.1 (19.2) 0.032
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Table 6.15: Patient-reported Functionality Domains by Performance
Status
Dependent: ECOG Score 0 1 2 3 p
Physical Functioning Mean (SD) 96.8 (7.2) 83.6 (16.7) 55.6 (27.8) 65.3 (28.8) <0.001
Role Functioning Mean (SD) 96.7 (13.6) 73.2 (30.3) 44.4 (50.9) 43.3 (46.5) <0.001
Emotional Functioning Mean (SD) 87.7 (17.3) 76.9 (23.3) 63.9 (33.7) 73.3 (43.5) 0.003
Cognitive Functioning Mean (SD) 94.7 (10.2) 83.1 (24.9) 66.7 (44.1) 70.0 (41.5) <0.001
Social Functioning Mean (SD) 96.1 (10.8) 73.4 (29.1) 55.6 (50.9) 50.0 (40.8) <0.001
Body Image Mean (SD) 97.4 (11.8) 87.6 (25.4) 88.9 (19.2) 60.0 (54.8) <0.001
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6.4 Discussion of CT-BCA Variable Relationship with QoL Metrics
6.4.1 Current QoL PROMs In Pre-Operative Patients
There is increasing interest in the use of PROMs to help define trial end-points and to assess patient quality
of life through the healthcare journey. Many of these PROMs have been validated in cancer patients, though
the patients used for validation of the PROM used in the current study were from a non-resectable lung cancer
cohort [172]. When considering the PROM outcomes recorded in the present study, this would seem to fit
with the symptomatology and reported functionality. Reporting instructions recommend a difference between
groups of 10 points to reach clinical significance. This was rarely seen, as the majority of the patients under
study had little symptomatology and good reported function. From this, it could perhaps be suggested that the
sensitivity of these instruments for detecting relevant QoL changes in a relatively well-preserved pre-operative
cohort is limited.
6.4.2 Ability of CT-BCA to Subdivide Current PROMs
The results noted above show that the symptoms and function reported by patients appears relatively unaffected
by CT cut-points in the current cohort. This may be related to the suggestion than the translation of CT-BCA
variables to patient symptomatology and reported function is non-linear. There is, within the literature, a
recognition that different populations across the globe will have different distributions for SMI and potentially
for SMD. It is known, for example, that South East Asian patients have a lower SMI than those of a western
European background [125].
What is also important to note, is that cut-points derived from a western European and North American
population may not maintain their relevance even within that population [107]. The SMI and SMD distribution
of patients shown in Chapter 5 gives weight to this suggestion, and it may be that each population under
study will accordingly need bespoke cut-points identified. The choice of population to use for such cut-point
identification studies is difficult: it is currently unusual for healthy individuals to undergo CT scanning; taking
cut-points from the population under study may be confounded by disease processes; and if studies are
multi-centre, cut-points derived at one centre may not be applicable to the other centres. Nevertheless, the
utility and repeated demonstration of prognostic value derived from published cut-points in differing populations
lends credence to their use in signposting disease progression.
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6.4.3 Ability of CT-BCA to Subdivide Objective Measures of Function
By their nature, patients recruited from a preoperative cohort must be sufficiently fit to undergo their planned
procedure. It is unusual in Scotland (and very possibly unethical) to offer surgery to those who are likely
to succumb during or immediately following surgery. Accordingly, those patients considered for operative
intervention will have sufficiently preserved physical function as to enable them to undergo major surgery.
Additionally, those considered “borderline” for such a procedure are assessed by multiple members of the
peri-operative team and may be declined for surgery if felt unfit. With this in mind, it is not unexpected to
find very few patients in the current study falling below the EWGSOP functional cut-point of a gait speed
less than 0.8ms-1. Whilst it would be intellectually pleasing to find CT-BCA variables neatly divided along
objective functional lines, this is not borne out by the data. The spread of patients with normal and low SMI
and SMD across the gait speed domain suggests that there is at best a limited relationship between CT-BCA
and gait speed.
Thus patients can have defined cachexia; or CT-BCA sarcopenia; or both, and still exhibit preserved physical
functioning. This finding seems to go against the accepted definition of cachexia as leading to “progressive
physical impariment”, although it could easily be that the patients in the current study are in fact in the
“pre-cachexia” stage of the process. This would suggest that the definition of cachexia, or the cut-points on




Relationship Between CT Body
Composition Variables and Muscle
Protein Content
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The relationship between skeletal muscle protein content of surgical biopsies and CT-BCA variables derived
from patients submitting these biopsies is currently unclear. As discussed in Chapter 1, CT-BCA is being used
as a trial outcome measure, and one assumption is that changes in CT-BCA (SMI and SMD) reflect changes
in muscle biochemistry and specifically protein content. Additionally, the reference values for muscle protein
content were derived from a small cohort of non-phenotyped American male trauma victims from the 1950s.
The relationship of these individuals to, and how closely they represent modern European patients is unknown,
as is the difference between healthy (LDN), non-cancer (AAA), and cancer (UGIC) patient muscle protein
content.
We aimed to define normal as measured by modern copper reduction protein analytic techniques, and to relate
this to UGIC and AAA groups.
7.1 Hypothesis and Research Questions
7.1.1 Hypothesis
There is a strong relationship between CT-BCA variables and skeletal muscle protein content.
7.1.2 Research Questions
• What is the skeletal muscle protein content of rectus abdominis muscle in the current study patients?
• Is there a difference in protein content between patient types?
• How does skeletal muscle volume relate to muscle protein content?
• How does skeletal muscle radio-density relate to muscle protein content?
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7.2 Methods for Investigating CT and Protein Content Relationship
Patients undergoing surgical resection for upper gastrointestinal cancer (UGIC) (22 gastric, 70 oesophageal,
24 pancreatic and 4 with other upper GI cancers) were recruited. This group includes those patients previously
recruited as part of another study. Additionally, non-cancer vascular aortic (AAA) (n=52) and healthy
live kidney donor (LDN) (n=53) patients were recruited. Patients were defined as cachectic if they met
the 2011 consensus definition criteria (as described in Chapter 1) [12]. Sarcopenia was defined using SMI
cut-offs according to BMI [18]. SMD was measured between -30 and 150 HU, with low SMD defined as
<41 HU with BMI <25 and <33 with BMI >25 [18]. Preoperative staging CT scans were analysed at
L3 level using semi-automated Slice-O-Matic software v4.2 (Tomovision Montreal-Canada), which defines
area measurements of skeletal muscle, subcutaneous fat, and visceral fat. Under general anaesthesia during
resectional surgery, rectus abdominis muscle biopsies were taken, snap-frozen in liquid nitrogen, and stored at
-80°C in monitored freezers prior to analysis. These biopsies were pulverized and weighed using an analytical
balance (Mettler Toledo), then lysed with Phosphosafe Extraction Reagent (Merck Millipore, Burlington, Mass.,
USA) before being homogenized and centrifuged. The supernatant was analysed for total soluble protein
(including myofibrillar and cystosolic) content using commercially available BCA protein assay kits (Pierce
Biotechnology, Thermo Fisher Scientific, Rockford, IL) [66].
Statistics including linear modelling, and Welch 2-sided t-tests; and plotting were performed in R [168], as
dicussed in Chapter 3.
7.2.1 Missing data analysis
An analysis was conducted with regard to missing data. As discussed in Chapter 3, the protein content analysis
was conducted at a professional laboratory, and subject to the analysis priorities of this laboratory. As such,
some of the samples were not analysed by the end of the study. Accordingly, there were cases in which protein
content was not available for inclusion. A comparison between cases with and without protein content was
undertaken to ascertain whether there was a significant difference in protein content with regard to potential
explanatory variables. This revealed statistically significant differences in age (64.7 vs 60.4 years, p = 0.009),
TUG (9.4 vs 8.6 seconds, p = 0.03), and gait speed (1.3 vs 1.6 m/s, p < 0.001) between patients with and
without protein content analysis. A further analysis suggested that the pattern of missingness would support
the decision to perform whole-case analysis as described in Chapter 3.
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Table 7.1: Protein Content (microg/mg wet weight) overall
Min Max Mean (sd)
30.99 335.4 125.88 (72.74)
Table 7.2: Protein Content (microg/mg wet weight) by Patient Type
Patient Type Min Max Mean (sd)
Live donor 44.45 335.4 126.76 (74.77)
Vascular 42.4 312.96 140.05 (86.09)
Cancer 30.99 314.82 120.7 (67.17)
7.3 Results for CT and Muscle Protein Content
7.3.1 Overall Protein Content
Across the entire cohort, mean muscle protein content was 125.88 (range 30.99-335.4) microg/mg wet weight.
In each group, the mean (range) protein content was: LDN 126.76 (44.45-335.4); AAA 140.05 (42.4-312.96);
UGIC 120.7 (30.99-314.82) microg/mg wet weight. These are shown in Table 7.1 and Table 7.2. Further
segregation of muscle protein content by patient diagnosis, by sex, and by SMD are shown in Table 7.3. The
overall protein content in this patient cohort is shown in Figure 7.1, and shows a normal distribution across all
patient groups.
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Table 7.3: Protein Content (microg/mg wet weight) by Patient Type, Sex, and SMD
Patient Type Sex SMD Min Max Mean (sd)
Live donor
Male Normal 59.59 303 123.85 (71.8)
Male Low 61.29 61.94 61.61 (0.46)
Female Normal 44.45 335.4 140.05 (80.62)
Female Low - - - (-)
Vascular
Male Normal 42.4 300.33 112.09 (73.4)
Male Low 62.2 296.06 162.95 (85.78)
Female Normal 84.12 96.72 88.76 (6.92)
Female Low 62.63 312.96 167.24 (121.72)
Cancer
Male Normal 50.99 314.82 131.32 (73.45)
Male Low 30.99 271.43 120.24 (66.54)
Female Normal 54.4 168.74 100.36 (33.45)













Live donor Vascular Cancer
Skeletal muscle protein content distribution
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Figure 7.1: Skeletal Muscle Protein Content by Patient Type
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Table 7.4: Welch 2-sided t-test of Muscle Protein Content in Normal vs Low SMD by Patient Type
Group Difference Normal SMD Low SMD CI (low) CI (high) p value
Live donor 71.071 132.685 61.614 37.644 104.498 <0.001
Vascular -57.435 106.703 164.138 -115.353 0.483 0.052
Cancer 7.820 124.036 116.217 -20.973 36.612 0.59
7.3.2 Relationship Between CT-BCA Variables and Skeletal Muscle Protein Content
Applying the Martin et al [18] SMI cut-points to divide patients into normal and low SMI did not reveal any
statistically significant differences in muscle protein content across any of the patient types. This can be seen
graphically in Figure 7.2, showing that the spread of skeletal muscle protein content does not appear to diverge
according to SMI cut-points.
Applying the Martin et al SMD cut-points to the same patients was expected to produce more of a difference
as radio-density had been thought to bear more of a relationship with skeletal muscle constituent parts [59].
This did show some differences, as shown in Table 7.4, however it has to be noted that there were few patients
in the low SMD LDN subgroup.
This is perhaps best illustrated in graphical form as seen in Figure 7.3 which shows that the spread of protein
content is not obviously segregated by clinically-derived SMD cut-points.
119












































Normal SMI Low SMI
Protein Content in Patient Subsets by SMI Cut−Points
Figure 7.2: Protein Content in microg/mg wet weight by Patient Group and SMI
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Protein Content in Patient Subsets by SMD Cut−Points
Figure 7.3: Protein Content in microg/mg wet weight by Patient Group and SMD
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Normal Fulfil cachexia criteria
Protein content in patient subsets
with cachexia criteria fulfilment
Figure 7.4: Protein Content in microg/mg wet weight by Patient Group With Regard to Cachexia
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Interestingly, if the same data are plotted with regard to whether the patients fulfil the international consensus
definition of cancer cachexia [12], the protein content distribution is that shown in Figure 7.4. It is worth noting
that this is a specifically “cancer” cachexia definition, that the LDN population weight loss was voluntary, and
that the AAA population do not have a recognised wasting disease despite their weight loss being involuntary.
Nevertheless, it is important to note that in these and the cancer group, once again clinical definitions which
should have a bearing on muscle composition do not appear to be usable to segregate patients into higher or
lower muscle protein content subsets.
It may be that dichotomising data to try to find differences would require more data points than currently
available to reach significance. In this case, it may be that relationships are present, and this should
be investigated. Accordingly, linear regression was performed to ascertain the presence or otherwise of a
relationship between CT-BCA variables and muscle protein content. These analyses were performed for each
patient group overall, and then within each group by sex and BMI as appropriate. The investigations revealed
no statistically significant relationships between SMD and skeletal muscle protein content, and are thus neither
tabulated nor plotted.
There were statistically significant relationships between protein content and SMI in all patients, in cancer
patients in general, and between protein content and SMI in high BMI male cancer patients within the cancer
group as detailed in Tables 7.5 (R2 = 0.0324, p = 0.028), 7.6 (R2 = 0.07, p = 0.012 for UGIC, others
non-significant), and 7.7 (R2 = 0.125, p = 0.02 in high BMI male UGIC, others non-significant). It is to be
noted, however, that the relationships are very weak, as shown in Figures 7.5, 7.6, and 7.7. The non-significant
UGIC relationships were not plotted. The weakness of the relationships reaching statistical significance leads
to the inference that although there is a potential relationship between CT-BCA variables and protein content
of skeletal muscle, it is unclear that changes in CT-BCA can be relied upon or interpreted to reflect changes
in muscle protein content during an intervention trial.
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Table 7.5: Linear Regression between Protein Content and Skeletal Muscle Index
r-squared p value
0.034 0.028
Table 7.6: Linear Regression between Protein Content and Skeletal Muscle Index
Group r-squared p value
Live donor 0.001 0.900
Vascular 0.013 0.537
Cancer 0.070 0.012
Table 7.7: Linear Regression between Protein Content and Skeletal Muscle Index in Upper GI Cancer patients
Group r-squared p value
Female 0.001 0.905
Low BMI Male 0.004 0.765























Linear Modelling of Protein Content and SMI in All Patients























Linear Modelling of Protein Content and SMI
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Linear Modelling of Protein Content and SMI
in High BMI Male Cancer Patients
Figure 7.7: Linear Modelling of Protein Content and SMI in Male High BMI Cancer Patients
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7.3.3 Multivariable Analysis of Protein Content
A multivariable model relating to skeletal muscle protein content was constructed as described in Chapter 3.
This found that the predictors of muscle protein content were: Age, Gait Speed, and BMI. Of note, during
the stepwise regression process, SMI was initially included in the model, but subsequently removed as having
insufficient effect on the model once all of the above variables were included. This model is shown in Table
7.8. The Akaike information criterion for this model, however, remains high suggesting that the model is not
well fitted. Additionally, for this model whole case analysis was performed, and as described above some of
the UGIC patients were recruited in an earlier study. This previous study did not collect as much detailed
phenotyping data as the more recent recruitment process; specifically gait speed was not measured. This
reduces the number of patients able to undergo whole case analysis in each group, with only 13 LDN, 18 AAA,
and 29 UGIC patients suitable for inclusion.
An exploratory investigation of multivariable modelling excluding gait speed as a potential explanatory variable
was performed. This returned SMI, age, and whether the patient had lost weight as candidate variables.
Comparing the 2 models revealed that although there were more cases to include, the fit of the second model
(SMI + age + weight loss) was much worse than that of the first model (age + gait speed + BMI).
It appears that the multivariable model mirrors the findings of the univariable analysis, with limited support
for any hypothesis relating CT-BCA variables to skeletal muscle protein content.
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Table 7.8: Multivariable Modelling of Predictors of Muscle Protein Content
Dependent: Protein Content unit value Coefficient (univariable) Coefficient (multivariable)
Age [29.0,90.0] Mean (sd) 125.9 (72.7) 0.85 (-0.19 to 1.89, p=0.108) 1.09 (-0.74 to 2.92, p=0.239)
Gait Speed (m/s) [0.4,2.5] Mean (sd) 125.9 (72.7) 62.92 (-2.86 to 128.70, p=0.060) 82.71 (18.34 to 147.09, p=0.013)
BMI [15.0,48.0] Mean (sd) 125.9 (72.7) 1.86 (-0.42 to 4.14, p=0.108) 5.20 (1.20 to 9.20, p=0.012)
Number in dataframe = 226, Number in model = 60, Missing = 166, Log-likelihood = -343.35, AIC = 696.7, R-squared = 0.17, Adjusted R-squared = 0.13
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7.3.4 Defining “Normal” and “Low” Skeletal Muscle Protein Content
In order to ascertain the possible effect of muscle protein content on CT-BCA and other clinical variables, it
was decided to derive a muscle protein content cut-point of 1 standard deviation (SD) below the mean of
the healthy LDN group to allow segregation of patients into those with “Normal” and “Low” protein content.
Whilst in Chapter 5 a cut-point of 2 SD below the mean was used to define “normal”, when this technique
was applied to protein content, there were no patients with protein content below the cut-point, and so this
was felt to be of little worth.
The mean protein content of the LDN group was 126.76 microg/mg wet weight, with a standard deviation
of 74.77. This gave a normal/low cut-point of 51.99 microg/mg wet weight, below which it could be said
that patients had “Low” muscle protein content. Applying this cut-point to the study population, however,
revealed that 1 LDN, 1 AAA, and 4 UGIC patients fell into the “Low” category. Clearly this definition is too
restrictive, however it is currently unclear what level of protein content should be chosen instead.
7.3.5 Relationship Between Skeletal Muscle Protein Content and Physical
Performance
Having investigated the relationship between CT-BCA and skeletal muscle protein content, the next step was
to investigate whether measurable biochemical composition of muscle related to objective measures of physical
performance. As described in the Methods section, timed-up-and-go tests were performed at the point of
recruitment, with gait speed being captured as a part of this test. This allowed 2 distinct components to be
analysed, capturing different aspects of patient physical functioning.
The analysis overall between gait speed and protein content did not reveal a statistically significant relationship,
with R-squared value at 0.0594 and p=0.061. Investigating further, however, and analysing patient groups
in isolation revealed a relationship reaching statistical significance for vascular patients as shown in Table 7.9,
and in Figure 7.8.
Indexing gait speed for height, as described by Hof [173] and Stansfield et al [174] did not reveal any new
significant relationships between protein content and indexed gait speed.
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Table 7.9: Linear Modelling of Protein Content and Gait Speed in All Patients
Group r-squared p value

















Linear Modelling of Protein Content and Gait Speed
in Vascular Patients
Figure 7.8: Linear Modelling of Protein Content and Gait Speed in Vascular Patients
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7.3.6 Protein content distribution and clinical phenotypes
As mentioned in Chapter 1, Johns et al [66] investigated the distribution of skeletal muscle protein content
according to 4 clinical phenotypes: 1. Weight loss >5% 1. Weight loss >10% 1. Low muscularity by CT-BCA
1. Low muscularity by CT-BCA and weight loss >2%
In their study, Johns et al recruited 32 upper GI cancer patients who underwent rectus abdominis biopsies,
finding statistically significant differences in protein content between those who did and did not exhibit class
I and class IV phenotypes. The present patient cohort was investigated to ascertain whether these clinical
phenotypes would be applicable, whether differences in protein content would reach statistical significance, and
which classes of phenotype would reach significance. Applying the clinical phenotypes to all groups revealed
statistically significant differences in protein content in the class II phenotype only (132 v 96.3 microg/mg
wet weight, p = 0.0045). Differences were seen in both the AAA (144 v 77.2 microg/mg wet weight, p =
0.0004) and UGIC (128 v 96.5 microg/mg wet weight, p = 0.0289) groups, however on closer inspection it
was revealed that there were only 2 patients in the AAA group who fulfilled the class II phenotype. As such, it
is unclear how much this result can be relied upon. These results are presented in tabular form in Table 7.10
and Table 7.11.
Table 7.10: Welch 2-sided t-test of Mean Skeletal Muscle Protein
Content In All Patients
Difference Normal Class II phenotype Low CI High CI p-value
35.2505 131.5053 96.2548 11.4651 59.0359 0.0045
Table 7.11: Welch 2-sided t-test of Mean Skeletal Muscle Protein
Content In Patients Who Do And Do Not Meet Class II Phenotype
Group Difference Normal Class II phenotype Low CI High CI p-value
Vascular 67.1753 144.3865 77.2112 33.1097 101.2408 4e-04
Cancer 31.1728 127.7026 96.5297 3.3672 58.9785 0.0289
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7.4 Discussion of Relationship Between Skeletal Muscle Protein
Content and CT Variables
The plots presented above, together with the tables detailing the statistical tests performed to demonstrate
differences in muscle protein content by CT-derived cut-points, show that there is not a clear relationship
between CT body composition measures of skeletal muscle and the protein content of that muscle. Accordingly,
attempting to draw conclusions about the content of skeletal muscle from CT-derived body composition
variables is fraught with difficulty and the potential to cause or report erroneous results. This is of relevance
when intervention trials use CT-BCA as outcome measures assuming that changes in CT-BCA can act as a
surrogate for changes in muscle protein content.
Additionally, the relationship between the protein content of skeletal muscle and objective physical performance
of patients similarly does not follow a linear trajectory. It is likely that the functioning of skeletal muscle in
patients seen clinically is not solely reliant on the protein content of that muscle. Other factors including
changes at the neuro-muscular junction; previous physical training; and even patient motivation or mood may
have an effect on how well the muscle functions, and how well that function can be translated into measurable
outcomes.
Recently, increasing interest in the relationship of CT variables to measurable patient outcomes has led to an
inference that certain variables relate to particular biochemical and biophysiological pathways and mechanisms
and components. The current analysis lend credence to the suggestion that these relationships may be more
complex and more difficult to interpret than previously considered.
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Chapter 8
Relationship Between CT-BCA Variables
and Muscle Fibre Cross-sectional Area
(CSA)
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As discussed in Chapter 1, work has previously been published investigating the differences in muscle fibre
cross-sectional area (CSA) between patients with cachexia, and those without [66]. This work was confined to
41 cancer patients, and CSA distribution in healthy controls is unknown. Additionally, the work done by Johns
et al utilised CT-BCA to classify patients into normal or low muscularity subgroups rather than investigating
whether there is a relationship between CSA and CT-BCA.
8.1 Hypothesis and research questions
8.1.1 Hypothesis
Muscle CSA distribution differs between patient types; will separate into distinct subgroups when
CT-BCA cut-points are applied; has a strong relationship with CT-BCA variables; and has a strong
relationship with muscle protein content.
8.1.2 Research Questions
• What is the distribution of muscle CSA in each patient type?
• Can a separation be seen in CSA distribution when CT-BCA is applied?
• What is the relationship between CSA and CT-BCA?
• What is the relationship between CSA and protein content?
8.2 Methods for Assessing the relationship between CT and CSA
Between 2015 and 2017, patients from upper GI cancer (UGIC, n=56), vascular (AAA, n=30), and live kidney
donors (LDN, n=24) were recruited. Skeletal muscle biopsies from the rectus abdominis muscle were collected,
processed, stored, and analysed as described in Chapter 3.
Statistics and plotting were performed in R [168]. Analyses included curve fit using locally estimated scatterplot
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smoothing (LOESS) modelling; weighted mean calculation; and t-tests and linear regression on the weighted
mean. Linear regression is reported using Adjusted R2.
8.3 Results of Skeletal Muscle Fibre CSA Analysis
The distribution of muscle fibre CSA in each patient type is presented in Figure 8.2for FTIIa (fast) fibres, and
in Figure 8.3 for Non-FTIIa (slow) fibres. As shown, every patient has data points for each fibre size, with
associated percentage composition of the light field as a percentage. Accordingly, the percentage composition
and fibre size were combined using a weighted mean (WM-CSA) analysis to give individual patients a single
value for muscle fibre size thus allowing comparisons between patients. Individual patient CSA examples are
shown in Figure 8.1.
Weighted mean CSA is presented in Table 8.1 for FTIIa (fast) fibres and in Table 8.2 for Non-FTIIa (slow)
fibres. The reader will note that the figures for each match exactly - perhaps in part related to the numbers
of patients in each subset. To ensure there was indeed a difference between fibre type CSA, WM-CSA was
analysed across all patients purely by sex, as shown in Table 8.3. This reveals that the WM-CSA is indeed
different between fibre types, and thus the matching numbers seen in the tables referred to above may be
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Figure 8.3: CSA Distribution in All Patients for Non-FTIIa (slow) fibres
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Table 8.1: Weighted Mean FTIIa (fast) Muscle Fibre CSA by Patient Type, Sex, and BMI
Patient Type Sex BMI Min Max Mean (sd) n
Live Donor
Male Normal 2730.24 3812.99 3155.77 (464.52) 4
Male High 4345.16 5484.92 4805.92 (419.47) 8
Female Normal 2392.60 2392.60 2392.6 (NA) 1
Female High 2248.12 4577.25 3520.45 (643.95) 11
Vascular
Male Normal 2976.55 5110.07 3652.46 (656.94) 8
Male High 1673.39 5127.23 3400.81 (994.29) 14
Female Normal 2977.47 3962.92 3506.32 (438.17) 4
Female High 1608.34 4423.58 2968.95 (1173.15) 4
Cancer
Male Normal 2302.23 4752.08 3433.2 (771.83) 15
Male High 1671.25 4829.34 3554.84 (756.36) 25
Female Normal 1954.56 4021.06 2863.09 (758.11) 8
Female High 1813.24 4577.25 3468.48 (934.46) 8
Table 8.2: Weighted Mean Non-FTIIa (slow) Muscle Fibre CSA by Patient Type, Sex, and BMI
Patient Type Sex BMI Min Max Mean (sd) n
Live Donor
Male Normal 2730.24 3812.99 3155.77 (464.52) 4
Male High 4345.16 5484.92 4805.92 (419.47) 8
Female Normal 2392.60 2392.60 2392.6 (NA) 1
Female High 2248.12 4577.25 3520.45 (643.95) 11
Vascular
Male Normal 2976.55 5110.07 3652.46 (656.94) 8
Male High 1673.39 5127.23 3400.81 (994.29) 14
Female Normal 2977.47 3962.92 3506.32 (438.17) 4
Female High 1608.34 4423.58 2968.95 (1173.15) 4
Cancer
Male Normal 2302.23 4752.08 3433.2 (771.83) 15
Male High 1671.25 4829.34 3554.84 (756.36) 25
Female Normal 1954.56 4021.06 2863.09 (758.11) 8
Female High 1813.24 4577.25 3468.48 (934.46) 8
Table 8.3: Weighted Mean CSA by Sex and Fibre Type
Sex Fibre Type Min Max Mean (sd)
Male
Non-FTIIa (slow) 1632.51 5684.04 3198.2 (880.11)
FTIIa (fast) 1671.25 5484.92 3625.28 (854.03)
Female
Non-FTIIa (slow) 1829.62 4258.24 3139.25 (738.08)
FTIIa (fast) 1608.34 4577.25 3268.64 (804.85)
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8.3.1 Relationship Between CSA and CT-BCA
As described by Johns et al [66], differences have been noted in muscle CSA between patients with low
muscularity as defined by CT and those with normal muscularity. The present study aimed to utilise the cohort
described above to more closely define this relationship.
8.3.1.1 SMI and SMI Cut-points
When investigating CSA and SMI, it seems reasonable to ascertain whether there is a relationship between the
two. Linear regression performed between SMI and CSA did not, however, reveal any statistically significant
relationship. For FTIIa (fast) fibres, using a linear model, R2 = 0.01 with p = 0.144. For Non-FTIIa (slow)
fibres using the same linear model, R2 = -0.07 with p = 0.644. These results are plotted in Figure 8.4 for
FTIIa (fast) fibres, and Figure 8.5 for Non-FTIIa (slow)fibres.
Considering that subgroup analysis may reveal a difference between groups for weighted mean CSA, attention
was turned to the Martin et al [18] subgroups within each cohort. The t-tests between normal and low SMI
groups for CSA are noted in Table 8.4 for FTIIa (fast) and in Table 8.5 for Non-FTIIa (slow) fibres.
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Linear Regression between SMI and Muscle Fibre CSA
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All patients
Figure 8.4: Relationship Between WM-CSA and SMI in FTIIa (fast) fibres
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Linear Regression between SMI and Muscle Fibre CSA
Non−FTIIa (slow) fibres
All patients
Figure 8.5: Relationship Between WM-CSA and SMI in Non-FTIIa (slow) fibres
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Table 8.4: Welch 2-sided t-test of FTIIa (fast) Muscle Fibre CSA by Sex and Patient Group Between Normal
and Low SMI
Patient Type Sex Difference Normal SMI Low SMI Confidence Interval (Low) Confidence Interval (High) p value
Live donor
Male -223.01 4181.53 4404.54 -1763.87 1317.85 0.73
Female -175.41 3353.37 3528.78 -1048.20 697.38 0.66
Vascular
Male -77.64 3446.44 3524.09 -809.21 653.92 0.83
Female 532.89 3504.08 2971.19 -1026.63 2092.41 0.43
Cancer
Male -55.71 3482.76 3538.47 -552.06 440.63 0.82
Female 338.48 3313.87 2975.39 -645.22 1322.17 0.47
Table 8.5: Welch 2-sided t-test of Non-FTIIa (slow) Muscle Fibre CSA by Sex and Patient Group Between
Normal and Low SMI
Patient Type Sex Difference Normal SMI Low SMI Confidence Interval (Low) Confidence Interval (High) p value
Live donor
Male -326.71 3369.52 3696.23 -1598.72 945.29 0.56
Female 58.51 3175.25 3116.74 -849.31 966.34 0.89
Vascular
Male -74.16 3115.06 3189.22 -771.44 623.12 0.83
Female 56.98 3204.53 3147.55 -1658.21 1772.17 0.94
Cancer
Male -225.98 3028.42 3254.40 -826.26 374.30 0.45
Female 43.98 3131.38 3087.40 -785.10 873.05 0.91
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8.3.1.2 SMD and SMD Cut-points
Whilst a relationship between CSA and SMI could be possible, it seems more likely that there would be
a relationship between CSA and SMD. This potential relationship could be explained by an increase in
radio-density being affected either by an increase in intra-cellular radio-dense material in large muscle fibres,
or by an increased proportion of extra-cellular or cell wall material in small muscle fibres.
Linear regression was performed for each fibre type across the entire cohort, and revealed R2 = -0.009, with p
= 0.965 for FTIIa (fast) fibres and R2 = 0.003 with p = 0.253 for Non-FTIIa (slow) fibres.
Plots showing this graphically are seen in Figure 8.6 for FTIIa (fast) and in Figure 8.7 for Non-FTIIa (slow)
fibres.
Subdividing the cohort and groups by SMD cut-points allowed t-testing between normal and low SMD as
shown in Table 8.6 for FTIIa (fast) and Table 8.7 for Non-FTIIa (slow) fibres. There were too few LDN
patients in the normal BMI group in each of the SMD subdivisions to perform a t-test. In the High BMI LDN
subgroup, the differences between normal and low SMD did not reach statistical significance.
Overall, these tests do not reveal any significant difference between patient type WM-CSA values when divided
by CT-BCA cut-points.
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Linear Regression between SMD and Muscle Fibre CSA
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All patients
Figure 8.6: Relationship Between WM-CSA and SMI in FTIIa (fast) fibres
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Linear Regression between SMD and Muscle Fibre CSA
Non−FTIIa (slow) fibres
All patients
Figure 8.7: Relationship Between WM-CSA and SMD in Non-FTIIa (slow) fibres
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Table 8.6: Welch 2-sided t-test of FTIIa (fast) Muscle Fibre CSA by Patient Type and by BMI Between Normal
and Low SMD
Patient Type Patient BMI Difference Normal SMD Low SMD Confidence Interval (Low) Confidence Interval (High) p value
Cancer
Normal 142.60 3675.05 3532.45 -678.31 963.51 0.69
High 593.45 3700.48 3107.03 -330.68 1517.59 0.19
Vascular
Normal 286.35 3409.20 3122.85 -515.92 1088.61 0.45
High -253.37 3418.74 3672.10 -838.61 331.88 0.38
Table 8.7: Welch 2-sided t-test of Non-FTIIa (slow) Muscle Fibre CSA by Sex and by Patient Group Between
Normal and Low SMD
Patient Type Patient BMI Difference Normal SMD Low SMD Confidence Interval (Low) Confidence Interval (High) p value
Cancer
Normal -336.95 3180.41 3517.36 -1293.18 619.27 0.43
High 33.95 3062.47 3028.52 -914.30 982.20 0.94
Vascular
Normal 339.86 3108.12 2768.26 -634.00 1313.72 0.46
High -157.34 3216.23 3373.57 -765.22 450.54 0.60
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8.3.2 Protein Content and CSA
Intellectually, a linear relationship between CSA and muscle protein content could be expected. This was
tested as shown in Figure 8.8 for FTIIa (fast) fibres, and Figure 8.9 for Non-FTIIa (slow) fibres. This suggests
a very weak, though statistically significant relationship between protein content and WM-CSA in fast fibres.
To further investigate this, an assessment of this same relationship was performed for a series of
CT-BCA-derived sub-groups.
There were no significant relationships noted between WM-CSA values in normal or low SMI or SMD groups
for Non-FTIIa (slow) fibres.
For FTIIa (fast) fibres, there were statistically significant relationships noted, as presented in Table 8.8 for
SMI, and in Table 8.9 for SMD. These show a statistically significant relationship only in the AAA cohort,
and specifically only in those with low SMI or low SMD.
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Linear Regression Between Protein Content and Muscle Fibre CSA
FTIIa (fast) fibres
All patients
Figure 8.8: Relationship Between WM-CSA and Protein Content in FTIIa (fast) fibres
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Linear Regression Between Protein Content and Muscle Fibre CSA
Non−FTIIa (slow) fibres
All patients
Figure 8.9: Relationship Between WM-CSA and Protein Content in Non-FTIIa (slow) fibres
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Table 8.8: Linear Regression between FTIIa (fast) Muscle Fibre CSA and Protein Content in All Patients by
SMI
Patient Type SMI R-Squared (adjusted) p value
Live donor
Normal SMI -0.06 0.68
Low SMI -0.11 0.65
Vascular
Normal SMI 0.04 0.24
Low SMI 0.33 0.01
Cancer
Normal SMI -0.02 0.56
Low SMI -0.01 0.41
Table 8.9: Linear Regression between Non-FTIIa (slow) Muscle Fibre CSA and Protein Content in All Patients
by SMD
Patient Type SMD R-Squared (adjusted) p value
Live donor
Normal SMD -0.03 0.5
Low SMD - -
Vascular
Normal SMD -0.02 0.41
Low SMD 0.29 0.01
Cancer
Normal SMD -0.01 0.37
Low SMD -0.03 0.7
153
8.3.3 Gait Speed and CSA
A consideration of objective physical functioning and muscle CSA is presented in Figure 8.10 for FTIIa (fast)
fibres, and Figure 8.11 for Non-FTIIa (slow) fibres. Linear regression subgroup analysis was performed to
investigate the relationship between WM-CSA and gait speed in Non-FTIIa (slow) muscle fibres for CT-BCA
subgroups (both SMI and SMD). This did not reveal any statistically significant relationships.
Similar subgroup analysis was performed for FTIIa (fast) fibres. In the LDN group, we were unable to
demonstrate a relationship due to small numbers in each subgroup. Results from the UGIC and AAA groups
are presented in Table 8.10 and in Table 8.11 for SMD and SMI respectively.
These tables suggest that there is in fact a relationship between WM-CSA and gait speed when sub-grouped
by CT-BCA, but that it is confined to subsets of AAA patients. Of note, within the AAA, normal BMI, low
SMI subset there are only 3 patients. As such, it is unclear whether chance may explain this relationship, and
indeed whether this relationship will continue in the face of a greater sample size.
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Linear Regression between Gait Speed and Muscle Fibre CSA
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All patients
Figure 8.10: Relationship Between WM-CSA and Gait Speed in FTIIa (fast) fibres
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Linear Regression between Gait Speed and Muscle Fibre CSA
Non−FTIIa (slow) fibres
All patients
Figure 8.11: Relationship Between WM-CSA and Gait Speed in Non-FTIIa (slow) fibres
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Table 8.10: Linear Regression between FTIIa (fast) Muscle Fibre CSA and Gait Speed, by SMD
Patient Type BMI SMD R-Squared (adjusted) p value
Vascular
Normal Normal SMD 0.94 0.11
Normal Low SMD 1 0.02
High Normal SMD - -
High Low SMD 0 0.34
Cancer
Normal Normal SMD -0.08 0.49
Normal Low SMD 0.88 0.01
High Normal SMD 0.61 0.01
High Low SMD 0.4 0.06
Table 8.11: Linear Regression between FTIIa (fast) Muscle Fibre CSA and Gait Speed, by SMI
Group BMI SMI R-Squared (adjusted) p value
Vascular
Normal Normal SMI 0.94 0.11
Normal Low SMI 1 0.02
High Normal SMI -0.33 0.99
High Low SMI -0.16 0.69
Cancer
Normal Normal SMI -0.2 0.97
Normal Low SMI -0.33 0.98
High Normal SMI -0.16 0.71
High Low SMI -0.12 0.97
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8.3.4 Multivariable Regression in CSA
Having considered the relationships between individual variables and WM-CSA for both FTIIa (fast) and
Non-FTIIa (slow) fibres, a multivariable analysis was then conducted to investigate and model potential
predictors of WM-CSA in this context. As discussed in Chapter 3, initial additive modelling was conducted,
and checked by stepwise removal.
When the FTIIa (fast) fibre types were considered, the variables identified for further interest were sex,
age, and protein content. This analysis revealed the model shown in Table 8.12. Closer inspection of
this model, however, reveals that the Akaike information criterion indicates poor model fitting, and so the
interpretability of this model is unclear. Additionally, it is to be noted that none of the identified variables
were CT-BCA variables which suggests that CT-BCA variables are not the strongest predictors of WM-CSA
in this population.
When Non-FTIIa (slow) fibre types were considered, there was only one variable identified for model
construction - weight. Since a single-variable model cannot be considered as a multivariable analysis this was
not included. It is interesting to note, however, that CT-BCA variables were once again not identified as
predictor variables in this case.
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Table 8.12: Multivariable Modelling of WM-CSA Predictors in FTIIa (fast) Fibres
Dependent: WM-CSA unit value Coefficient (univariable) Coefficient (multivariable)
Sex Male Mean (sd) 3625.3 (854.0) - -
Female Mean (sd) 3268.6 (804.9) -356.63 (-694.33 to -18.94, p=0.039) -387.00 (-712.38 to -61.63, p=0.020)
Age [29.0,90.0] Mean (sd) 3508.6 (851.3) -17.66 (-30.95 to -4.37, p=0.010) -14.47 (-27.50 to -1.44, p=0.030)
Protein Content [31.0,335.4] Mean (sd) 3508.6 (851.3) -2.40 (-4.37 to -0.42, p=0.018) -2.27 (-4.20 to -0.34, p=0.022)
Number in dataframe = 226, Number in model = 109, Missing = 117, Log-likelihood = -881.35, AIC = 1772.7, R-squared = 0.14, Adjusted R-squared = 0.12
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8.3.5 Defining Normality
Utilising the muscle biopsy results obtained from the LDN population, an attempt to define “normal” WM-CSA
was undertaken.
In line with previous work on sarcopenia by Baumgartner et al [7], the mean and standard deviation for the
LDN population were obtained for WM-CSA. These are is shown in Figure 8.12 for FTIIa (fast) fibres, and
Figure 8.13 for Non-FTIIa (slow) fibres. These show very few patients below the cut-point, suggesting that
very few patients have a low WM-CSA. Additionally, the WM-CSA is a crude measure of rather granular data,
and as such it may be that it is not optimum for this particular task.
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WM−CSA for all patients with 2SD below mean
FTIIa (fast) fibres
Figure 8.12: Weighted-Mean CSA with Normal Line (fast fibres)
161

















WM−CSA for all patients with 2SD below mean
Non−FTIIa (slow) fibres
Figure 8.13: Weighted-Mean CSA with Normal Line (slow fibres)
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Chapter 9
Relationship Between CT-BCA Variables
and Inflammation
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As described in Chapter 1, the effect of SI on cancer patient outcomes can be quite marked. Additionally,
alterations in CT-BCA variables appear to relate to cancer patient outcomes and this has led to the development
of cut-points below which patient outcomes appear to deteriorate. The relationship between SI and CT-BCA
variables, however, is unclear; the effect of SI on CT-BCA and the potential clinical impact of this merits
investigation, because SI is a significant factor in cachexia, and thus CT-BCA is influenced by the condition is
purports to measure.
9.1 Hypothesis and Research Questions
9.1.1 Hypothesis
Systemic inflammation has minimal measurrable on CT-BCA variables.
9.1.2 Research Questions
• What differences are demonstrable between CT-BCA at differenct time-points prior to; during; and
following severe SI?
• How do these differences, if any, relate to ongoing SI?
9.2 Methods for Investigating Relationship Between CT-BCA and
Inflammation
Between August 2012 and October 2016, patients who underwent Ivor-Lewis oesophago-gastrectomy (ILOG),
and who developed post-operative anastomotic leak, were identified retrospectively from a prospective local
audit database. Routine preoperative staging CT scans closest to time of surgery were analysed with regards
to body composition (preop scans). Those patients who developed symptoms or signs of sepsis (delirium,
pain, pyrexia, tachycardia, hypotension, leucocytosis), or who on clinical grounds (drain fluid turbidity,
increasing oxygen requirement) were suspected of suffering a breakdown of the oesophago-gastric intrathoracic
anastomosis, underwent early postoperative CT scanning and these were analysed (early scans). Patients
were excluded from analysis if an early postoperative CT scan was not available. Where available, any delayed
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follow-up scans were also retrieved for analysis to assess the reversibility of changes noted on post-operative
scans (late scans after sufficient time for resolution of SI). If the formal report from the radiologist indicated
recurrent disease or an ongoing inflammatory process, these follow-up scans were excluded from subsequent
analysis to exclude the confounding possibility of altered body composition because of tumour-derived
metabolic derangement (cachexia) or ongoing SI. Following major surgery, patients are known to become
significantly oedematous, leading to a well-recognised increase in body weight [175]. However, due to their
critical illness state, patients are not routinely weighed during standard clinical care in the early postoperative
period. For this reason, stratification of CT body composition results by patient BMI to identify sarcopenia
was not performed, as the preoperative weight is unlikely to remain accurate in the postoperative phase,
and furthermore, the influence of excess oedema on stratification calculations is unknown. Accordingly, the
current study is focussed on tissue area measurements. Preoperative, early postoperative, and late follow-up
CT scans were analysed as described in Chapter 3. Routine blood sampling was performed, including plasma
C-reactive protein (CRP) levels measured by automated turbidimetry, and plasma albumin levels measured
by dye-binding techniques. Variables were compared between the preoperative, postoperative, and follow-up
groups using a Paired Sample t-test in R [168].
9.3 Results for Analysis of Relationship Between CT-BCA and
Inflammation
During the study period, 18 patients with anastomotic leak who had undergone ILOG met criteria for inclusion.
Demographic data are presented in Table 9.1. Postoperative scans were performed at median 9 days post-op
(range 5-44), and follow-up scans at 430 days (126-1191). The CT variables shown in Table 9.1 are represented
in Figure 9.1 for SMA, and in Figure 9.2 for SMD. Mean and standard deviation representations of this data
are shown in Figure 9.3 for SMA and in Figure 9.4 for SMD.
These figures clearly demonstrate in graphical form the differences across time-points enumerated in Table 9.1.
Between the preoperative, early, and late scans it can be seen that SMA first rises and then dips; and SMD
dips and then rises. This combination of changes, in conjunction with a known elevation of inflammatory
marker (CRP), suggests that these CT-BCA alterations are linked to the patients’ ongoing and underlying
inflammatory response.
Whilst visually appealing, a consideration of the figures will reveal that the error-bars, which are set at 1 standard
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deviation from the mean, appear to overlap. It may be, therefore, that the visible differences represent a chance
finding only. Accordingly, we proceeded to undertake a series of paired t-tests to ascertain whether there was
a difference between the preop, early, and late time-points in order to determine firstly whether the dip or
rise represented a true change, and secondly whether the recovery value (late) retained a significant difference
from the initial value (preop).
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Table 9.1: Demographic distribution of inflammatory patient data
Dependent: Sex Male Female p
Age Mean (SD) 63.8 (9.0) 62.7 (9.0) 0.851
Tumour type ACC 13 (81.2) 3 (100.0) 1.000
SCC 3 (18.8)
Final_stage 1 5 (31.2) 0.405
3 6 (37.5) 1 (33.3)
4 5 (31.2) 2 (66.7)
SMA (Preop) Mean (SD) 154.4 (19.7) 85.4 (5.3) <0.001
SMA (Early) Mean (SD) 162.9 (28.4) 122.9 (8.0) 0.032
SMA (Late) Mean (SD) 140.0 (19.4) 123.7 (19.2) 0.290
SMD (Preop) Mean (SD) 32.1 (8.3) 36.6 (7.3) 0.391
SMD (Early) Mean (SD) 28.1 (8.0) 27.7 (7.3) 0.934
SMD (Late) Mean (SD) 33.7 (5.8) 30.4 (4.8) 0.456
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Skeletal Muscle Radio−Density at 3 Time−points
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Mean Skeletal Muscle Radio−Density at 3 Time−points
Figure 9.4: Mean and SD Timepoint Distribution of Skeletal Muscle Radio-Density
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Table 9.2: Pairwise t-tests of CT SMA Variables by Time-point
CT Time-point 1 CT Time-point 2 p value
Preop Early postop 0.08
Preop Late postop 0.46
Early postop Late postop 0.09
Table 9.3: Pairwise t-tests of CT SMD Variables by Time-point
CT Time-point 1 CT Time-point 2 p value
Preop Early postop 0.04
Preop Late postop 0.73
Early postop Late postop 0.05
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9.4 Discussion Analysing Relationship Between CT-BCA and Inflammation
The current study shows that in an ILOG cohort, body composition variables change between preoperative and
post-complication CT scans in the context of severe SI. The cause for these changes are likely to differ between
the measured variables in question; for example, although fat was not measured, a theoretical alteration in
visceral fat area is likely to be related to operative technique which includes greater omental fat attached
to the stomach being pulled into the thoracic cavity. Conversely, subcutaneous fat area is unlikely to be
affected by operative technique. Similarly, the increase in skeletal muscle area noted will likely represent tissue
oedema in context of inflammation rather than a true increase in skeletal muscle bulk, and this is reflected
further in the observed decreases in SMD. The relationship between SMI and severe inflammation has been
seen before in colorectal cancer patients [166] though radio-density has not been investigated. Oedema is
due to changes in capillary fenestration sizes in SI resulting in albumin leakage and associated differences in
osmotic pressure leading to increased tissue water content. The initial response to trauma and surgery also
includes secretion of hormones with multiple effects. The release of arginine vasopressin from the posterior
pituitary affects the kidneys by promoting resorption of sodium and thus water. The secretion of renin results
in an increase aldosterone again promoting sodium and water retention [166]. An alternative explanation
for the observed reduction in SMD is altered distribution of intravenous contrast during SI. Whilst the scans
examined were all performed in the portal venous phase to ensure comparable body composition variables
were obtained [59], systemic effects of inflammation on gross and micro- circulation should be considered. In
severe inflammation and in septic states, the myocardium is known to be depressed [176] which may result in
differences between “non-inflammatory” and “inflammatory” scans despite careful contrast gating. Additionally,
severe inflammation is known to influence the microvasculature of multiple tissues [166]. These microscopic
effects may alter the tissue bed uptake of contrast media thus altering the radio-density of the tissues. Contrast
distribution may be affected further by the intravascular volume status of the patient and the quality of medical
resuscitation. Therefore, one possible confounder of the present study is the lack of information regarding the
volaemic status of the patients at time of CT scanning. It has been shown that SMD does not closely correlate
with intramuscular protein content as seen in Chapter 7, and this may be because SMD is influenced by other
patient factors such as SI highlighting the difficulties of using SMD as an outcome measure in trials of cachexia
therapeutics. At time of follow-up scan, it is notable that SMD had returned to levels comparable to those
recorded preoperatively, and that SMI did likewise. This would suggest that these variables mirror the biphasic
“ebb and flow” of SI, and that as the inflammatory state returns towards normal, the CT variables do likewise.
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An explanation for this observation is the presence and then resolution of tissue oedema altering muscle volume
and radio-density for the duration of the inflammatory response.
The alteration of CT-BCA variables in response to inflammation, and particularly the increase in SMI with
inflammation, has important connotations in the field of cancer cachexia. The elevation of SMI in severe SI,
may be one end of a continuum. This could translate to SMI appearing to be preserved at lower levels of SI such
as those seen in cancer patients, when in fact their true SMI is falling. This may mean that those patents who
on CT-BCA do not meet cachexia criteria are in fact cachectic if tissue oedema could be controlled for - their
*“dry* muscle mass” is below the cachexia cut-point. This would suggest that ongoing SI at clinically relevant
levels may firstly mask the development of cachexia by volume standards, and secondly may be detectable in the
alteration of muscle radio-density which has been labelled ”myosteatosis”. Accordingly, the findings seen and
reported - namely the poor outcomes amongst patients with low SMD and even more so those with both low
SMD and sarcopenia may represent a combination of increased oedema (giving ”myosteatosis”) and significant
loss of muscle volume (enough to reach”sarcopenia” criteria), thus partially explaining the deleterious effects
observed in patients with both [68]. Accordingly, the degree of SI present in cancer patients at time of CT-BCA
should be delineated and may in fact represent a more powerful prognostic component of global assessment
than previously considered.
Given these findings, and the potential underlying pathophysiology, it could be suggested that SI in addition





10.1 CT-derived Definitions of Musculature
As described in Chapter 5, past work has focussed on the use of CT cut-points which have been derived from
populations including healthy and diseased participants. The evolution of these cut-points from the original
definition, and the introduction of CT as a replacement for DEXA is common throughout the sarcopenia
and cachexia literature. Latterly, some authors have been noting that different populations exhibit different
musculature and different muscle bulk [125]. Taking this argument to its logical conclusion, some investigators
are concerned that each study should define sarcopenia in the studied population [107].
This approach may be attractive, but will lead to more questions regarding what is meant by sarcopenia and
how it should be defined. In taking the lowest 2.5% or 10% or 33% of the population under study and using
them to define sarcopenia, the investigators will also be including patients with a disease process which has
led them to study inclusion. Considering that the original definition was “2 standard deviations below that
of healthy” appendicular muscle mass, using a definition measure constructed from unhealthy patients will
merely select out those with the worst measures amongst the already deteriorating. This will result in excellent
separation of Kaplan-Meier curves, but will not necessarily reflect the prevalence of sarcopenia in the disease
population.
In the present study, it was possible to utilise those selected healthy patients undergoing live donor nephrectomy
as part of a transplant programme. This allowed the comparison the cut-points derived historically with modern
locally-sourced healthy patients. Additionally, this allowed local cut-points to be derived in a similar fashion
to that done in the index study by Baumgartner et al[7].
10.1.1 ”Healthy Sarcopenia”
The results shown in Chapter 5 include the derivation and application of de-novo cut-points from a selected
healthy population. This produced some surprising results, particularly in the number of LDN patients who
met the published criteria for sarcopenia. Whilst there will be sarcopenic individuals in any population, the
proportion of such individuals found in the LDN population who met sarcopenia definitions was unexpectedly
high. This being the case, the question has to be whether this proportion is the result of a cut-point which is
incorrect. The cut-point may be incorrect due to the derivation being from an un-matched population (such
as using Western European cut-points in South-East Asian cohorts), or it may be incorrect due to changing
methodology of measurement. In the present study, however, the methodology used (as described in Chapter
3) is the standard technique described in the sarcopenia literature. Additionally, the reference population used
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for the index definition paper and the subsequent DEXA to CT, and indeed the BMI-stratification papers, all
used populations derived from Western Europeans.
From this, it may be that “health” includes a degree of sarcopenia. As measures of musculature are continuous
variables with the cut-point placed arbitrarily across a defined level of variable, an alteration in the underlying
population will lead to more or fewer being above or below the line. It may be that the population attending
the centre in question has shifted towards a lower musculature and that this could explain the increase in
”healthy sarcopenia”. In any case, using locally-derived sarcopenia definitions as described by Baumgartner
et al (specifically 2 standard deviations below the mean of a healthy population) results in a cut-point below
which very few patients fall. This means that either the population are not sarcopenic and by extension not
cachectic, or this method of producing a cut-point is not accurate for CT-BCA.
10.1.2 ”Non-Cancer Cachexia”
The international consensus defining cachexia specifically relates to cancer, and the definitions used from this
apply most strongly to the UGIC patients recruited for the present study. What is interesting to note, however,
is that there are some patients who fall under the “cachectic” umbrella definition who do not exhibit evidence
of cancer. The concept of other diseases causing cachexia is not new, and indeed both renal and cardiac
cachexia are recognised, as is cachexia from chronic severe respiratory disease. What has not been widely
described is that of a vascular aneurysmal disease causing cachexia. Clearly mesenteric ischaemia will lead to
cachexia from anorexia and malabsorption. Thoracic and abdominal aortic aneurysmal disease is not known
to exhibit such a phenotype, however.
The present study reveals that there is a non-negligible proportion of patients with aortic vascular disease who
fall into cachexia definitions, leading to the question of whether this disease can lead to cachexia or whether
the cachexia definition needs to be revised, perhaps on a population-specific basis as above.
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10.2 Using CT to Subdivide QoL Metrics
Although published CT-BCA cut-points may result in unexpected classification of patients, nevertheless the
cut-points may be useful for interpreting QoL metrics. Ideally, CT cut-points would allow an easy separation
of patients into those with preserved, and those with deterioration in QoL.
10.2.1 QoL metric choice
The metrics chosen were the ones which were felt to be most appropriate for the population under study
- specifically the UGIC population. Whilst additional QLQ-C30 cachexia bolt-on questionnaires have been
developed, these were not available at the time of study design. The other questionnaires, and indeed the base
QLQ-C30, were chosen to reflect a broad spectrum of general quality of life without being overly onerous to
complete in a brief clinic visit. These metrics, although including response levels which should capture any
“non-normal” response, are nevertheless primarily aimed at patients with cancer, and appear specifically to be
aimed at those cancer patients with more advanced disease.
We were unable to find questionnaires which were aimed at both healthy and cancer patients, which were
sufficiently slimline as to be acceptable to add-on to a brief clinic visit. This may represent a significant gap in
the QoL toolbox but conversely it may be that there are few studies investigating those patients with generally
preserved function and QoL or their healthy counterparts.
10.2.2 Absence of Relationship Between CT-BCA and QoL
The paucity of domains reaching both clinical and statistical significance across CT-BCA muscle variables, as
described in Chapter 6, is in itself fairly interesting.
Hypotheses relating CT-BCA to clinical outcomes as demonstrated by Martin et al, by Mourtzakis et al, and
by Rollins et al, suggest CT can detect muscular changes which influence or signpost prognosis. Were this the
case, it would seem logical to suppose that a measurable deterioration in muscle composition should translate
to a measurable deterioration in those QoL domains most closely related to muscular functioning. In the
present study, we were unable to clearly demonstrate this relationship.
The explanation for this could come from multiple sources.
Firstly, it could be that there is no real relationship between muscle bulk and muscle function. This is an
attractive hypothesis when considering real-world examples in the realm of athletics. Champion weight-lifters,
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and champion long-distance runners are highly-trained, and highly-functional individuals. Both phenotypes
compete internationally, and both undergo years of physical preparation and physique adjustment through
training to reach the peak of their sports. Both have very different amounts of muscle, however, and by
comparison with the weight-lifters the runners could be considered sarcopenic. This is clearly an extreme
example, and serves to highlight and perhaps explain the apparent disconnect between muscle size and function,
particularly with regard to QoL measures which as discussed above may not be sufficiently sensitive to detect
subtle changes in a pre-operative population.
Secondly, it may be that there is in fact a relationship between muscle size and function, but there is a threshold
above which evolved resilience and redundancy compensate for slow deterioration. This could possibly explain
why there are some patients who have preserved function and QoL despite having very low volumes of muscle,
and why those patients below these thresholds deteriorate rapidly. It may also be the case that true muscle
deterioration is masked by systemic inflammation on CT as discussed in Chapter 9.
Thirdly, and with regard to muscle radio-density, the constituent parts of muscle which give rise to radio-density
are imperfectly understood, as discussed in Chapter 7 and Chapter 8. Thus an attempt to explain differences
in QoL by coercing these CT-BCA variables (specifically SMD) into binary categories may be unhelpful. Unless
the cut-point used to define the categories is carefully chosen, any subtle differences in QoL will be lost.
Fourthly, it maybe that there were no real differences in QoL across the population of preoperative patients.
This was certainly the case for the LDN cohort, as could be expected in a healthy population. There were
differences when considering the AAA and UGI cohorts but those which reached both clinical and statistical
significance were difficult to explain. This could be because there is a rational explanation which we have yet
to discover, or because this in fact represents a Type II error, and a larger sample size would eliminate the
differences.
10.2.3 Function and QoL
The differences within each cohort when split by function-related PROMs appear much more marked, and
suggest that these may be more useful to characterise QoL within each group. What needs to be remembered,
however, is that these PROMs are also in part QoL assessments in their own right. Accordingly, despite the
attractive appearances of the data, what is being measured is one QoL PROM stratified by another.
Looking into more objective functional assessments such as gait speed, using these PROMs does not allow
significant separation between groups. Again, this is not particularly surprising given the population under
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study. Patients who met inclusion criteria were those who were sufficiently physically fit to undergo major
surgery, and so their objective functioning by definition will be preserved.
10.2.4 QoL Measurement
Clearly the measurement and quantification of patient-reported QoL is important to assist in decision-making
both for the physician and for the patient. The ability to understand objective measures which may influence
QoL is a worthwhile target for research, and is one which should be pursued. The current difficulty is in not
knowing either the relationship between CT-BCA variables and muscle function, or the relationship between
muscle function and QoL. Closer investigation of these relationships will improve accuracy of measurements
and should lead to better prediction of QoL in the future.
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10.3 Relationship Between CT and Muscle Biochemistry
Having considered the importance of defining the relationship between CT and muscle constituents above, it
then follows that an investigation should be conducted into this. Ideally, the use of CT-BCA variables would
allow researchers to subdivide cohorts with carry-through into muscle biochemical distributions.
10.3.1 Relationship Between CT and Muscle Protein
As discussed in Chapter 7, both CT-BCA and muscle protein content were analysed in each cohort.
One major advantage of the present study is the quantification of the protein content of ”normal, healthy”
muscle. Analytical techniques have moved on from the 1950s and 1960s when ”reference man” was defined.
Concerns regarding the differences between these original and more modern techniques are discussed in Chapter
7 but the fact remains that the present study contains a worthwhile analysis of muscle protein content in a
healthy cohort.
The values gathered for this protein content are remarkably similar to those measured in the previous millennium,
and despite concerns regarding differing methodology the spread of protein content values in this larger cohort
encompassed those of history.
Attempts to relate CT-BCA to these muscle protein content values proved less fruitful than hoped, particularly
with regard to radio-density. It had been hypothesised that protein formed a sufficiently significant part of the
muscle fibre that alterations in the protein content would be reflected in alterations in muscle radio-density.
The absence of such a relationship would tend to suggest that there in another component to the cell which
lends a greater radio-density or -lucency and which is not related to protein content. The lack of difference in
protein content when patients were stratified by CT-BCA cut-points or by the international consensus definition
would also suggest that clinically important differences or changes in patient phenotyping are not reflected in
muscle protein content and that there is another component which remains to be measured and defined.
10.3.2 Relationship Between CT and CSA
As discussed in Chapter 8, and following on from the discussion above regarding a missing component of
the cell, another hypothesis to explain differences in muscle radio-density was that the cell wall lent more to
radio-density than protein content. The supposed mechanism behind this was that a larger number of smaller
cells would proportionally have a greater amount of cell wall per unit area than a smaller number of larger cells.
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Accordingly, if this were to be the case, explanations for functional outcomes could be built from this.
The use of a weighted mean to reduce very minute data to a single number was a technique which was used
to allow testing between groups and to allow regression analysis at the cost of data ganularity. Alternative
analysis techniques are, however, not suitable for analysing the quantity and type of data generated by the
semi-automated CSA measurement equipment.
Analysis using the weighted mean did not reveal significant relationships between CSA and CT-BCA variables.
This suggests that the cell wall as an explanation for muscle radio-density is not the final story and that there
may be yet another reason for muscle to have greater or lesser radio-density, as discussed in Chapter 7 and
Chapter 8.
10.3.3 CT and Biochemistry
Basic biochemical analyses of muscle samples obtained from healthy, cancer, and non-cancer populations have
revealed values which are comparable to those of history. Additional analysis reveals interesting distributions
of muscle cell size but does not fully explain a relationship between CT and the aspects of muscle biochemistry
studied.
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10.4 Relationship Between CT and Systemmic Inflammation
The analysis conducted in Chapter 9 reveals an additional facet to consider in the complex interaction between
CT and muscle composition.
The severe inflammation triggered by anastomotic breakdown in oesophagetomy is marked but settles with
resolution of the leak and with time. As diagnosis is often by CT, this allows an excellent opportunity to examine
the changes in body composition brought about by systemic inflammation in a cancer population similar to
that in the wider study cohort. The changes noted in CT-BCA across the time between the pre-operative scan
and the post-operative, post-leak scan are marked.
One attractive hypothesis to unify the CT-BCA changes combines knowledge of the physiology of inflammation
with observed differences in CT-BCA. With an early upsurge in inflammatory markers including CRP, comes
a corresponding retention of water manifesting as tissue oedema. This oedema results in the an increase in
tissue volume, and a trend for the radio-density of the tissue towards that of water. This nicely matches
the observed changes in SMI and SMD. An increase in SMI between the pre-operative and post-leak scans
was seen, which returned towards the pre-operative level in the late scan. Concurrently, a reduction in SMD
between the pre-operative and post-leak scans was seen, which again returned towards the pre-operative level
in the late scan. Both these changes, and their resolution, match the phases of systemic inflammation.
In examining the anastomotic breakdown population, the study was able to demonstrate clearly the effect of
systemic inflammation on CT-BCA variables. Translating these changes to the UGIC population, and to cancer
populations in general, would lead to the suspicion that systemic inflammation as previously observed will have
a marked effect on CT-BCA in those patients.
It may be that SMI in cancer patients is thus elevated by tissue oedema in the presence of systemic inflammation,
with concurrent reduction in SMD. This in turn would suggest that there is a population of patients who appear
to have preserved muscle mass but in whom this may in fact be artificially elevated by oedema. Additionally,
this population would have concurrently reduced SMD. This may in part explain the noted deleterious additive
effects of reduced SMI with reduced SMD noted in a palliative pancreatic cancer population [68].
Indeed, the findings are important in the field of cachexia in that they suggest that without a knowledge of
the state of systemic inflammation of the patient, true cachexia may be masked by tissue oedema, and that






CT-BCA alone may not be sufficiently reliable to be used alone as an outcome measure for
intervention trials purporting to influence patient function or quality of life.
• CT-BCA cut-points are not shown in this analysis to readily translate between populations.
• CT-BCA variables are not shown in this analysis to accurately predict skeletal muscle protein content.
• CT-BCA variables are not shown in this analysis to accurately predict other measures of muscle
biochemistry such as cell CSA.
• CT-BCA variables are not shown in this analysis to accurately predict objective patient physical function.
• CT-BCA variables appear to have little impact on preoperative patient QoL in selected patients, in the
current analysis.
• CT-BCA variables appear to be significantly influenced by SI and thus it would seem reasonable to
attampt to avoid interpretation in isolation.
The current study investigated the relationships between CT-BCA variables and other components of patient
assessment in an attempt to clearly define a linked pathway between what can be measured by CT and clinically
relevant facets of patient life in cancer and cachexia. The study also attempted to underpin the values obtained
from CT scans with biochemical explanations for each finding.
The application of CT-BCA cut-points derived in a North American population to a Scottish population
including Cancer, Vascular, and Healthy Kidney Donor patients results in an expected prevalence of cachexia
and sarcopenia in the cancer group, but a much increased prevalence of sarcopenia in the non-cancer groups
and a significant proportion of vascular patients meeting cancer cachexia diagnostic criteria. The results from
this suggest that these cut-points may not be as clear-cut as previously considered. The results also point to
a hitherto unrecognised facet of vascular disease, specifically weight loss. It may be that these patients are
presenting with more advanced conditions than the pre-operative cancer patients but in a group without a
known weight losing condition, this is important to recognise.
Investigating the relationship between CT-BCA and muscle biochemistry should have yielded more positive
results. The suspicion was that protein content gave some degree of radio-density to skeletal muscle. The lack
of relationship between protein content and muscle radio-density was surprising. Looking further into other
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aspects of muscle biochemistry in the form of CSA might have been expected to reveal a relationship with
muscle mass, or with muscle radio-density. The absence of such a relationship would suggest that there are
other components to account for variation in SMD and that looking to CT as a means to infer muscle protein
content is flawed.
If CT-BCA variables struggle to classify patients into sarcopenic and non-sarcopenic, and show little relationship
with biochemical components of muscle, perhaps they may be of use in predicting patient function and QoL as
it is known that CT-BCA variables have a relationship with poor outcome? Again, however, the relationship
was not to be found. With regards to physical functioning and in particular gait speed, it may be that the
population under study is not the correct one as by their nature these patients must have preserved function.
When considering QoL, however, it would be expected that those with worse QoL would be likely to have more
advanced disease, and thus would be identifiable by CT-BCA. Again, however, this was not shown to be the
case. It appears that CT-BCA variables are unable to predict changes in QoL with any strength. Once again
this could be because of the patient group selected having preserved QoL or because the subtle differences
in QoL are not captured by the questionnaires used, however attempts to draw conclusions about QoL from
CT-BCA should be done with care.
The relation of CT-BCA and conclusions based on these variables with outcomes can be visually summarised
in Figure 11.1. Accordingly, a reconsideration of the relationship between muscle mass on CT and function
must be considered. Rather than a linear relationship, a more complex series of curves may link mass and
function, with sharp deterioration in function following the arrival at a critical level of skeletal muscle mass.
This is illustrated in Figure 11.2, and together with the findings demonstrated in the present study to date
could help to inform future cachexia study design and recruitment.
Both of these figures, it has to be remembered, are based upon the findings of this study and as such there
may well be other aspects of the relationship between CT-BCA and cachexia which are not tested and which
may influence the interpretation of the study findings when taken in a wider context. Whilst the study has
been unable to substantiate links between SMI, SMD, and QoL/PF etc., nevertheless it is likely that there is
a relationship between muscle mass and function, possibly more marked at the extremes of the curves. It may
be that the x-axis (marked “muscle mass”) may require re-labelling to another measure of muscle, such as e.g.
“quality”, though what this represents and how it should be measured (whether a new measurement entirely,
or some combination of current measures) is uncertain at present.
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Figure 11.1: Relationship Between CT and Outcomes
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Figure 11.2: Proposed New Cachexia Model Linking Muscle Mass and Function
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11.1 Future Directions
11.1.1 Body Composition and Muscle Biochemistry
The increasing sophistication of analysis packages for interrogating cross-sectional images gathered as part of
routine clinical care, together with the increased availability of such imaging in routine clinical care should
generate large quantities of data for analysis. Whilst this may take some time before it could be classified as
”big data”, nevertheless a combination of a minimum agreed dataset with an international collaborative effort
may result in a very powerful tool for research and guiding future efforts.
Another technique for measuring skeletal muscle which is being reported at present is the use of D3-Creatine
dilution. The technique is described by Shankaran et al [177] and involves the administration of a single dose
of tracer, followed by a fasted urine sample at a future date. The authors showed a strong correlation with
bioimpedence spectroscopy and propose this as a simple, rapid method for measuring muscle mass. Indeed,
this technique has been used in a large cohort study of male ageing [178], and has shown strong associations
with clinically relevant outcomes in older males. Such a technique is clearly of more use in research than
in widespread clinical practice, and may be more onerous for patients than undergoing their routine imaging.
Nevertheless, a replication of the current study with the addition of this tracer may allow greater analysis and
interpretation of both CT-BCA and muscle biochemistry.
Advances in CT-BCA interpretation, and increased usage of MRI scanning should increase the amount of
data available for interpretation. It will be interesting to see how these techniques relate to physiological and
biochemical measures - both at the cellular and at the whole body level.
11.1.2 Quality Of Life and Function
Currently-used quality of life measures are not aimed at patients with preserved QoL and function. Whilst
there are QoL tools aimed at patients suffering cachexia these are undergoing validation, and it is unclear how
much better they would be in a comparable cohort to the current study.
In a similar fashion, tools used to measure function objectively are likely to be of limited sensitivity for detecting
changes in a selected population with preserved function. The prevalence of reduced function in a preoperative
cohort is small, and thus the chance of a test correctly identifying this must be interpreted accordingly.
This is not to say that such measures should be ignored - rather that either more sensitive tests should be
developed to capture subtle changes, or that the outcome of these tests should be interpreted as a continuum
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s u m m a r y
Introduction: Cancer cachexia is a multifactorial syndrome characterized by skeletal muscle loss. Cross-
sectional analysis of CT scans is a recognized research method for assessing skeletal muscle volume.
However, little is known about the relationship between CT-derived estimates of muscle radio-density
(SMD) and muscle protein content. We assessed the relationship between CT-derived body composi-
tion variables and the protein content of muscle biopsies from cancer patients.
Methods: Rectus abdominis biopsies from cancer patients (n ¼ 32) were analysed for protein content and
correlated with phenotypic data gathered using CT body composition software.
Results: Skeletal muscle protein content varied widely between patients (median mg/mg wet
weight ¼ 89.3, range 70e141). There was a weak positive correlation between muscle protein content
and SMD (r ¼ 0.406, p ¼ 0.021), and a weak positive correlation between protein content and percentage
weight change (r ¼ 0.416, p ¼ 0.018).
Conclusion: The protein content of skeletal muscle varies widely in cancer patients and cannot be
accurately predicted by CT-derived muscle radio-density.
© 2017 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
1. Introduction
Cancer cachexia has been defined as a multifactorial syndrome
characterized by ongoing loss of skeletal muscle mass that cannot
be fully reversed by conventional nutritional support [1]. Cachexia
affects the majority of patients with advanced cancer and is asso-
ciated with a reduction in treatment tolerance, response to therapy,
quality of life and duration of survival. The assessment and classi-
fication of cachexia is important for patient prognostication and
treatment guidance. Modern cross-sectional imaging techniques,
combined with software planimetry, have been proposed as one
method for the assessment of skeletal muscle and fat mass in
cachectic patients. In this technique, the anatomical limits of
different tissue areas are defined by radio-density (measured in
Hounsfield units (HU)). Lean mass (LM) and total fat mass can then
be predicted by calculating skeletal muscle and fat areas at the level
of the third lumbar vertebra (L3), and extrapolating these values to
the whole body by using validated regression equations [2].
Increased fat infiltration of skeletal muscle (myosteatosis) results in
lower skeletal muscle radio-density (SMD) on CT [3].
For cancer patients, image analysis can be performed on CT
scans undertaken as part of the patient's routine staging in-
vestigations. Low skeletal muscle index (SMI, defined as skeletal
muscle area normalized for height in m2 [4]), as assessed by CT, has
been shown to be associated with poor prognosis in awide range of
solid epithelial malignancies. Moreover, reduced SMD is also
thought to be an independent predictor of adverse outcome in
respiratory and GI cancer patients [5]. However, it is not known
whether reduced SMD may also reflect variation in skeletal muscle
protein content. We aimed to ascertain whether body composition
variables measured by standard L3 CT scan analytic software are
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related to the measured protein content of skeletal muscle biopsies
in humans.
2. Methods
Patients undergoing surgical resection for upper gastrointes-
tinal cancer (4 gastric, 12 oesophageal, 3 junctional, 12 pancreatic
and 1 duodenal) were recruited. Patients were defined as weight-
losing if their weight at diagnosis was >5% less than their pre-
illness stable weight [1]. Sarcopenia was defined using SMI cut-
offs according to BMI [4]. SMDwasmeasured between30 and 150
HU, with low SMD defined as <41 HU with BMI <25 and <33 with
BMI >25 [4].Routine blood sampling was performed, including
plasma C-reactive protein (CRP) levels measured by automated
turbidimetry. Preoperative staging CT scans were analysed at L3
level using semi-automated Slice-O-Matic software v4.2 (Tomovi-
sion Montreal-Canada), which defines area measurements of
skeletal muscle, subcutaneous fat, and visceral fat.
Under general anaesthesia during resectional surgery, rectus
abdominis muscle biopsies were taken, snap-frozen in liquid ni-
trogen, and stored at80 C inmonitored freezers prior to analysis.
These biopsies were pulverized and weighed using an analytical
balance (Mettler Toledo), then lysed with Phosphosafe Extraction
Reagent (Merck Millipore, Billerica, MA, USA) before being ho-
mogenized and centrifuged. The supernatant was analysed for total
soluble protein (including myofibrillar and cytosolic) content using
commercially available BCA protein assay kits (Pierce Biotech-
nology, Thermo Fisher Scientific, Rockford, IL) [6].
Data were analysed using descriptive statistics. For variables of
interest, correlation analysis was performed by non-parametric
Spearman's rank coefficient, and comparison of groups was by
ManneWhitney U-test using IBM SPSS Statistics (IBM Corp.
Released 2013. IBM SPSS Statistics for Windows, Version 22.0.
Armonk, NY: IBM Corp.). Microsoft Excel was used for graphical
analyses. Ethical approval for this study was granted by the local
Research Ethics Committee.
3. Results
Thirty-two (n ¼ 32; M:F 26:6) cancer patients (median age 64.5
years, range 43e83) were included. 17 (53.1%) were weight-stable
and 15 (46.9%) were weight-losing. Two patients had Stage 1 dis-
ease, 6 had Stage 2 disease, 15 had Stage 3 disease, 5 had Stage 4
disease, and in 4 patients disease stage was not recorded. By pre-
established CT criteria [4], 19 (59.4%) were sarcopenic and 13
(40.6%) were not sarcopenic; 25 (78.1%) had normal SMD and 7
(21.9%) had low SMD (related to myosteatosis).
Results are shown in Table 1. Median skeletal muscle protein
content (mg/mg wet weight) varied significantly between cancer
patients, and was significantly lower in the weight-losing patients
compared with the weight-stable group (88.1 range (71e97) versus
92.3 (83e141) p ¼ 0.027). There was a weak positive correlation
between protein content and percentage weight change (r ¼ 0.416,
p ¼ 0.018) (Fig. 1). However, muscle protein content was similar in
sarcopenic and non-sarcopenic patients as defined by CT (88.3
(71e141) versus 89.7 (74e128), p ¼ 0.79). Muscle protein content
was lower in the “low SMD” group than the “normal SMD” group
(median 93.1, range 71e141 versus 83.2, 74e90; p ¼ 0.03), and
there was a weak positive correlation between muscle protein
content and SMD (r ¼ 0.406, p ¼ 0.021) (Fig. 1b). Muscle protein
content did not correlate significantly with any other CT marker of
body composition, including muscle area, stature-adjusted muscle
area, visceral adipose tissue area, or subcutaneous adipose tissue
area. Additionally, muscle protein content did not correlate signif-
icantly with age, weight, BMI, or plasma CRP.
SMD correlated negatively with age (r ¼ 0.543, p ¼ 0.001) and
visceral adipose tissue area (r ¼ 0.384, p ¼ 0.04), but not levels of
systemic inflammation as indexed by plasma CRP (r ¼ 0.175,
p ¼ 0.337), suggesting that myosteatosis increased with age and
visceral adiposity.
There was no significant difference in skeletal muscle radio-
density, skeletal muscle index, skeletal muscle protein content,
visceral adipose tissue area, subcutaneous adipose tissue area, or
percentage weight change across categories of cancer stage.
4. Discussion
In the present study, there was substantial variation in the
skeletal muscle protein content of the cancer patients. The median
level observed was reduced compared with values used to inform
standard reference tables and reference man [7] (average 172 mg/
mg wet weight; range 166.9e177.5; n¼ 3 healthy, youngmales). As
such, the present findings are consistent with previous compart-
mental body composition of weight-losing GI cancer patients using
measurement of whole body nitrogen, potassium and water [8].
The latter study identified that, compared with healthy controls,
both muscle mass and protein content are reduced by >60% with a
coefficient of variation for muscle protein content rising from 31%
to 77% in the weight-losing individuals compared with the weight-
stable controls [8]. Factors that might contribute to a reduced
protein content in the wet weight of muscle from cancer patients
include increased protein degradation, reduced protein synthesis,
increased intramuscular fat (myosteatosis) [3], or the relative
expansion of extracellular water space [9]. Alternatively, in com-
parison with reference man, there may be differences based on
different methodologies: the colorimetric protein assay used in the
present study is sensitive to certain amino-acid residues that may
not be present in the same proportion in all tissues and, although
precise, may not be as accurate as a physico-chemical assay for
nitrogen as an index of protein mass. For example, the BCA tech-
nique relies on the reduction of Cu2þ to Cuþ by protein with sec-
ondary detection of the reduced copper; this renders it susceptible
to the presence of other reductive agents present in the sample.
Nitrogen assays, however, will be affected by non-protein nitrogen
sources and also by non-muscle protein. Comparative studies in
this field have been performed in the food industry but remain to
be done in human skeletal muscle.
There was a weak correlation between muscle protein content
and the degree of weight loss in the present study (Fig. 1b). A
reduction in the myofibrillar content of muscle could explain
Table 1
Weight, weight change, CT body composition variables and protein content of rectus
abdominis muscle biopsy of 32 patients with upper GI cancer.
Variable Median Range
Premorbid stable weight (kg) 81.6 57e137
Premorbid BMI (kg/m2) 27.0 20.4e43.9
Weight at time of biopsy (kg) 75.3 52.4e133
Percentage weight change (%) 3.7 25 to þ10.9
L3 muscle area (cm2) 132.4 86.9e235
Skeletal muscle index (cm2/m2) 46.8 33.9e76.8
L3 SMD (HU) 39.2 25e56
Muscle protein content (mg/mg wet weight) 89.3 70e141
Muscle protein content
(weight-losing patients) (mg/mg wet weight)
88.1 71e97
Muscle protein content
(weight-stable patients) (mg/mg wet weight)
92.3 83e141
Muscle protein content
(low SMD patients) (mg/mg wet weight)
83.2 74e90
Muscle protein content
(normal SMD patients) (mg/mg wet weight)
93.1 71e141
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previous studies in cancer patients that have shown a reduction in
muscle strength when expressed in relation to the cross-sectional
area of the muscle [10]. Current intervention studies rely on
cross-sectional imaging to look for a positive effect of anabolic
agents on muscle, using volume as the index measure, with the
assumption that the muscle protein content remains constant. The
present results show substantial variation in muscle protein con-
tent and suggest that CT-derived muscle volume does not neces-
sarily relate to muscle protein mass. That some weight-stable
patients had biopsies that demonstrated a relatively low muscle
protein content (Fig. 1b) may reflect the concept that in cachexia
there may be a pre-cachectic state where metabolic change occurs
ahead of weight-loss [1].
Limitations of the present study include the absence of healthy
controls, the diverse patient cohort and the relatively small sample
size. Also, although the protein extraction method allows mea-
surement of total soluble (including myofibrillar) protein, it may
not reflect total cellular protein, as the insoluble pellet remaining is
likely to contain polymerized-protein filaments and some nuclear
and organelle proteins. Additionally, the analytical CT software
produces amean HUmeasurement of all skeletal muscle present on
a CT scan slice, whereas the biopsies represent only a small portion
of one of the many different muscles present at L3.
Whereas weight-losing patients (i.e. cachexia) had much lower
protein content than weight-stable individuals a similar pattern
was not observed for sarcopenic versus non-sarcopenic individuals.
Whilst weight-loss is a dynamic measure, sarcopenia may result
from a variety of current and historical events and it would prob-
ably require a much larger cohort of patients to dissect out the
difference.
4.1. Conclusions
The present study suggests that, in cancer patients, muscle
protein content varies widely and cannot accurately be predicted
by CT image analysis.
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 CURRENTOPINION The relationship between muscle mass and
function in cancer cachexia: smoke and mirrors?
Michael I. Ramage and Richard J.E. Skipworth
Purpose of review
Randomized clinical trials of cancer cachexia interventions are based on the premise that an increase in
the muscle mass of patients is associated with consequent improvements in muscle function, and ultimately,
quality of life. However, recent trials that have succeeded in demonstrating increases in lean body mass
have been unable to show associated increases in patient physical function. In this review, we examine the
potential causes for this lack of association between muscle mass and function in cancer cachexia, paying
particular attention to those factors that may be at play when using body composition analysis techniques
involving cross-sectional imaging. Moreover, we propose a new population-specific model for the
relationship between muscle mass and physical function in patients with cancer cachexia.
Recent findings
The ROMANA 1 and 2 trials of anamorelin (a novel ghrelin agonist) and the POWER 1 and 2 trials of
enobosarm (a selective androgen receptor modulator) were able to demonstrate improvements in patient lean
body mass, but not the functional co-primary endpoints of handgrip strength and stair climb power, respectively.
We report similar confirmatory findings in other studies, and describe potential reasons for these observations.
Summary
The relationship between muscle mass and muscle function is complex and unlikely to be linear.
Furthermore, the relationship is influenced by the techniques used to assess nutritional endpoints [e.g.
computed tomography (CT)]; the nature of the chosen physical function outcome measures; and the sex
and severity of the recruited cachectic patients. Such factors need to be considered when designing
intervention trials for cancer cachexia with functional endpoints.
Keywords
body composition, cachexia, cancer, muscle
INTRODUCTION
Regulatory agencies have previously stipulated that
intervention trials in cancer cachexia should use
nutritional and functional co-primary endpoints
[1]. With this in mind, it would seem to make prima
facie sense that nutritional outcomes that assess
muscle size should correlate with muscle function
in any case, at least in terms of explosive measures of
function, such as strength and power. Weightlifters
have large muscles by definition. However, the rela-
tionship between muscle mass and muscle function
is more complex than would be expected at first
glance. In contrast to weightlifters, marathon run-
ners tend to be slighter in build with less pronounced
musculature, and their performance is not linked
with muscle mass [2]. It is arguably this latter endur-
ance-type performance that would be of most clinical
benefit toelderly patientswithcancercachexia.How-
ever, at the present time, there are no agreed recom-
mendations or guidelines for physical function or
nutritional outcome measures that should be
assessed in trials of intervention for cachexia.
The use of muscle mass as a nutritional outcome
measure [or lean body mass (LBM) as a surrogate
outcome measure] appears to be relatively reliable in
clinical trials looking to assess the effect of pharma-
cological interventions. To this end, the effect of
anamorelin, an oral ghrelin receptor antagonist
(Helsinn) was studied in a series of trials named
ROMANA 1, 2, and 3. In ROMANA 1 and 2, a 12-
week treatment period increased LBM [assessed by
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dual-energy X-ray absorptiometry (DXA)] in
patients with stage 3 or 4 nonsmall cell lung cancer,
but not hand grip strength (HGS: the functional
co-primary end-point) [3
&
]. When the treatment
period was extended for another 12 weeks in
patients with a preserved Eastern Clinical Oncology
Group (ECOG) status (2), there was again a failure




In comparison, enobosarm [a nonsteroidal
selective androgen receptor modulator (GTx)] was
analysed in the POWER (Prevention and treatment
Of muscle Wasting in patients with cancER) 1 and 2
studies. These studies found that the use of enobo-
sarm was also associated with an increase in LBM,
but not with increased function as measured by the
co-primary end-point of at least 10% improvement
in stair climb power [5]. Several recent observational
studies have been able to show associations between
muscle mass and physical function in a range of
muscle wasting conditions, including chronic kid-
ney disease [6], elderly age [7], hip fracture [8],
inflammatory myopathies [9] and sarcopenia in
the context of obesity and metabolic syndrome
[10]. Thus, inability of cachexia trials to demon-
strate a related and synchronous increase in muscle
mass and function is somewhat unexpected, and in
this review, we describe the potential reasons for this
observed lack of association. In particular, we will
discuss both artefactual factors that relate to meth-
ods of assessment of nutritional and physical func-
tion outcome measures, and physiological factors
that relate to the recruited patient population. Fur-
thermore, we propose a new nonlinear model to
express the relationship between muscle mass and
patient function in cancer cachexia.
REASON FOR THE LACK OF
ASSOCIATION BETWEEN MUSCLE MASS
AND FUNCTION IN CANCER CACHEXIA
Factors in the assessment of body
composition and nutritional outcome
measures
Imaging techniques to assess body composition and
reduced muscle volumes have been used success-
fully for the last 30–40 years, and include computed
tomography (CT) [11], MRI [12,13], ultrasound and
DXA [14]. Age-related loss of muscle (termed ‘sarco-
penia’) was originally defined diagnostically by
Baumgartner et al. [14] as being below 2 standard
deviations of the mean appendicular muscle mass of
a group of healthy individuals undergoing DXA
scanning. With the standard use of CT for clinical
diagnostic purposes in cancer, CT body composition
analysis has emerged widely as a new potential gold
standard to identify sarcopenia in cancer patients.
Moreover, CT cut points for sarcopenia are described
for diagnostic purposes using the consensus defini-
tion of cancer cachexia [15]. In the future, it seems
likely that CT body composition analysis will be
used as both an inclusion criterion and an outcome
measure in RCTs for cachexia. However, the exact
methodology to utilize is still unclear, and the final
chosen technique will influence the observed rela-
tionship with physical function.
Computed tomography skeletal muscle
index
Recognizing the increasing use of CT in cancer
staging, Mourtzakis et al. [11] utilized a cohort of
patients undergoing both DXA and CT to produce
an equation converting the original DXA measures
of LBM to those of muscle cross-sectional area pro-
duced by CT at the lumbar L3 level. Such area
measurements can be indexed for height to derive
estimates of whole-body muscularity (skeletal mus-
cle index: SMI), which in turn have been shown to
be of prognostic value in terms of patient survival
and postoperative morbidity [16,17
&
]. Noting the
increasing prevalence of obesity in the general pop-
ulation [18], Martin et al. [19] used a cohort of lung
and gastrointestinal cancer patients to advance the
use of sarcopenic diagnostic cut-points by assessing
the influence of patient sex and whether or not they
had high or low BMI. A method of relating the
original research by Baumgartner et al. to the current
KEY POINTS
 There has been an unexpected inability of cachexia
trials to demonstrate a related and synchronous
increase in muscle mass and function.
 The best methodology for measuring body composition
is still unclear, and the final chosen technique will
influence any observed relationship with physical
function.
 The identity of the best physical function outcome
measure to relate nutritional outcome measures is
unknown, and its relationship to body composition
measures is unclear.
 There is likely to be an error in the understanding of the
nature of the relationship between muscle mass and
function, and we propose a new non-linear model.
 The true relationship between muscle mass and function
remains to be determined, and improved consensus
regarding the assessment of body composition is
required to ascertain this.
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cancer patient phenotype seen in modern practice is
of paramount clinical importance. However, despite
such efforts to validate and standardize L3-CT diag-
nosis of sarcopenia, authors continue to use differ-





], with no agreed consensus.
Although frustrating, such a varied approach is
understandable when one considers the various
populations that have been studied. The cut-points
derived by Martin et al. [19] were from a Canadian
cohort, which from the Alberta census consists of a
70% European origin population [23]. It is known
that for DXA scanning, cut-points for defining sar-
copenia are different in European populations and
Asian populations. Specifically, the EWGSOP (Euro-
pean Working Group on Sarcopenia in Older Peo-
ple) [24] defines low muscle mass in European
females below 5.5 kg/m2, whereas in a Korean pop-
ulation, Kwon et al. [21] found the cut-point to be
4.4 kg/m2. Similarly, for CT-derived variables, Fuji-
wara et al. [25] found different cut-points in a Japa-
nese cohort to those developed in the Canadian
group. Some studies have shown that it is sarcopenic
obesity that carries the worst clinical risk [26],
whereas more recently, the negative prognostic
impact of subcutaneous fat [27,28] has been dem-
onstrated. Indeed, we have previously identified a
high prevalence of sarcopenia in healthy controls
when using cut points derived in a cancer popula-
tion [29]. It, therefore, seems that population-spe-
cific cut-points for SMI need to be derived in any
trial population before assessing muscle function.
Computed tomography skeletal muscle
radiodensity
An alternative way to assess muscle nutritional
response to pharmacological intervention by CT
would be to assess muscle quality rather than quan-
tity, by measuring the radio-density of skeletal mus-
cle in Hounsfield Units. The effect of low skeletal
muscle radiodensity (SMD) on outcome has been
noted in several diseases. In pancreatitis, Grinsven
et al. [30] found a decrease in muscle radio-density
during the course of the disease resulted in poorer
survival. Similar findings were noted in pancreatic
cancer by van Dijk et al. [31
&&
] where in a prospective
study involving 199 patients with head of pancreas
cancer, medium or low muscle radio-density was
associated with worsened survival. Poorer survival
was also noted in patients with endometrial cancer
studied by Paula et al. [32], and in patients with
palliative pancreatic cancer studied by Rollins et al.
[17
&
]. In these cohorts, the combination of low
muscle mass with low SMD appeared to worsen
outcome. In the latter study, previously published
muscle mass and density cut-points [19] were used
to stratify patients into sarcopenic/normal and
myosteatotic/normal. Both sarcopenia and myo-
steatosis carried poorer prognosis, but in combina-
tion these factors were synergistic in their survival
reduction. However, there is some preliminary evi-
dence that SMD may correlate more closely with
physical function in elderly cancer patients com-
pared with SMI [33].
The inference, in line with the observations of
Martin et al. [19], is that low SMD is the result of
altered muscle composition at a cellular level, and
that protein is replaced by intramuscular fat. How-
ever, once again, this assumption may not represent
the entire picture. We have previously demon-
strated a positive, but only poor, correlation
between SMD and rectus abdominis muscle protein
content in an upper gastrointestinal cancer cohort
[34
&
], suggesting that any change in CT variables
may not necessarily confer an equivalent change in
muscle composition.
Similar to SMI, it seems that radio-density cut-
points also require specific development for each
population under study. Studies performed by dif-
fering centres have found differing radio-density
cut-points apply to their cohorts [31
&&
,35], and a
recent review noted similar findings [36] through-
out the literature.
Increasing interest in muscle radio-density has
led to concerns regarding the effect of intravenous
CT contrast media on body composition variables
derived from scans performed in different phases.
Earlier authors did not disclose which CT scan phases
were used in their manuscripts [11,19]. However,
work carried out by van Vugt et al. [37
&&
] investigated
50 liver transplant patients undergoing triple-phase
CT scans and found statistically and clinically signif-
icant differences in SMD between noncontrast and
contrast-enhanced scan phases, but not in muscle
area. Applying the Martin et al. [19] criteria to these
values resulted in 80% of patients having low SMD in
unenhanced scan phases whilst 50 and 38% had low
SMD in arterial and portal venous phases, respec-
tively. In a population of pancreatic cancer patients,
Rollins et al. found that there was a statistically
significant difference between contrast phases on
CT; however, there was a linear relationship between
these phases, which could be translated via simple
equations to provide comparable values [23]. In more
closely defining the relationship between contrast
phases, these authors have moved the literature for-
ward to allow abdominal CT scans performed for any
clinical indication to be compared. However, such
phase-dependent values will obviously impact
on any statistical relationship with physical function
outcome measures. This problem can be com-
pounded further by other CT technique-dependent
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variables such as tube potential [38]. Authors are now
turning to complex nonlinear trimodal regression
analysis techniques of entire radiodensitometric
muscle distributions to compare with standard CT
metrics and lower limb muscle function [39].
Factors in the assessment of physical
function outcome measures
The identity of the best physical function outcome
measure to relate nutritional outcome measures,
including CT, is unknown. There is a lack of physical
function tests that specifically analyse upper
abdominal/L3 muscle activity. Equally, it is an
unproven assumption that L3-CT should, in some
way, correlate with either targeted assessments of
isolated limb strength and power, or complex
whole-body assessments of physical function [e.g.
Timed-Up and Go-Test (TUG)] [40]. For example, we
have shown previously that cancer cachexia defined
using CT-derived sarcopenic cut-points can be iden-
tified in patients with normal TUG times [41].
We have previously advocated physical activity
meters as devices to measure global patient function
in the free-living environment [42,43]. The advan-
tage of such devices is that they offer multiple out-
come measures from a single application. However,
once again, for the purposes of clinical trial design, a
single outcome measure is required to be prechosen
as co-primary endpoint. HGS has been used widely
in nutritional studies in this role, and has been vali-
dated in various populations [44,45]. However, as
described previously, it was unsuccessful in the
ROMANA studies. From a clinical perspective, it
might seem that measures of upper limb physical
function might be less meaningful or less affected
by pharmacological intervention when compared
withmeasuresof lower limbphysical function,which
in turn might dictate activities of daily living and
overall exercise limitation. However, stair climb
power was unchanged in the POWER studies [5].
Patient factors in the trial population
An alternative explanation for the failure of previ-
ously trialled interventions to achieve significant
improvements in functional end-points is an error
in understanding of the nature of the relationship
between muscle mass and function. To date, trial
design has assumed a strong and linear relationship
between muscle mass and function. However,
it seems likely that, the relationship will alter depen-
dent on the patient’s morbid status at the time. The
prolonged immobility, reduced food intake, and
muscle depletion of a patient with refractory
cachexia are likely to accelerate the rate of functional
decline compared with a patient with precachexia.
Equally, a patient with precachexia/cachexia may be
more responsive or demonstrate faster functional
improvements after weight/muscle gain compared
with a patient with refractory cachexia, who may
be functionally bedbound. Therefore, rather than a
linear relationship between muscle mass and physi-
cal function, we propose a more complex sigmoid
relationship that pursues a delayed path on recovery
following initial decline (see Fig. 1). We suggest that
in the early stages of disease, functionality is main-
tained despite loss of muscle mass, and that outcome
measures of functionality currently in use are insuf-
ficiently sensitive to detect the subtle changes at this
stage. These precachectic patients are likely to have a
minimal functional effect from increasing muscle
mass but would be most likely to benefit from pro-
phylactic intervention to prevent further muscle
mass loss and subsequent functional decline. Sec-
ondly, after a significant amount of muscle mass
has been lost, function begins to decline at an
increased rate. It is these cachectic patients who,
we suggest, are likely to have the greatest maximal
effect from interventions to preserve muscle mass.
Thirdly, once a critical mass of muscle has been lost,
function declines rapidly and likely in an irreversible
fashion, resulting in refractory cachexia. Interven-
tions at this stage to improve muscle mass and func-
tion are unlikely to be successful because of the
refractory nature of the patient’s condition, and a
palliative approach may be more appropriate. The
high rates of patient attrition in previous cancer
cachexia trials means that is highly likely that they
have recruited significant numbers of such patients.
In recruiting for future trials, it would be important to
recognize these patients as a distinct sub-group in
whom mass and functional improvements may be
futile. Fourthly,postintervention,wesuggest that the
recovery of muscle mass long precedes functional
recovery. This is frequently seen in studies of patients
recovering from critical illness. Finally, we suggest
that the curve described by patients on the cachexia
pathway can be shifted in a deleterious direction by
the presence of systemic inflammation, comorbid-
ities, or advanced age as frequently reported in the
literature and seen clinically. This hypothetical
model requires evidence in the form of larger obser-
vational studies, in combination with data from cur-
rent clinical trials. Furthermore, it is highly likely that
if proven, such a model will require adjustment for
patient age [46] and sex [47], with transient factors
such as sleep, depression and fatigue [48], as well as
menopausal and habitual exercise status [49]. For
example, we have shown previously that lower limb
muscle strength and power assessments exhibit sex-
ual dimorphism in patients with cancer cachexia
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[50]. However, the aim is that by carrying out model
validation work, target groups for intervention trials
can be identified accurately and the appropriate out-
come measures more easily chosen.
CONCLUSION
Imaging methodology and physical function inves-
tigation have advanced greatly over the last 30–40
years. Increasing numbers of variables can, thus, be
interrogated and related to patient outcomes; how-
ever, the absence of a consensus on interpreting and
reporting these outcomes, and the methods used to
collect them, has led to variability in practice and
conflicting findings. The true relationship between
muscle mass and function remains to be deter-
mined, and is undoubtedly influenced by both var-
iability in reporting practice and patient factors.
Larger modeling studies based on best practice
methodology are required to ascertain accurately
the relationship between muscle mass and function
at all timepoints on the cachectic patient’s journey.
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Patient Information and Consent Forms
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Biochemical and functional biomarkers of cachexia: 
Information for non-cancer patients 
 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Talk to 
others about the study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you 
take part. 
 Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of the study? 
The purpose of this research study is to find out what causes people who have 
cancer to suffer muscle wasting, lose weight and feel tired. This wasting is a 
significant problem for patients as it causes a reduction in both quality and 
quantity of life. In order to find out what causes this problem and if there is any 
way to predict its development, we are asking patients about to undergo surgery 
for cancer if they would undergo a variety of tests before, during, and after their 
operation. These tests are mainly to measure changes in the size and function 
of the patients’ muscle and fat, and to see whether these changes can be 
predicted. In particular, we would like to take small samples of muscle, tumour, 
fat, blood, and urine during the patients’ operation to see if there are any 
biochemical changes. We aim to follow up the patients by asking for more blood 
and urine, as well as a needle test of the thigh muscle at clinic appointments up 
to 12 months after the operation. These tests are designed to cause the 
minimum of discomfort or inconvenience for anyone involved.  
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In order to find out whether the changes we see in these tests are purely related 
to cancer, we are also asking patients who do not have cancer, but are having 
surgery for other reasons, to join the study as a control group for comparison. 
The control group will take part in the some, but not all, of the tests undertaken 
by the cancer patients.  
 
Why have I been invited? 
You have been invited because you will soon be having surgery unrelated to 
cancer. You will be one of the healthy controls. We aim to recruit 20 participants 
in total. Patients undergoing purely keyhole (laparoscopic) surgery are not 
being invited for technical reasons. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form by 
one of the research team. You will still be free to withdraw at any time in the 
future and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care that you receive. 
 
What will happen to me if I take part? 
If you take part, you will be asked to undergo certain tests before your operation, 
during your operation, and at 2-3 appointments after the operation. The study 
appointments before and after your operation will be timed to coincide with your 
normal clinic appointments. Therefore, no extra visits to hospital are required if 
you choose to take part in this study. We anticipate the research visits will add 
no more than 15 minutes to your appointment. However, if for any reason we 
are unable to coincide your study appointments with your normal clinic 
appointments, we will provide taxi transport to and from the Royal Infirmary of 
Edinburgh’s Clinical Research Facility. The tests will include: 
 
Muscle Wasting in Cancer – Control Participant Information Sheet  
Version 2  15.10.2015                                                                                                                Page 3 
of 11 
 
 A blood test: The amount of blood taken is approximately the same as one 
teaspoonful (5ml), and it will be taken from your arm in the usual fashion. 
  
 
 A urine test: This will be performed in the usual fashion. The amount of urine 
taken is 20-30ml.  
 
 Tests of normal activity: We would like to see how much activity you do 
during a normal week. To help assess this, we may ask you to wear a small, 
light physical activity meter on your thigh, under a waterproof dressing, for a 
week at a time. This does not inconvenience most patients, and they quickly 
forget that they are wearing it. These monitors can be returned by post in a 
pre-paid envelope you will be given. 
 
 Test of functional ability (timed up-and-go and 6 minute walk): This test 
will measure your ability to get up out of a chair and walk a few metres then 
turn around and go back to your chair. It will only take a few minutes. The 6 
minute walk test measures how far you can walk in 6 minutes. This will be 
done over a measured course, and should not be tiring. It can be stopped at 
any time if necessary.  
 
 A questionnaire: This will take approximately 15 minutes to complete but 
can be taken home to do. We can provide a stamped-addressed envelope to 
post it to us if you take it home. 
 
 CT scan review: We also ask that you give us permission to review the CT 
scans that you will have had performed as part of your routine care. This review 
is simply to assess the amounts of muscle and fat in your body, and does not 
influence your treatment in any way. The review will be performed by a member 
of the research team. 
  
We would initially plan to carry out all of the above tests at one appointment 
prior to the date of your operation. If, after carrying them out, you found that 
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these tests were acceptable to perform (as we would hope), we would ask you 
to repeat the same tests, including the blood and urine samples, at the usual 
follow-up clinic appointments after your surgery for a period of up to 12 months. 
 
If at one of the appointments after your operation you are still willing to 
participate, we would ask that you give us permission to take a thigh muscle 
biopsy at that time. This will be performed under local anaesthetic injection but 
will otherwise be the same as the one that you had during your operation. This 
will involve a local anaesthetic injection, and will leave a small scar of 2-3 
millimetres (which will be closed with paper stitches). This biopsy is usually well-
tolerated, but may leave you with some discomfort for a day or so, and a small 
bruise. We will re-confirm your permission to perform this test at that time. 
 
In addition to the tests described above, we will also ask permission to take 
tissue samples during your operation, whilst you are asleep (under general 
anaesthetic): 
 
 A muscle biopsy: Whilst you are asleep (under general anaesthetic) during 
your operation, small muscle samples will be removed from both your 
abdominal wall and your thigh. The abdominal muscle sample will be pea-sized 
and will be taken from the incision through which your operation is being 
performed. This will not complicate your operation. The amount of muscle 
removed from the front of your thigh is even smaller and is taken via a tiny 
incision (a few millimeters long) through which a needle is introduced. This 
incision will be closed by paper stitches and will leave a small mark which will 
fade.  If you consent to have a thigh muscle biopsy in the outpatient clinic, this 
will be done under local anaesthetic.  
 
  A fat biopsy: When you are asleep under general anaesthetic, a small piece 
of fat (again, about the size of a pea) will be taken from just under the skin and 
also from the fat layer inside of your abdomen. 
 
 Blood and urine tests:  If not taken in clinic before your operation, these 
could be taken whilst asleep under general anaesthetic. 
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What do I have to do? 
Apart from attendance at the appointments before your operation, and after you 
operation, no other responsibilities are required from your participation. We 
would like your permission to monitor your case for up to 5 years after your 
operation to see how things are going. 
 
What are the possible disadvantages and risks of taking part? 
We have taken every step in the design of this study to minimise any possible 
disadvantages and risks. 
The tissue samples taken during your operation may cause a slightly increased 
risk of bleeding. This risk is very small, and the nature of the samples, together 
with the samples being taken by the operating surgeon, means the risk is very 
small indeed. 
Regarding the thigh muscle biopsy, you may experience some mild discomfort 
and stiffness in the leg following the procedure, but this should wear off after a 
few hours. Also, approximately 1 in 200 people suffer with bruising following the 
procedure. This has been described as similar to a “dead leg” but fades in 1-2 
days. 
If you have are having a repeat thigh muscle biopsy this will be performed under 
a local anaesthetic injection. The anaesthetic agent may sting for a few seconds 
as it is being administered.  
If you have any problems after the needle test, please contact the research 




What are the possible benefits of taking part? 
We cannot promise that the study will help you directly, but the information we 
receive might help improve the treatment of patients with cancer and cancer-
associated weight loss. 
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What happens when the research study stops? 
Following your appointment after your operation, no further appointments are 
required. However, if any of your blood, muscle,  or urine samples remain, we 
would ask your permission to store these samples (in anonymised form) in the 
University of Edinburgh so that we can consider them for use in future research 




What if relevant new information becomes available? 
If any new treatments for your medical conditions become available during the 
time of the study, they will not be withheld from you because of your 
participation in this study, should you need them. Furthermore, if you require 
any treatment during the course of the study, it will not be withheld from you 
because of your participation in this study.   
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time. However, we would ask your 
permission to keep in contact with you to monitor your progress. In this way, 
any information that was collected during the time of your participation in the 
study may still be used for research purposes. Any stored blood or tissue 
samples that can still be identified as yours will be destroyed if you wish. 
If for any reason you become unable to make decisions regarding your health, 
we would stop collecting information and samples from you, and we would not 
invite you to any more appointments. We would ask to keep and use any 
samples we had already collected. 
What if there is a problem? 
 Complaints: If you have a concern about any aspect of this study, you 
should ask to speak with the researchers who will do their best to answer 
your question. If you remain unhappy and wish to complain formally, you 
can do this through the NHS Complaints Procedure. Details can be 
obtained from the hospital. 
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If you wish to make a complaint about the study, please contact NHS 
Lothian: 
NHS Lothian Complaints Team 
2nd Floor 
Waverly Gate 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 
Tel: 0131 465 5708 
Email: craft@nhslothian.scot.nhs.uk 
 
 Harm: In the unlikely event that something goes wrong and you are 
harmed during the research and this is due to someone’s negligence 
then you may have grounds for a legal action for compensation against 
NHS Lothian but you may have to pay your legal costs. The normal 
National Health Service complaints mechanisms will still be available to 
you (if appropriate). 
 
 
Will my taking part in this study be kept confidential? 
Yes. All information which is collected about you during the course of the 
research will be kept strictly confidential. However, we would like to inform your 
GP of your involvement in this study but we will require your permission to do 
this. All other information about you which leaves the Royal Infirmary of 
Edinburgh will have your name and address removed so that you cannot be 
recognised from it. 
If any information comes to light during the study which may have a bearing on 
your care, we would aim to inform the team looking after you, and with your 
consent would also inform your GP. 
Muscle, blood, fat and urine samples collected during the study may be 
transferred for the purpose of analysis to associated researchers within and 
outside the European Economic Area, including to commercial companies such 
as Novartis (a pharmaceutical company). All samples will be anonymised prior 
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to sending and therefore you will not be identifiable. However, there will be a 
link from your samples to your records so we can match any changes in your 
case (or your withdrawal) to your samples. 
 
What will happen to any samples I give? 
A portion of the blood samples will be immediately analysed by the Department 
of Biochemistry at the Royal Infirmary of Edinburgh. The remainder of the blood 
samples, along with the muscle, fat, and urine samples, will be transferred to 
the University of Edinburgh for analysis. The only individuals who will have 
direct access to these samples will be the members of the research team 
behind this study. The samples will be analysed in the University of Edinburgh 
by various biochemical techniques in order to measure the levels of certain 
‘markers’ of wasting within the various tissues.  
To make sure all information remains confidential, all personal identifiers 
on your sample will be removed and replaced with a code. Your personal 
and medical history data will be stored separately and will not be 
processed. The key that links your data to the code on the sample will be 
stored in a secure location to which only authorized personnel of the 
SCHOOL of CLINICAL SCIENCES will have access. This is a “linked-
anonymised” system. Your coded samples may also be transferred for 
analysis to third parties in or outside the UK. This can include 
collaborating academic institutions or pharmaceutical companies, which 
contribute to this research project. 

Following all of these different analyses, if any of the samples remain, we would 
ask your permission to store these samples long-term (in anonymised form) in 
the University of Edinburgh so that we can consider them for future research 
studies (if a local Ethics Committee deems the studies appropriate). Professor 
Kenneth Fearon, Professor of Surgical Oncology, will act as custodian for any 
stored samples. The only other individuals who will have direct access to the 
stored samples will be the members of the research team behind the current 
study. We would aim to store the samples until they are used. 
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Will any genetic tests be done on the samples that I give? 
We have no plans to perform genetic analysis within the remit of this current 
study. However, following this current study, we would ask your permission to 
store any remaining samples so that we may consider them for use in future 
research studies that we may carry out (if a local Ethics Committee deems the 
study appropriate). Future studies could potentially involve genetic analysis, but 
such studies are at a very early stage of planning and not yet in progress. Any 
results from future genetic studies will not have any healthcare implications for 
you and hence we would not normally feed these results back to you. 
 
What will happen to the results of the current research study?  
The results of this study will be published in medical journals, reports and 
textbooks. Results will be made available to study participants through the 
Cancer Research UK website. You will not be identifiable in any 
report/publication or report unless you have specifically consented to release 
such information. 
 
Who is organising and funding the research? 
The research is being organised and sponsored by the University of Edinburgh. 
The research is being funded by Novartis. 
 
Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by the 
South East Scotland Research Ethics Committee. NHS Lothian Management 
Approval has been obtained, and this study has also been reviewed by 




You may contact me (the main researcher) directly by telephoning 0131 242 
6520 for further information at any time. Alternatively, if you wish to discuss this 
research study with someone independent of the research team, you can 
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contact Professor Wigmore in the Department of Surgery, who is acting as an 
independent advisor – contact 0131 242 3615.  
Many thanks for your time. 
 
Mr. Michael Ramage 
Clinical Research Fellow 
Department of Surgery 
Royal Infirmary of Edinburgh
 Participant Consent Form Version 2 - 15 Oct 2015 
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Biochemical and functional biomarkers of cachexia in cancer patients 
 
Please initial 
1. I agree to take part in the above-titled study.  
 
2. I confirm that I have read and understand the information sheet version 2 dated 15/10/2015 
for the above study. I have had the opportunity to consider the information and ask questions, and I 
have had these answered satisfactorily. 
 
3. I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected. 
 
4. I understand that relevant sections of any of my medical notes and data collected during the 
study may be looked at by individuals from the Sponsor [University of Edinburgh and NHS Lothian], 
from the NHS organisation or other authorities, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to my records. 
 
5. I agree to my GP being informed of my participation in the study. 
 
6. I agree to my GP being informed of any information found during the study which may have a 
bearing on my care.  
 
7. I agree to the storage of anonymised samples taken during the course of this study so that they 
may be considered for use in future research studies (pending a favourable ethical opinion by Lothian 
Local Research Ethics Committee). 
 
8. I agree to the use of samples taken during the course of this study in possible future genetic 
studies (pending a favourable ethical opinion by Lothian Local Research Ethics Committee). (Optional. 
Only initial if you agree) 
 
9. I understand that my anonymised samples and anonymised data may be distributed to third 
parties such as academic institutions or pharmaceutical companies in or outside of the UK who 
participate in the project 
 
10. I understand that the results of this study may be used for future commercial development of 




________________________ ________________ ___________________ 




_________________________ ________________ ___________________ 
Person taking consent Date  Signature 
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Biochemical and functional biomarkers of cachexia: 
Information for cancer patients  
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. Talk to others 
about the study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take 
part. 
 Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of the study? 
The purpose of this research study is to find out what causes people who have 
cancer to suffer muscle wasting, lose weight and feel tired. This wasting is a 
significant problem for patients as it causes a reduction in both quality and quantity 
of life. In order to find out what causes this problem and if there is any way to 
predict its development, we are asking patients about to undergo surgery for 
cancer if they would undergo a variety of tests before, during, and after their 
operation. These tests are mainly to measure changes in the size and function of 
the patients’ muscle and fat, and to see whether these changes can be predicted. 
In particular, we would like to take small samples of muscle, tumour, fat, blood, 
and urine during the patients’ operation to see if there are any biochemical 
changes. We aim to follow up the patients by asking for more blood and urine, as 
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well as a needle test of the thigh muscle at clinic appointments up to 12 months 
after the operation. These tests are designed to cause the minimum of discomfort 
or inconvenience for anyone involved. 
 
In order to find out whether the changes we see in these tests are purely related 
to cancer, we are also asking patients who do not have cancer, but are having 
surgery for other reasons, to join the study as a control group for comparison. The 
control group will take part in the some, but not all, of the tests undertaken by the 
cancer patients.  
 
Why have I been invited? 
You have been invited because you will soon be having surgery for cancer. We 
aim to recruit 100 participants in total. Patients undergoing purely keyhole 
(laparoscopic) surgery are not being invited for technical reasons. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given 
this information sheet to keep and be asked to sign a consent form by one of the 
research team. You will still be free to withdraw at any time in the future and without 
giving a reason. A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care that you receive. 
 
What will happen to me if I take part? 
If you take part, you will be asked to undergo certain tests before your operation, 
during your operation, and at 2-3 appointments after the operation, for up to 12 
months. The study appointments before and after your operation will be timed to 
coincide with your normal clinic appointments. Therefore, no extra visits to hospital 
are required if you choose to take part in this study. We anticipate the research 
visits will add no more than 15 minutes to your appointment. However, if for any 
reason we are unable to coincide your study appointments with your normal clinic 
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appointments, we will provide taxi transport to and from the Royal Infirmary of 
Edinburgh’s Clinical Research Facility. The tests will include: 
 
 A blood test: The amount of blood taken is approximately the same as one 
teaspoonful (5ml), and it will be taken from your arm in the usual fashion.   
 
 A urine test: This will be performed in the usual fashion. The amount of urine 
taken is 20-30ml.  
 
 Tests of normal activity: We would like to see how much activity you do during 
a normal week. To help assess this, we may ask you to wear a small, light 
physical activity meter on your thigh, under a waterproof dressing, for a week at 
a time. This does not inconvenience most patients, and they quickly forget that 
they are wearing it. These monitors can be returned by post in a pre-paid 
envelope you will be given. 
 
 Test of functional ability (timed up-and-go and 6 minute walk): This test will 
measure your ability to get up out of a chair and walk a few metres then turn 
around and go back to your chair. It will only take a few minutes. The 6 minute 
walk test measures how far you can walk in 6 minutes. This will be done over a 
measured course, and should not be tiring. It can be stopped at any time if 
necessary.  
 
 A questionnaire: This will take approximately 15 minutes to complete but can 
be taken home to do. We can provide a stamped-addressed envelope to post it to 
us if you take it home. 
 
 CT scan review: We also ask that you give us permission to review the CT scans 
that you will have had performed as part of your routine care. This review is simply 
to assess the amounts of muscle and fat in your body, and does not influence your 
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treatment in any way. The review will be performed by a member of the research 
team. 
  
We would initially plan to carry out all of the above tests at one appointment prior 
to the date of your operation. If, after carrying them out, you found that these tests 
were acceptable to perform (as we would hope), we would ask you to repeat the 
same tests, including the blood and urine samples, at the usual follow-up clinic 
appointments after your surgery for a period of up to 12 months. 
 
If at one of the appointments after your operation you are still willing to participate, 
we would also ask that you give us permission to take a thigh muscle biopsy at 
that time. This will be performed under local anaesthetic injection but will otherwise 
be the same as the one that you had during your operation. This will involve a local 
anaesthetic injection, a small scar of 2-3 millimetres (which will be closed with 
paper stitches), and may leave you with a bruised feeling for a day or so. We will 
re-confirm your permission to perform this test at that time. 
 
In addition to the tests described above, we will also ask permission to take tissue 
samples during your operation, whilst you are asleep (under general anaesthetic): 
 
 A muscle biopsy: Whilst you are asleep (under general anaesthetic) during your 
operation, small muscle samples will be removed from both your abdominal wall 
and your thigh. The abdominal muscle sample will be pea-sized and will be taken 
from the incision through which your operation is being performed. This will not 
complicate your operation. The amount of muscle removed from the front of your 
thigh is even smaller and is taken via a tiny incision (a few millimeters long) through 
which a needle is introduced. This incision will be closed by paper stitches and will 
leave a small mark which will fade.  If you consent to have a thigh muscle biopsy 
in the outpatient clinic, this will be done under local anaesthetic.  
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  A fat biopsy: When you are asleep under general anaesthetic, a small piece of 
fat (again, about the size of a pea) will be taken from just under the skin and also 
from the fat layer inside of your abdomen. 
 
 Blood and urine tests:  If not taken in clinic before your operation, these could 
be taken whilst asleep under general anaesthetic. 
 
 A tumour biopsy: We will ask you permission for a sample of tumour to be taken 
from the specimen removed at your operation. This will be done after the tumour 
has been removed. 
 
What do I have to do? 
Apart from attendance at the appointments before your operation, and after you 
operation, no other responsibilities are required from your participation. We would 
like your permission to monitor your case for up to 5 years after your operation to 
see how things are going. 
 
What are the possible disadvantages and risks of taking part? 
We have taken every step in the design of this study to minimise any possible 
disadvantages and risks. 
The tissue samples taken during your operation may cause a slightly increased 
risk of bleeding. This risk is very small, and the nature of the samples, together 
with the samples being taken by the operating surgeon, means the risk is very 
small indeed. 
Regarding the thigh muscle biopsy, you may experience some mild discomfort and 
stiffness in the leg following the procedure, but this should wear off after a few 
hours. Also, approximately 1 in 200 people suffer with bruising following the 
procedure. This has been described as similar to a “dead leg” but fades in 1-2 
days. 
If you have are having a repeat thigh muscle biopsy this will be performed under a 
local anaesthetic injection. The anaesthetic agent may sting for a few seconds as 
it is being administered.  
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If you have any problems after the needle test, please contact the research team 
directly using the number at the end of this sheet. 
 
What are the possible benefits of taking part? 
We cannot promise that the study will help you directly, but the information we 
receive might help improve the treatment of patients with cancer and cancer-
associated weight loss. 
 
 
What happens when the research study stops? 
Following your appointment after your operation, no further appointments are 
required. However, if any of your blood, muscle,  or urine samples remain, we 
would ask your permission to store these samples (in anonymised form) in the 
University of Edinburgh so that we can consider them for use in future research 




What if relevant new information becomes available? 
If any new treatment for cancer or cancer-associated wasting becomes available 
during the time of the study, it will not be withheld from you because of your 
participation in this study should you need it. Furthermore, if you require any 
treatment for cancer or other conditions during the course of the study (e.g. 
chemotherapy or radiotherapy), it will not be withheld from you because of your 
participation in this study.   
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time. However, we would ask your 
permission to keep in contact with you to monitor your progress. In this way, any 
information that was collected during the time of your participation in the study may 
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still be used for research purposes. Any stored blood or tissue samples that can 
still be identified as yours will be destroyed if you wish. 
If for any reason you become unable to make decisions regarding your health, we 
would stop collecting information and samples from you, and we would not invite 
you to any more appointments. We would ask to keep and use any samples we 





What if there is a problem? 
 Complaints: If you have a concern about any aspect of this study, you 
should ask to speak with the researchers who will do their best to answer 
your question. If you remain unhappy and wish to complain formally, you 
can do this through the NHS Complaints Procedure. Details can be obtained 
from the hospital. 
If you wish to make a complaint about the study, please contact NHS 
Lothian: 
NHS Lothian Complaints Team 
2nd Floor 
Waverly Gate 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 
Tel: 0131 465 5708 
Email: craft@nhslothian.scot.nhs.uk 
 
 Harm: In the unlikely event that something goes wrong and you are harmed 
during the research and this is due to someone’s negligence then you may 
have grounds for a legal action for compensation against NHS Lothian but 
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you may have to pay your legal costs. The normal National Health Service 
complaints mechanisms will still be available to you (if appropriate). 
 
Will my taking part in this study be kept confidential? 
Yes. All information which is collected about you during the course of the research 
will be kept strictly confidential. However, we would like to inform your GP of your 
involvement in this study but we will require your permission to do this. All other 
information about you which leaves the Royal Infirmary of Edinburgh will have your 
name and address removed so that you cannot be recognised from it. 
If any information comes to light during the study which may have a bearing on 
your care, we would aim to inform the team looking after you, and with your consent 
we would also inform your GP. 
Muscle, blood, fat and urine samples collected during the study may be transferred 
for the purpose of analysis to associated researchers within and outside the 
European Economic Area, including to commercial companies such as Novartis (a 
pharmaceutical company). All samples will be anonymised prior to sending and 
therefore you will not be identifiable. However, there will be an available link from 
your samples to your records so we can match any changes in your case (or your 
withdrawal) to your samples. 
 
What will happen to any samples I give? 
A portion of the blood samples will be immediately analysed by the Department of 
Biochemistry at the Royal Infirmary of Edinburgh. The remainder of the blood 
samples, along with the muscle, fat, and urine samples, will be transferred to the 
University of Edinburgh for analysis. The only individuals who will have direct 
access to these samples will be the members of the research team behind this 
study. The samples will be analysed in the University of Edinburgh by various 
biochemical techniques in order to measure the levels of certain ‘markers’ of 
wasting within the various tissues.  
To make sure all information remains confidential, all personal identifiers on 
your sample will be removed and replaced with a code. Your personal and 
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medical history data will be stored separately and will not be processed. The 
key that links your data to the code on the sample will be stored in a secure 
location to which only authorized personnel of the SCHOOL of CLINICAL 
SCIENCES will have access. This is a “linked-anonymised” system. Your 
coded samples may also be transferred for analysis to third parties in or 
outside the UK. This can include collaborating academic institutions or 
pharmaceutical companies, which contribute to this research project. 

Following all of these different analyses, if any of the samples remain, we would 
ask your permission to store these samples long-term (in anonymised form) in the 
University of Edinburgh so that we can consider them for future research studies 
(if a local Ethics Committee deems the studies appropriate). Professor Kenneth 
Fearon, Professor of Surgical Oncology, will act as custodian for any stored 
samples. The only other individuals who will have direct access to the stored 
samples will be the members of the research team behind the current study. 
 
Will any genetic tests be done on the samples that I give? 
We have no plans to perform genetic analysis within the remit of this current study. 
However, following this current study, we would ask your permission to store any 
remaining samples so that we may consider them for use in future research studies 
that we may carry out (if a local Ethics Committee deems the study appropriate). 
Future studies could potentially involve genetic analysis, but such studies are at a 
very early stage of planning and not yet in progress. Any results from future genetic 
studies will not have any healthcare implications for you and hence we would not 
normally feed these results back to you. 
 
What will happen to the results of the current research study?  
The results of this study will be published in medical journals, reports and 
textbooks. Results will be made available to study participants through the Cancer 
Research UK website. You will not be identifiable in any report/publication or report 
unless you have specifically consented to release such information. 
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Who is organising and funding the research? 
The research is being organised and sponsored by the University of Edinburgh. 
The research is being funded by Novartis. 
 
Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by the 
South East Scotland Research Ethics Committee. NHS Lothian Management 
Approval has been obtained, and this study has also been reviewed by members 








You may contact me (the main researcher) directly by telephoning 0131 242 6520 
for further information at any time. Alternatively, if you wish to discuss this research 
study with someone independent of the research team, you can contact Professor 
Wigmore in the Department of Surgery, who is acting as an independent advisor 
– contact 0131 242 3615.  
Many thanks for your time. 
 
Mr. Michael Ramage 
Clinical Research Fellow 
Department of Surgery 
Royal Infirmary of Edinburgh
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Biochemical and functional biomarkers of cachexia in cancer patients 
 
Please initial 
1. I agree to take part in the above-titled study.  
 
2. I confirm that I have read and understand the information sheet version 2 dated 15/10/2015 
for the above study. I have had the opportunity to consider the information and ask questions, and I 
have had these answered satisfactorily. 
 
3. I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected. 
 
4. I understand that relevant sections of any of my medical notes and data collected during the 
study may be looked at by individuals from the Sponsor [University of Edinburgh and NHS Lothian], 
from the NHS organisation or other authorities, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to my records. 
 
5. I agree to my GP being informed of my participation in the study.  
 
6. I agree to my GP being informed of any information found during the study which may have a 
bearing on my care 
 
7. I agree to the storage of anonymised samples taken during the course of this study so that they 
may be considered for use in future research studies (pending a favourable ethical opinion by Lothian 
Local Research Ethics Committee). 
 
8. I agree to the use of samples taken during the course of this study in possible future genetic 
studies (pending a favourable ethical opinion by Lothian Local Research Ethics Committee). (Optional. 
Only initial if you agree) 
 
9. I understand that my anonymised samples and anonymised data may be distributed to third 
parties such as academic institutions or pharmaceutical companies in or outside of the UK who 
participate in the project 
 
10. I understand that the results of this study may be used for future commercial development of 





________________________ ________________ ___________________ 




_________________________ ________________ ___________________ 




 Date of Consent  _______ NorSto ___ 
 Date of Operation _______ NorOes ___ 
 TRI0159 No  _______ Tum ___ 
 OCCAMS Y/N _______ EOTB Y/N ______ 
Questionnaires  QLQ-C30 Y/N EQ-5D Y/N REFS / PG-SGA Y/N 
Exposures  Smoking – Current/Never/Ex-smoker Quit _______   Alcohol – U/Wk  
  Cigarettes per day   Years smoked for  Prev excess Y/N 
 
Family History _____________________________________________________________________ 
Medications and duration Aspirin __________ Co-Morbidities MI  CCF  
PPI __________   PVD  CVA  
    Statin __________   Dementia COPD  
    Anticoagulant ____   ConTissDis Ulcer  
    Steroid __________   Liver (mild)  DM (OK) 
    Blockers __________   Hemiplegia CKD>3  
Measurements  ______ Kg _______ m (current)  DM (damage) Tumour  
_______ Kg loss over  _______ Weeks     Leukaemia Lymph  
_______ Kg 4 weeks ago _______ Kg 1 year ago    Mod/Sev Liver disease  
Exercise tolerance  (Current) 0-100m / 100-1000m / u/l Metastatic tumour  
   (4 weeks ago) 0-100m / 100-1000m / u/l AIDS    
   (1 year ago) 0-100m / 100-1000m / u/l (Tick = Yes, Cross = No) 
Timed up-and-go Lap 1 (sit-to-stand)  ______  Bloods Hb   _____ 
   Lap 2 (3m walk)  ______   Albumin _____ 
   Lap 3 (turn)  ______   eGFR  _____ 
   Lap 4 (3m walk)  ______   CRP  _____ 
   Total   ______   HbA1c  _____ 
PFTs FEV1 (l/min)/%predicted _____ _____%  Urea  _____ 
 FVC (l/min)/%predicted  _____ _____%  Creatinine _____ 
 FEV1/FVC   _____% _____% 
 
  
PATIENT ID  
Tumour 
Type Adenocarcinoma / Squamous Cell Carcinoma / Nil / Other ____________ 
Site Oesophagus / Junction / Stomach / Pancreas / Nil / Other ____________ 
Staging 
CT Tumour ______  PET Tumour ______  EUS Tumour ______ 
 Nodes ______   Nodes ______   Nodes ______ 
 Mets ______   Mets ______   Mets ______ 
Diagnostic Laparoscopy Y/N 
Chemotherapy      Post-Chemo staging 
Neo-adjuvant / Palliative / Curative / None  Complete Response  
2xCF / 3xECX / 4xECX / 3xEOX / 6xEOC / 6xECF  Partial Response  
Other ____________________________  Stable Disease  
Not Started / Completed / Incomplete   Progressive disease – still curative  
 Complications _______________  Progressive disease – Palliative  
 Patient choice _______________ 
Surgery 
Date __________  Operator CD / RJES / GWC / AMXP / PJXL / Other __________ 
Abdominal –  Open / Laparoscopic / Laparoscopic converted to open 
Thoracic –    Open / Thoracoscopic / Thoracoscopic converted to open 
Thoracoabdominal / Trans-hiatal / Thoracoscopic 
Whipples / Central liver resection for cholangiocarcinoma   
Vascular – TAAA / AAA / Aorto-femoral bypass for occlusive disease / Mesenteric bypass 
Other – Live donor nephrectomy / Incisional hernia / Other ___________________ 
Pathology 
Final staging Tumour _____ Nodes _____ Mets _____    R0 / R1 
Nodes  Number__/___ Above diaphragm Y/N Below diaphragm Y/N 
Lymphovascular invasion Y/N  Perineural invasion Y/N 
Extramural vascular invasion Y/N  Circumferential margin +ve / -ve 
Proximal margin  +ve / -ve Distal margin  +ve / -ve 
PG-SGA 
1. Weight 
In summary of my current and recent weight: 
I currently weigh about  _____ Kg I am currently about _____ cm tall 
1 month ago I weighed _____ Kg 6 months ago I weighed _____ Kg 
In the last 2 weeks my weight has Decreased Not changed Increased 
2. Food Intake 
As compared to my normal diet, I would rate my food intake during the past month as: 
Unchanged  Increased  Decreased 
I am now taking 
 Normal food, but less than a normal amount 
 Little solid food     Only liquids    
Only nutritional supplements   Very little of anything 
 Only tube feedings or nutrition by vein 
3. Symptoms 
I have had the following problems that have kept me from eating enough during the past 3 weeks: 
No problems eating 
No appetite, just didn’t feel like eating  Vomiting 
Nausea      Diarrhoea 
Constipation     Dry mouth 
Mouth sores     Smells bother me 
Things taste funny or have no taste  Feel full quickly 
Problems with swallowing   Fatigue 
Pain – where? _______________  Other _____________________ 
4. Activities and functions 
Over the past month, I would generally rate my activity as: 
 Normal with no limitations   
Not my normal self, but able to be up and about with fairly normal activities 
Not feeling up to most things, but in bed or chair less than half the day 
Able to do little activity, and spend over half the day in bed or chair 
Pretty much bed ridden, rarely out of bed  
 
Please imagine this pre-drawn circle is a clock. I 
would like you to place the numbers in the correct 
position and then place the hands to indicate a time 








In the past year, how many times have you been admitted 
to hospital? 
0 1-2 Over 2 
In general, how would you describe your health? Excellent / 
very good / 
good 
Fair Poor 
With how many of the following activities do you require 
help? 
Meal preparation / shopping / transportation / telephone / 
housekeeping / laundry / managing money / taking 
medications 
0-1 2-4 5-8 
When you need help, can you count on someone who is 
willing and able to meet your needs? 
Always Sometimes Never 
Do you use 5 or more different prescription medications on 
a regular basis? 
No Yes  
At times, do you forget to take your prescription 
medications? 
No Yes  
Have you recently lost weight such that your clothing has 
become looser? 
No Yes  
Do you often feel sad or depressed? No Yes  
Do you have a problem with losing control of urine when 
you don’t want to? 
No Yes  
Two weeks ago, were you able to:    
(1) Do heavy work around the house like washing 
windows, walls, or floors without help? 
Yes No  
(2) Walk up and down stairs to the second floor without 
help? 
Yes No  
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By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today.
Mobility
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed 
Self-Care
I have no problems with self-care 
I have some problems washing or dressing myself 
I am unable to wash or dress myself 
Usual Activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
Pain / Discomfort
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
Anxiety / Depression
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
3












To help people say how good or bad a health state is, 
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0.
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 










EORTC QLQ-C30 (version 3)  
 
We are interested in some things about you and your health. Please answer all of the questions yourself by circling the 
number that best applies to you. There are no "right" or "wrong" answers. The information that you provide will 
remain strictly confidential. 
 
Please fill in your initials:  
Your birthdate (Day, Month, Year):  
Today's date (Day, Month, Year):  31  
__________________________________________________________________________________________ 
  Not at A Quite Very 
  All Little a Bit Much 
1. Do you have any trouble doing strenuous activities,  
 like carrying a heavy shopping bag or a suitcase? 1 2 3 4 
 
2. Do you have any trouble taking a long walk? 1 2 3 4 
 
3. Do you have any trouble taking a short walk outside of the house? 1 2 3 4 
 
4. Do you need to stay in bed or a chair during the day? 1 2 3 4  
 
5. Do you need help with eating, dressing, washing  
 yourself or using the toilet? 1 2 3 4 
 
 
During the past week:  Not at A Quite Very 
  All Little a Bit Much 
 
6. Were you limited in doing either your work or other daily activities? 1 2 3 4 
 
7. Were you limited in pursuing your hobbies or other 
 leisure time activities? 1 2 3 4 
 
8. Were you short of breath? 1 2 3 4 
 
9. Have you had pain? 1 2 3 4 
 
10. Did you need to rest? 1 2 3 4 
 
11. Have you had trouble sleeping? 1 2 3 4 
 
12. Have you felt weak? 1 2 3 4 
 
13. Have you lacked appetite? 1 2 3 4 
 
14. Have you felt nauseated? 1 2 3 4 
 
15. Have you vomited? 1 2 3 4 
 
16. Have you been constipated? 1 2 3 4 
 








During the past week:  Not at A Quite Very 
  All Little a Bit Much 
 
17. Have you had diarrhea? 1 2 3 4 
 
18. Were you tired? 1 2 3 4 
 
19. Did pain interfere with your daily activities? 1 2 3 4 
 
20. Have you had difficulty in concentrating on things, 
 like reading a newspaper or watching television? 1 2 3 4 
 
21. Did you feel tense? 1 2 3 4 
 
22. Did you worry? 1 2 3 4 
 
23. Did you feel irritable? 1 2 3 4 
 
24. Did you feel depressed? 1 2 3 4 
 
25. Have you had difficulty remembering things? 1 2 3 4 
 
26. Has your physical condition or medical treatment 
 interfered with your family life? 1 2 3 4 
 
27. Has your physical condition or medical treatment 
 interfered with your social activities? 1 2 3 4 
 
28. Has your physical condition or medical treatment 
 caused you financial difficulties? 1 2 3 4 
 
 
For the following questions please circle the number between 1 and 7 that  
best applies to you 
 
29. How would you rate your overall health during the past week? 
 
  1 2 3 4 5 6 7 
 
 Very poor      Excellent 
 
 
30. How would you rate your overall quality of life during the past week? 
 
  1 2 3 4 5 6 7 
 






EORTC  QLQ – OG25  
 
Patients sometimes report that they have the following symptoms or problems. Please indicate the 
extent to which you have experienced these symptoms or problems during the past week. Please 
answer by circling the number that best applies to you. 
 
During the past week: Not A Quite Very 
  at all little a bit much 
31. Have you had problems eating solid foods? 1 2 3 4 
32. Have you had problems eating liquidised or soft foods? 1 2 3 4 
33. Have you had problems drinking liquids? 1 2 3 4 
34. Have you had trouble enjoying your meals? 1 2 3 4 
35. Have you felt full up too quickly after beginning to eat? 1 2 3 4 
36. Has it taken you a long time to complete your meals? 1 2 3 4 
37. Have you had difficulty eating? 1 2 3 4 
38. Have you had acid indigestion or heartburn? 1 2 3 4 
39. Has acid or bile coming into your mouth been a problem? 1 2 3 4 
40. Have you had discomfort when eating? 1 2 3 4 
41. Have you had pain when you eat? 1 2 3 4 
42. Have you had pain in your stomach area? 1 2 3 4 
43. Have you had discomfort in your stomach area? 1 2 3 4 
44. Have you been thinking about your illness? 1 2 3 4 
45. Have you worried about your health in the future? 1 2 3 4 
46. Have you had trouble with eating in front of other people? 1 2 3 4 
47. Have you had a dry mouth? 1 2 3 4 
48. Have you had problems with your sense of taste? 1 2 3 4 
49. Have you felt physically less attractive as a result 
 of your disease or treatment? 1 2 3 4 
 
Please go on to the next page 
ENGLISH 
 EORTC QLQ-OG25 Copyright 2007 EORTC Quality of life group. All rights reserved  
 
During the past week: Not A Quite Very 
  at all little a bit much 
50. Have you had difficulty swallowing your saliva? 1 2 3 4 
51. Have you choked when swallowing? 1 2 3 4 
52. Have you coughed? 1 2 3 4 
53. Have you had difficulty talking? 1 2 3 4 
54. Have you worried about your weight being too low? 1 2 3 4 
55. Answer this question only if you lost any hair:  
 If so, were you upset by the loss of your hair? 1 2 3 4 
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